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ABSTRACT 
Regulation of Tight Junction Barrier Function by Phospholipase C 
(Under the direction of Dhiren R. Thakker, Ph.D.) 
 
The intestinal epithelium presents a formidable barrier to the absorption of orally 
administered drugs and macromolecules. It is comprised of a monolayer of diverse epithelial 
cells connected via multi-protein junctional complexes at the apical membrane. The tight 
junction, the most apical component of the junctional complex, is generally considered to be 
the major barrier regulating the passage of molecules between adjacent cells and into the 
systemic circulation. Over the last fifteen years, evidence has emerged supporting a role for 
phospholipase C (PLC) enzymes, an important class of intracellular signaling molecules, in 
the regulation of tight junction function; however, unequivocal evidence to support such a 
role for any PLC isozyme has yet to be established. Studies in this dissertation were intended 
to develop a clearer understanding of the molecular mechanism involved in the regulation of 
intestinal epithelial tight junctions via the PLC-catalyzed signal transduction cascade. 
Specifically, the goal was to explore whether a cause-effect relationship exists between the 
inhibition of PLC activity and increased paracellular permeability via specific modulation of 
epithelial tight junctions. 
The mRNA expression profile of PLC isozymes in Caco-2 cells, an in vitro model for 
the human intestine, was established and directly compared to the human intestine. Results 
demonstrated that PLCβ1, PLCβ3, PLCγ1, PLCγ2, PLCδ3, and PLCε were all expressed at 
the mRNA level in Caco-2 cells. Importantly, each of these isozymes was also detected in all 
iii 
regions of the human small intestine. Further studies were intended to implicate PLC 
isozymes in the regulation of human intestinal tight junctions by determining the potency of 
previously reported PLC inhibitors to increase paracellular permeability and inhibit PLC 
activity in Caco-2 cells. The potency of a series of homologous alkylphosphocholines 
(APCs) to inhibit PLCβ activity varied forty five fold and correlated significantly with their 
potency to enhance paracellular permeability, suggesting that inhibition of PLCβ activity is 
associated with increased paracellular permeability. Further, structurally unrelated PLC 
inhibitor, U73122, also increased paracellular permeability and inhibited PLCβ activity. 
In order to establish a cause-effect relationship between PLC inhibition and increased 
paracellular permeability in epithelial cells, RNA interference was used to suppress the 
expression of specific PLC isozymes in MDCK cells, and the effect on tight junction 
function and structure was evaluated. Surprisingly, depletion of PLCβ3 and PLCγ1 (the only 
isozymes of their respective families detected in these cells), alone or in combination, had no 
impact on either tight junction assembly or on the barrier function of already formed tight 
junctions, suggesting that a cause-effect relationship does not exist between inhibition of 
these PLC families and tight junction function in epithelial cells. These results further 
implied that putative PLC inhibitors, APCs and U73122, increase paracellular permeability 
via mechanisms independent of their effects on PLC enzymes. 
Additional studies established that APCs disrupt apical membrane order at 
concentrations that also increase paracellular permeability in Caco-2 cells, providing an 
explanation for the observed effects on tight junction function. Unexpectedly, U73122 was 
found to increase the activity of hPLCβ3 in a cell free system, rather than inhibit its activity, 
providing an alternative hypothesis to explain the observed increase in paracellular 
iv 
permeability following treatment of epithelial cells with this compound. This novel 
interaction between U73122 and PLC was due to alkylation of the protein at cysteine 
residues by the highly reactive maleimide moiety in U73122. 
In summary, studies in this dissertation have significantly enhanced the current 
understanding of the role PLC enzymes play in the regulation of tight junction function, and 
have raised questions regarding previous reports that inhibition of these enzymes leads to 
increased paracellular permeability in epithelial cells. 
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CHAPTER 1 
 
 
 
 
INTRODUCTION 
 
  
A. Introduction 
The ability to deliver medicines orally to reach the systemic circulation has 
significant advantages and is a primary goal for the majority of therapeutic indications; this 
objective presents a formidable challenge in the discovery and development of new drug 
candidates. Components of both the intestinal lumen as well as the intestinal wall serve to 
protect the body from the external environment and regulate the access of orally ingested 
substances into the body. The following sections present a summary of some of the unique 
obstacles imposed by the human intestine, with significant focus on the composition and 
regulation of intercellular junctional complexes that provide a foundation for the structure 
and function of the intestinal epithelium.  
B. Oral Drug Absorption 
Oral administration is the preferred route of delivery for the majority of therapeutic 
agents; unfortunately, oral absorption is often limited due to the anatomical, biochemical, and 
physiological barrier imposed by the gastrointestinal (GI) tract. The small intestine is the 
longest segment of the GI tract, and is the primary site of absorption for orally administered 
nutrients, vitamins, and medicines. Composed of three ill-defined regions, i.e. duodenum, 
jejunum, and ileum, the small intestine incorporates special physical features such as mucosal 
folds on its inner surface, as well as the macro and microvilli of the epithelium, to provide 
optimal surface area for the absorption of ingested substance. 
The intestinal epithelium consists of a continuous monolayer of diverse cell types that 
line the wall of the intestinal lumen, and presents a formidable barrier to the entry of 
exogenous molecules into the systemic circulation. Absorptive enterocytes are the 
predominant cell type of the intestinal epithelium; they act not only to limit the entry of 
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potentially harmful exogenous molecules and toxins, but also to facilitate the absorption and 
retention of essential vitamins, nutrients, ions, and water. Enterocytes are polarized cells that 
maintain distinct apical and basolateral cell membranes, each with unique lipid and protein 
composition. For example, only the apical membrane contains glycosphingolipids1, 2 that 
serve to increase the stability of this lumenal-facing membrane through increased 
intermolecular hydrogen bonds3-5. Both membranes contain a variety of different influx and 
efflux proteins that facilitate movement of both endogenous and exogenous substrates into 
and out of the cytosol in both directions. Furthermore, enterocytes express a diverse array of 
metabolic enzymes, including cytochrome P450s and esterases, that metabolize orally 
administered drugs and limit their absorption into the systemic circulation. 
Depending on their physico-chemical properties, drug molecules and nutrients move 
across the intestinal epithelium via one of three pathways: by passive diffusion through 
epithelial cells across cell membranes (transcellular pathway), by a transporter mediated 
process across cell membranes (transcellular carrier-mediated pathway), or by passive 
diffusion between adjacent epithelial cells through the intercellular space (paracellular 
pathway) (Figure 1.1). Lipophilic molecules are able to easily partition into the lipid rich 
environment of cell membranes and move across cell monolayers via the transcellular route, 
while hydrophilic molecules are not. As a result, hydrophilic molecules must move across 
cell monolayers via the paracellular route if they are not substrates for specific absorptive 
membrane transporters. Passive paracellular diffusion is severely restricted, not only by the 
extremely low surface area as compared to the transcellular pathway, but also by the 
presence of tight junctions, multi-protein complexes that connect adjacent cells and create a 
physical barrier within the intercellular space. Tight junctions limit the oral bioavailability of  
3 
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Figure 1.1. Transport across an epithelial cell monolayer. Drug molecules cross a monolayer 
of epithelial cells by one of three pathways: (1) by passive diffusion through epithelial cells 
across cell membranes (transcellular pathway), (2) by a transporter mediated process across 
cell membranes (transcellular carrier-mediated pathway), or (3) by passive diffusion between 
adjacent epithelial cells through the intercellular space (paracellular pathway). 
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hydrophilic drugs; therefore, this class of drugs often require alternative, less desirable, 
routes of administration that make them useful for physicians and patients. Numerous 
approaches have been devised with the objective of increasing the intestinal absorption of 
hydrophilic drugs and macromolecules. One such approach involves the co-administration of 
a paracellular permeability enhancer (PPE), or a molecule that specifically increases 
paracellular passive diffusion by modulating the structure and/or function of intestinal 
epithelial tight junctions. However, despite two decades of active research, a safe and 
effective PPE has not yet been discovered and approved for use in humans. 
C. Tight Junctions 
Neighboring epithelial cells are connected to one another via multi-protein junctional 
complexes near the apical membrane consisting of tight junctions, adherens junctions, and 
desmosomes. The tight junction, the most apical component of the junctional complex6, is 
generally considered to be the major barrier to the passage of molecules between adjacent 
cells and through the intercellular space. The tight junction is comprised of transmembrane 
proteins that combine to form the physical barrier of the tight junction by spanning the 
intercellular space and interacting with transmembrane proteins on neighboring cells, as well 
as membrane scaffolding proteins that link the transmembrane proteins to the actin 
cytoskeleton and arrange them adjacent to important cytosolic regulatory proteins (Figure 
1.2). There exists an abundance of evidence suggesting that these dynamic multi-protein 
structures are under an impressive degree of regulation, and that their barrier function can be 
modulated in response to physiological, pharmacological, and pathophysiological stimuli. 
The following sections will review both the protein composition of epithelial tight junctions, 
as well as regulatory mechanisms thought to influence their structure and function. 
5 
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Figure 1.2. Schematic representation of an epithelial tight junction including major proteins 
and their interactions. Tight junctions are a multi-protein complex composed of several 
transmembrane and cytosolic proteins. Transmembrane proteins (e.g. claudins, occludin, 
junctional adhesion molecules) interact through their extracellular domains with 
transmembrane proteins in adjacent cells, as well as with cytosolic proteins and the actin 
cytoskeleton. Cytosolic proteins (e.g. zonula occludens) interact with each other, and serve as 
a scaffold to link the tight junction to the cytoskeleton, as well to organize regulatory proteins 
that control tight junction function. Adapted from a figure provided by Dr. Alan Fanning 
(School of Medicine, Department of Cellular and Molecular Physiology, University of North 
Carolina at Chapel Hill). Not all known tight junction proteins are depicted. 
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1. Tight Junction Structure 
Tight junctions contain more than forty different proteins with numerous functions 7. 
The current view of the tight junction8 includes four transmembrane proteins: occludin 
(approximately 65 kDa), claudins (approximately 20-27 kDa), junctional adhesion molecules 
(approximately 40 kDa), as well as the recently identified tricellulin (approximately 64 kDa). 
The extracellular domains of these proteins are thought to interact homophilically and 
heterophilically with one another, and with the extracellular domains of the same set of 
proteins on neighboring cells. These interactions create continuous circumferential belts of 
anastomizing strands, often referred to as fibrils, that create a physical barrier separating the 
apical and basolateral cell membranes as well as a selective intercellular pathway for ions, 
solutes, and in some cases, whole cells9-11. 
Occludin was the first protein identified to be a critical component of tight junctions 
12-14, and contains four transmembrane domains that form two extracellular loops that contain 
a high content of tyrosine and glycine residues13. The N-terminal cytosolic domain contains 
sequences predicted to bind to src homology 3 domains (SH3)15, while the C-terminal 
cytoplasmic tail, highly concentrated with charged amino acids, binds directly to the 
cytoskeleton16, as well as to tight junction-associated proteins (i.e. zonula occludens-1 (ZO-
1), ZO-2, and ZO-3) that also interact with the cytoskeleton 17-20. While the N-terminus and 
extracellular domains appear to be critical for normal tight junction barrier function21-26, 
conflicting evidence exists as to whether the C-terminal domain is essential for proper 
targeting and localization of occludin to the cell periphery, as well as for maintaining normal 
barrier function27, 28. Consistent with these conflicting results, the importance of occludin as a 
component of the tight junction physical barrier remains controversial. For example, over-
7 
expression of chick occludin in Madin-darby canine kidney (MDCK) cells initially decreased 
mannitol permeability compared to control; however, after an extended incubation, mannitol 
permeability increased to 50% of control and was accompanied by an unexpected and 
disconcordant increase in transepithelial electrical resistance (TEER)29. Some studies suggest 
that occludin does play a critical role in junctional formation and maintenance, as its 
exogenous expression in occludin-null fibroblasts leads to its co-localization with ZO-1 at 
points of cell-cell contact30. On the other hand, mounting evidence suggests that the role of 
occludin in tight junction barrier function may be less critical. For example, disruption of the 
occludin gene in embryonic stem cells did not prevent the formation of functional strands31, 
and ex vivo permeability studies across intestinal tissues from occludin knockout mice 
maintained normal permeability function32, despite observed phenotypic changes including 
gastric inflammation in these occludin null mice33. 
The functional role of occludin may instead be more organizational in nature, as its 
coiled-coil cytoplasmic domain has been shown to interact with a wide variety of 
intracellular proteins in addition to the aforementioned scaffolding ZO proteins, including 
JEAP, VAP-33, protein kinase C (PKC) ζ, c-Yes, and phosphatidylinositol (PI) 3-kinase34-37. 
Consistent with reported interactions with protein kinases, numerous phosphorylation sites 
have been identified in both cytoplasmic domains of occludin38 that may serve to regulate its 
localization and function. Indeed, it has been reported that highly phosphorylated occludin is 
concentrated to tight junctions in MDCK cells39, and phosphorylation is likely a key 
mechanism regulating the physiological function of occludin. To date, an unambiguous role 
for occludin in the maintenance and regulation of tight junctions has not been clearly defined. 
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While occludin was the first tight junction protein identified, it is the claudin family 
of proteins that are believed to constitute the primary physical components of tight 
junctions40, 41. Claudins, like occludin, contain four transmembrane domains, although they 
bear no sequence similarity to occludin. To date, more than twenty members of the claudin 
family have been identified10, 42-44, and evidence to date suggests that claudins are responsible 
for creating the variable barrier properties (i.e. permeability selectivity and transepithelial 
electrical resistance) that exist between tight junctions in different tissues45, 46, and even in 
different regions of the same tissues47, 48. For example, the longitudinal (i.e. duodenum to 
colon) and radial (i.e. villous to crypt) expression of claudins in the mouse intestine has been 
established and found to vary49, 50, suggesting that previously observed differences to ion flux 
along the human small intestine may result from notable differences in claudin expression 
between each region51. An abundance of in vitro studies have further implicated claudins as 
the primary determinants of tight junction barrier properties. Expression of claudin-1 and 
claudin-2 in fibroblasts, cells that lack constitutive tight junction strands, induced tight 
junction formation52. Furthermore, expression of claudin-2 in high resistance MDCK strain I 
cells that do not normally express this isoform, dramatically reduced the resistance to that of 
MDCK strain II cells that typically do express this isoform53. In addition, overexpression of 
claudin-4 in MDCK strain II cells induced a decrease in conductance likely related to the 
concomitantly observed decrease in sodium permeability54. More recent studies have 
confirmed the importance of individual claudins in the charge selectivity of the paracellular 
pathway55-58, firmly establishing these proteins as the unique functional differentiating 
components of tight junction barrier properties. 
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The continuing emergence of data suggesting claudins as the variable regulators of 
tight junctions between different tissues make claudins intriguing targets in human disease. 
In fact, several human diseases are thought to be caused by mutations in specific claudin 
isoforms. Mutations in the gene encoding claudin-14 cause autosomal recessive deafness59, 
mutations in the gene encoding claudin-16 lead to excessive loss of magnesium and calcium 
and subsequent autosomal recessive renal hypomagnesemia and hypercalciuria60, while 
mutations in claudin-19 lead to chronic renal failure and severe visual impairment61. Further, 
changes in claudin expression levels have been noted in conjunction with onset of intestinal 
diseases such as irritable bowel syndrome62, Crohn’s disease63, Barret’s Esophagus64, as well 
as esophageal, gastric, and colon carcinomas65-68. In addition to notable changes to claudins 
in human disease, knockout and transgenic mice have confirmed the important role for these 
proteins in the barrier function of tight junctions in different tissues, including the brain69 and 
skin70-72. Data from these and other studies provide support for a crucial role for claudins in 
creating and regulating selective channels through the tight junction barrier. 
A third family of transmembrane proteins, junctional adhesion molecules (JAM)11, 
has also been localized to tight junctions strands of both endothelial and epithelial cells73 and 
has been shown to interact with junctional proteins occludin, cingulin, ZO-174, Par-375, 
MUPP-176, MAG-177, as well as atypical PKC isozymes75. JAMs are single transmembrane 
proteins with a relatively short cytoplasmic C-terminal domain and an N-terminal 
extracellular domain composed of two Ig-like loops. The exact function of JAMs at the tight 
junction is not clearly defined; evidence suggests they play a role in early tight junction 
assembly78 as well as in direct interactions of junctional complexes with immune cells (e.g. 
leukocytes), including their transmigration across cell monolayers73 specifically through the 
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intercellular space79. More recent evidence implicates these proteins in regulation of tight 
junction permeability in both the kidney and intestine80, although their reported expression in 
platelets81 and cells of the immune system82 obscures their potential importance in 
specifically regulating tight junction barrier function in epithelial cells. 
Most recently, another tetraspanning protein, tricellulin, has been localized to tight 
junction strands83, and appears to be concentrated at points of tricellular contact. Early 
studies suggest an important role for tricellulin in epithelial tight junctions, as RNAi 
mediated depletion compromised epithelial barrier integrity83. In addition, recessive 
mutations in the gene encoding tricellulin cause nonsyndromic deafness in the inner ear, 
likely related to the loss of a conserved region in the cytosolic domain of the protein that 
binds ZO-184. Additional studies are required to fully appreciate the specific role this novel 
protein may play in the assembly and regulation of tight junctions, specifically at tricellular 
contacts. 
Three cytosolic proteins, referred to as tight junction-associated proteins or zonula 
occludens (ZO) proteins, link the transmembrane proteins of the tight junction to the actin 
cytoskeleton, and also serve as a scaffold on which to organize various regulatory proteins 
(e.g. kinases, phosphatases, and transcription factors) near their cellular substrates. ZO 
proteins are all phosphoproteins, suggesting they may be phosphorylation targets for some of 
the signaling proteins they serve to organize. They are members of the membrane associated 
guanylate kinase family (MAGUK) and are the major constituents of the cytosolic domain of 
the tight junction. MAGUK proteins are characterized by having one to five N-terminal PDZ 
repeats (each ZO protein contains three), an SH3 domain, and a C-terminal region 
homologous to guanylate kinases85. PDZ domains are known to mediate protein-protein 
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interactions and typically bind to short amino acid motifs, usually ending in valine, at the C-
termini of interacting proteins86. 
ZO-1 is the first tight junction associated protein identified with a mass of 
approximately 210 kD87; ZO-1 is also observed at some types of adherens junctions in non-
epithelial cells88. The N-terminal half of ZO-1 interacts with the C-terminal tail of occludin13, 
89, claudin19, ZO-289, and ZO-319, while the C-terminal half of ZO-1 interacts with F-actin, 
cortactin, and protein 4.1, and anchors the protein to the cellular cytoskeleton89-92. It has also 
been shown to interact via its SH3 domain with a serine protein kinase (ZAK)93, a 
transcription factor, ZONAB, which plays a role in epithelial cell proliferation94, and small 
G-proteins, such as Gα12 92. ZO-1 has also been recently reported to form homodimers via its 
second PDZ domain95. Knockdown experiments in both mouse and canine epithelial cells 
have demonstrated that ZO-1 is not essential for the formation of tight junctions; however, 
both studies revealed a pronounced delay in the assembly of functional tight junctions 
following calcium switch96, 97. 
ZO-2, a 160 kDa protein, has also been found to interact with the C-terminal half of 
occludin98 in addition to the N-terminal half of ZO-189, cingulin99, and the C-terminal domain 
of claudins through its PDZ1 domain19. ZO-2 also associates with actin as well as the actin 
binding protein 4.1 through its C-terminal praline rich domain16, 19, 100, 101. The sub cellular 
localization of ZO-2 appears to be dependent on the degree of cell-cell contact in epithelial 
cells; in confluent monolayers, ZO-2 appears primarily at the tight junction, while in sub-
confluent cells it demonstrates speckled nuclear localization, where it has been shown to 
interact with DNA binding proteins102, and co-localize with nuclear splicing factors103, 
suggesting a potential role for ZO-2 in the transmission of regulatory signals from the 
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nucleus to the cell periphery. Nuclear localization of this MAGUK protein is consistent with 
the identification of several nuclear localization and export signal sequences104, 105. More 
recently, ZO-2 has been hypothesized as a candidate tumor suppressor protein due to its high 
homology to other tumor suppressors106, as well as its lack of expression in a number of 
cancers107, 108. A very recent report highlights the importance of ZO-2 in the formation and 
maintenance of tight junctions, as RNAi-mediated depletion in MDCK cells caused 
significant abnormalities in the barrier function of tight junctions in these cells109; although 
results from other recent cellular knockdown studies contradict this finding96, 110, obscuring 
the absolute requirement of this protein for tight junction function and maintenance. 
The most recently identified ZO-3, a 130 kDa protein, is the only ZO expressed 
exclusively in epithelial cells111. It interacts with ZO-1, occludin, claudins, as well as actin 
filaments, but not with ZO-216, 18, 19. Independent ZO-1•ZO-2 and ZO-1•ZO-3 complexes 
have been found in vivo16; therefore, the tight junction associated proteins do not exist in a 
single trimeric grouping (i.e., ZO-1•ZO-2•ZO-3 complex). ZO-3 knockout mice and RNAi 
depleted mouse teratocarcinoma F9 cells appear normal with no obvious abnormalities in 
tight junction function and architecture110; however, overexpression of the N-terminal half of 
ZO-3 in MDCK cells caused marked changes in actin organization and delayed tight junction 
assembly112, 113. Additional studies will be necessary to clarify the role of ZO-3 in tight 
junction assembly and maintenance. 
In addition to the ZO family of proteins, several other tight junction specific 
peripheral membrane proteins have been identified, including membrane associated 
guanylate kinase inverted proteins (MAGI-1, 2, 3)114-117, the partitioning defective proteins 
(PAR-3 and PAR-6), the multi-PDZ domain protein-1 (MUPP-1), the MAGUK protein 
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associated with Lin-7 (PALS-1), cingulin118, 119, 7H6 antigen120, 121, symplekin122 and others. 
All have been identified as cytosolic components of the tight junction, yet their functional 
role in tight junction structure and function has not been extensively evaluated and will not 
be discussed in detail. The function of some of these proteins has been recently reviewed123. 
2. Tight Junction Function 
Research over the past 50 years has exposed the tight junction as a highly dynamic 
and complex multi-protein structure, selectively permeable to certain hydrophilic molecules 
including ions, nutrients and drugs. The current analogies for the tight junction are as a 
“gate,” because it allows passage of small hydrophilic molecules but acts as a barrier to 
larger hydrophilic ones, and as a “fence,” because it forms an intramembrane diffusion 
barrier that restricts the intermixing of apical and basolateral membrane components124, 125. 
The outer leaflet of the “fenced in” apical membrane is preferentially enriched in 
glycosphingolipids and sphingomyelin1, 2, 126, 127. The tight junction prevents the diffusion of 
such phospholipids out of the exoplasmic leaflet of the apical membrane, whereas 
phospholipids in the cytoplasmic leaflet of the apical membrane are free to diffuse into the 
basolateral membrane128. For example, when asymmetric liposomes containing over 85% of 
a fluorescent lipid in the exoplasmic leaflet were fused with the apical plasma membrane of 
MDCK cell monolayers, the fluorescent lipid did not move to the basolateral side. When 
symmetric liposomes, which contained the fluorescent lipid in both leaflets, were fused to the 
apical membrane, redistribution of the fluorescent lipid to the basolateral membrane occurred 
immediately125. The fence function further restricts to movement of apical membrane 
components to the apical membranes of neighboring cells. For example, an endogenous 
glycolipid (Forssman antigen), present in the exoplasmic leaflet of the apical membrane of 
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MDCK strain II cells was unable to pass to the apical membrane of MDCK strain I cells 
(which lack this glycolipid) under conditions where these cells are co-cultured and connected 
by tight junction strands. In addition, fluorescent lipids, which have been fused into the 
plasma membrane of one MDCK cell, do not diffuse to neighboring cells while the tight 
junction between cells is intact129. 
This fence function of the tight junction maintains the polarity of enterocytes, and is 
related to the gate function, as the maintenance of distinct membrane environments is directly 
related to the passage of molecules between adjacent cells and the subsequent exposure of 
such molecules to distinctly different membranes. However, the gate and fence function of 
the tight junction can be uncoupled, as ATP depletion increased the flux of the hydrophilic 
compound inulin across MDCK cell monolayers (i.e. disrupted gate function); however, a 
fluorescent phosphatidylcholine that was incorporated into the exoplasmic leaflet of the 
apical membrane remained confined to that membrane (i.e. maintained fence function)130. 
Undoubtedly, the biological function of the tight junction is quite complex, and the proteins 
and signal transduction cascades involved in maintaining and regulating these functions 
remain to be clearly defined. 
The gate function of the tight junction is highly dynamic and regulates the movement 
of hydrophilic molecules across the intestinal epithelium. The tight junction restricts 
movement of non-charged solutes on the basis of molecular radius; however, this size-
dependent restriction is still not well understood. Experiments have shown that tight junction 
permeability of polyethylene glycols (PEG) with different molecular radii is markedly 
reduced at a molecular radius of approximately four angstroms across epithelial cell 
monolayers131, implying that the size restriction is not linearly related to molecular radius. 
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Instead, these data suggest the existence of two distinct sets of tight junction pores, small 
restrictive pores accessible to molecules less than four angstroms, and larger non-restrictive 
pores accessible to molecules of increasingly larger radii. This in vitro observation is similar 
to the in vivo PEG absorption profiles produced for rat, dog, and human, suggesting the tight 
junction has a molecular radius of approximately five angstroms in vivo132. Interestingly, 
increased tight junction permeability by depletion of extracellular calcium or treatment with 
sodium caprate had different effects on the size restriction of permeability of PEGs across 
Caco-2 and T84 cell monolayers. Although both treatments markedly increased permeability, 
depletion of extracellular calcium abolished the size restriction imposed by untreated cell 
monolayers, while treatment with sodium caprate did not131, implying that these two 
approaches to modulate barrier function may be mediated via distinct molecular mechanisms. 
The gate function of epithelial tight junctions is clearly complex, and assessing changes to 
this functional aspect of junctional complexes in response to physiological and 
pharmacological stimuli should be performed with multiple and detailed approaches. 
3. Assessing Changes to Tight Junction Barrier Function 
The barrier function of epithelial tissues is typically assessed via measurement of two 
parameters, the transepithelial electrical resistance (TEER) and the monolayer permeability 
of hydrophilic molecules. Tight junctions restrict the movement of ions across monolayers of 
epithelial cells, giving rise to an electrical potential difference, measurable as electrical 
resistance. The paracellular space has a significantly lower resistance and accordingly higher 
conductance to ion flow compared to cell membranes, even in the presence of ion channels. 
Studies suggest that as much as 75% of the ionic conductance across moderately leaky 
epithelia, such as those found in the small intestine, is through the paracellular pathway 133, 
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134. Therefore, an increase in ionic conductance, and a concordant decrease in TEER, is 
thought to be a reflection of an increase in paracellular permeability, as opposed to 
transcellular permeability, of ions across a cell monolayer. A number of studies have 
confirmed this hypothesis. For example, treatment of Caco-2 cells with an ionophore 
specifically increased the cellular membrane conductance to ions rather than the paracellular 
conductance, and had no effect on TEER135. However, changes in TEER are not always 
reflective of an increase in monolayer permeability to solutes, as increased levels of cAMP 
and cGMP in intestinal epithelia led to significant and long lasting transepithelial potential 
changes, but no increase in permeability of macromolecules136. In addition, manipulation of 
the expression of specific claudins has been shown to alter TEER55, 56 without measurable 
changes to solute flux54; therefore, in addition to the measurement of TEER, it is crucial to 
also include an evaluation of changes to the permeability of non-charged solutes, preferably 
of varying molecular radii. 
Hydrophilic solutes are unlikely to move across lipid rich cell membranes; therefore, 
unless they are substrates for membrane transporters, they must rely on movement through 
the paracellular pathway between adjacent cells. As a result, increased epithelial monolayer 
permeability to hydrophilic solutes is typically a reflection of changes in paracellular 
permeability, rather than transcellular permeability. A number of small and large hydrophilic 
solutes have been utilized as markers for changes in paracellular permeability. Small 
molecules typically include neutral compounds such as mannitol (Mr = 4 Å) or urea (Mr = 
2.7 Å)137, cations such as atenolol (Mr = 4.8 Å)137, ranitidine138, or creatinine (Mr = 3.2 Å)139, 
or anions such as fluorescein (Mr = 5.5 Å) or 51Cr-EDTA (Mr = 5.4 Å)140. Mannitol is clearly 
the most often used paracellular marker, as a number of convincing studies support the 
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hypothesis that mannitol traverses epithelial monolayers via the paracellular route141-143. 
Positively charged hydrophilic solutes are typically more permeable than neutral or anionic 
solutes of similar size, presumably due to the anionic nature of cell membranes and the 
intercellular space137, 144. Hydrophilic macromolecules such as inulin (Mr = 7.5 Å) and 
fluorescein isothiocyanate dextrans (Mr = 14-60 Å)140 are also frequently used to assess 
changes in paracellular permeability of epithelial monolayers, often in concert with small 
molecules in order to more accurately assess the extent of changes to the paracellular space. 
Recently, a number of groups have employed the use of polyethylene glycol polymers of 
increasing size to completely characterize the size restrictions of the paracellular pathway131, 
145, although the linear structure of PEGs allows significant flexibility that may cloud 
interpretations made using these polymers145. 
The relative tightness of epithelial tight junctions varies both among and within 
individual tissues. For example, intestinal tight junctions vary in tightness longitudinally, 
consistent with absorptive functions in different regions. The upper small intestine is 
significantly leakier than the colon, in accordance with the role of the small intestine in the 
rapid absorption of orally ingested vitamins and nutrients, and the role of the colon in 
regulating and retaining total body water as well as preventing entry of bacterial toxins. 
Typically, a leaky epithelium has a low TEER (high permeability), 10-50 ohm*cm2, while a 
tight epithelium has a high TEER (low permeability), > 1000 ohm*cm2. Regardless of the 
relative tightness of the epithelia under evaluation, both TEER and hydrophilic solute flux 
should be used in concert to characterize both baseline paracellular permeability, as well as 
PPE induced changes to the permeability barrier. 
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4. Physiological and Cellular Regulation of the Tight Junction 
Tight junctions are not static; instead they are a highly dynamic but stable cellular 
structures maintained by numerous protein-protein interactions that respond to various 
physiological, pharmacological, and pathophysiological stimuli from both inside and outside 
the cell. Physiological regulation of the tight junction was first reported by Pappenheimer and 
Reiss139, who proposed that “solvent drag” through the paracellular space is responsible for a 
significant proportion of total nutrient absorption following a meal. It has since been 
postulated that this apparent increase in absorption is the result of activation of the sodium 
dependent glucose transporter leading to contraction of the actin myosin ring via PKC-
mediated phosphorylation of myosin light chain146, 147; although this hypothesis remains 
controversial148, as subsequent studies have reported conflicting results with respect to 
increased absorption of paracellular permeants co-administered with glucose51, 149, 150. 
In addition to nutrients such as glucose, a number of other endogenous molecules 
have been reported to alter the barrier function of both endothelial and epithelial tight 
junctions. For example, hormones and neurotransmitters such as vasopressin, angiotensin II 
and epinephrine151, nucleotides such as ADP and ATP152, and growth factors such as 
hepatocyte growth factor153, platelet derived growth factor (PDGF)154, and epidermal growth 
factor (EGF)155, have all been reported to modulate tight junction permeability in a number 
of cellular models. Cytokines, such as tumor necrosis factor-α156, interferon-γ157, and 
numerous interleukins158, 159 have emerged in recent years as important factors regulating 
tight junction function, with particular relevance to a number of intestinal inflammatory 
diseases including Crohn’s, ulcerative colitis, and inflammatory bowel disease160, in which 
intestinal tight junction permeability is compromised. More recently, interferon-γ and 
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interleukin-4, cytokines that are known to negatively regulate one another, have been shown 
to have opposing effects on tight junction permeability in T84 cells mediated via claudin-2 
expression161. Apical treatment with interferon-γ decreased claudin-2 expression and 
decreased paracellular permeability, while apical treatment with interleukin-4 increased 
claudin-2 expression and increased paracellular permeability, suggesting intricate and 
opposing physiological mechanisms controlling the barrier function of intestinal tight 
junctions. Interestingly, basolateral treatment of the same cell line with interferon-γ for 
extended time periods has been reported to increase, rather than decrease, paracellular 
permeability162, suggesting membrane dependent effects of this cytokine on tight junction 
function. Consistent with these recently described compensatory cytokine-mediated 
regulatory mechanisms, pre-incubation of T84 cells with transforming growth factor-β has 
been reported to attenuate the effects of interferon-γ on barrier function163, supporting a 
highly complex physiologic regulation of tight junction function in the human intestine. 
Two primary intracellular molecular mechanisms are typically associated with 
alterations to the function of mature epithelial tight junctions, namely, reorganization of the 
actin cytoskeleton9 and changes to the phosphorylation state of tight junction proteins164 
(Figure 1.3). It is well established that the apical junctional complex, including the tight 
junction, is located adjacent to a dense band of actin and myosin, typically referred to as the 
perijunctional actin myosin ring. The actin cytoskeleton associates with the plasma 
membrane, specifically through this dense band of filaments just beneath the tight junction at 
the level of the adherens junction165. As indicated previously, actin binds directly to cytosolic 
as well as transmembrane proteins of the tight junction16, 90; therefore, the stability of actin 
filaments directly impacts the structure and function of tight junctions. It has long been  
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Figure 1.3. Schematic representation of the two major intracellular molecular mechanisms 
associated with the regulation of tight junction function leading to increased paracellular 
permeability through the intercellular space. Following an extracellular stimuli (or 
intracellular stimuli, not depicted), numerous signaling pathways may lead to changes to the 
phosphorylation state of specific tight junction proteins (left cell) or alterations to the 
organization of the perijunctional actin myosin ring (right cell) that lead to transient opening 
of the paracellular space. See Figure 1.2 (page 6) for identification of depicted proteins. 
Adapted from a figure provided by Dr. Alan Fanning (School of Medicine, Department of 
Cellular and Molecular Physiology, University of North Carolina at Chapel Hill). Not all 
known tight junction proteins are depicted. 
 
21 
recognized that disruption of the actin cytoskeleton, for example by actin-depolymerizing 
drugs such as cytochalasin and phalloidin, leads to extensive disruption of tight junction 
barrier properties166, 167. The regulation of tight junctions via reorganization of the actin 
cytoskeleton is known to be mediated via numerous signaling molecules such as the small 
GTPases Rac, Rho, and Cdc42. All three of these proteins have been shown to be important 
regulatory enzymes regulating barrier function through actin filaments. Expression of either 
dominant negative or constitutively active forms of Rac, Rho, and Cdc42 has been 
specifically demonstrated to alter actin organization by a number of laboratories168-170, 
consistent with inactivation of these proteins by Clostridium difficile toxins that also leads to 
disorganization of actin filaments171. Indeed an abundance of studies have established the 
fundamental and critical requirement of filamentous actin organization in the maintenance of 
tight junction barrier function in epithelial cells, although additional studies are clearly 
necessary to determine the exact mechanisms and regulatory components involved in the 
multifaceted interaction between tight junctions and the perijunctional actin myosin ring. 
In addition to alteration and disruption of the actin cytoskeleton, changes to the 
phosphorylation state of a number of tight junction proteins has been observed in conjunction 
with changes to tight junction barrier function. For example, phosphorylation of myosin light 
chain induces the perijunctional actin myosin ring to contract and has been associated with a 
loosening of the tight junction172, a result that suggests these two molecular mechanisms are 
intimately related. Reversible phosphorylation of proteins is probably the most important 
regulatory modification of cellular components, involved in such crucial cellular functions as 
mitosis, metabolism, growth and differentiation, and gene expression. The primary 
components of the tight junction, ZO-1, ZO-2, ZO-3, occludin, and claudins, are all 
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phosphoproteins38, 39, 173-176, and changes to the phosphorylation state of these proteins at 
tyrosine, serine, and threonine residues is believed to be an important step in the regulation of 
tight junction function. Further, a number of PKCs have been shown to directly 
phosphorylate tight junction proteins, e.g. ZO-1177, ZO-2174, occludin178, and claudins179. 
Disruption of tight junction integrity by ATP depletion induced a decrease in 
phosphorylation of several tight junction regulatory proteins, followed by a subsequent 
increase in phosphorylation and re-establishment of tight junction integrity during ATP 
repletion176. The phosphorylation state of occludin correlates with occludin localization and 
function at the tight junction180; thus, the phosphorylation of occludin may be involved in 
tight junction assembly39. Interestingly, two strains of MDCK cells that differ markedly in 
TEER (thirty fold) have a similar number of tight junction strands and content of ZO-1181; 
however, the level of phosphorylation of ZO-1 in the low resistance strain is approximately 
twice that of the high resistance strain182. Differences in claudin expression have since been 
attributed to the difference in resistance between these two strains of MDCK cells, although a 
possible relationship between claudin expression and ZO-1 phosphorylation state has not 
been further explored. Increased tyrosine phosphorylation of both ZO-1 and ZO-2 following 
treatment of MDCK cells with a tyrosine phosphatase inhibitor correlates with increased tight 
junction permeability183.  Additionally, dephosphorylation of ZO-1, occludin, and claudin-1 
have been observed concomitantly with reduction in TEER and increase in mannitol and 
inulin flux across MDCK cells transfected with a protein phosphatase (PP)2A holoenzyme, 
ABαC184. More recently, PKCθ phosphorylation of claudin-1 and claudin-4 in Caco-2 
cells175 and PKCε phosphorylation of claudin-4 in ovarian cancer cells 179 have been 
demonstrated to be important factors in the regulation of tight junction barrier function in 
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these cell lines. Although alteration in the phosphorylation state of tight junction proteins has 
often been associated with altered tight junction permeability, a direct cause-effect 
relationship between the phosphorylation of a tight junction protein and increase paracellular 
permeability has not been established unequivocally. 
D. Regulation of the Tight Junction by Phospholipase C Enzymes 
1. Isozyme Families and Catalytic Function 
Phosphoinositide-specific phospholipase C (PLC) isozymes comprise a group of 
related enzymes that specifically cleave the polar head group from inositol containing 
phospholipids, and play important roles in the regulation of many cellular functions. PLC 
isozymes are activated in response to both intracellular and extracellular stimuli, including 
hormones, growth factors, G-proteins, and neurotransmitters, leading to hydrolysis of 
phosphatidylinositol 4,5-bisphosphate (PIP2) to form the classic intracellular second 
messengers, inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). Highly soluble IP3 is 
released into the cytosol, and is known to bind to receptors at the endoplasmic reticulum 
where it induces calcium release, and thereby functions to regulate intracellular calcium 
levels185, 186. More recent reports have demonstrated sequential phosphorylation of IP3 by 
novel kinases to generate additional inositol polyphosphates IP4, IP5, IP6, and IP7, which have 
been shown to be necessary for mRNA export, DNA repair, and proper regulation of gene 
expression187-189. Increased levels of DAG, either alone or in conjunction with increased 
calcium, activate the novel and conventional PKC isozymes, respectively190-192. 
In the late 1980’s and early 1990’s, three mammalian PLC isozymes (β, γ, and δ) 
were first isolated and their corresponding DNA sequences were determined193, 194. To date, 
six families of PLC (β, γ, δ, ε, ζ, and η) consisting of thirteen total isozymes have been 
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identified in humans, including PLCβ1, β2, β3, β4, PLCγ1, γ2, PLCδ1, δ3, δ4, PLCε, PLCζ, 
PLCη1, and η2195-198 (Figure 1.4). It is noteworthy to point out that PLCδ2, originally 
identified in bovine tissue, has recently been recognized as the human homolog of PLCδ4, 
and therefore not a distinct human isozyme199. PLCs vary in molecular size from the 
approximately 70 kDa PLCδ to the much larger 250 kDa PLCε, and share little sequence 
similarity even within isozyme families. They do share a common core domain structure 
which includes the PH domain, EF domain, C2 domain, and the highly conserved catalytic 
core made up of two regions, known as X and Y domains200, 201 (Figure 1.4). The catalytic 
domain contains alternating α-helices and β-strands to form an incomplete triose phosphate 
isomerase (TIM) barrel. Inositol-containing substrates are an absolute requirement for PLC 
activity, as the 2-position hydroxyl in the inositol ring participates in a unique intramolecular 
nucleophilic attack on the phosphorous to produce a cyclic intermediate. A PLC active site 
histidine then abstracts a proton from water promoting hydrolysis of the cyclic 
phosphodiester intermediate197. 
Outside of the highly conserved catalytic domains, the remaining domains have 
unique and important functions. Although EF domain of PLCs have interesting similarities to 
calcium saturated forms of calmodulin, they do not appear to bind this metal in PLCs, 
leaving the importance of this domain yet to be discovered202. Instead, the C2 domain is 
thought to bind calcium in a fashion that may stabilize the interaction of PLCs to the 
membrane. Most PLCs contain a pleckstrin homology domain (PH), conventionally believed 
to be specifically involved in membrane binding203, have been recently established as 
mediators of protein-protein interactions as well204, 205. The lack of amino acid conservation 
in PH domains between isozyme families suggests that this domain may be responsible for 
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Figure 1.4. Domain organization and amino acid sequence comparisons among human PLC 
isozymes. Six families of PLC isozymes are distinguished by different structural domains. 
Figure was reproduced from published sources.195, 211. 
 
Legend: Cys (cysteine rich region), CDC25 (guanine nucleotide exchange domain, PH 
(pleckstrin homology domain), EF (EF-hand domain), X and Y (core catalytic domains, i.e. 
TIM barrel), C2 (calcium and lipid binding domain), CT (C-terminal domain), RA1 and RA2 
(Ras-associating domains). 
 
Note: CT domains contain PDZ binding motifs and are unique between PLCβ and PLCη. 
PLCη contains alternatively sliced variants lacking this motif. 
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isozyme specific regulation in distinct membrane regions206. PLCγ isozymes contain two PH 
domains, the second of which is split by a number of src homology domains (SH). SH2 
domains are uniquely responsible for targeting of these isozymes to phospho-tyrosine 
residues and are involved in their activation by receptor tyrosine kinases (RTKs), while the 
SH3 domain binds with high affinity to proline rich sequences in other proteins, including 
actin207. PLCβ and PLCη isozymes contain a carboxy terminal (CT) region rich in basic 
residues. This unique domain has been found to be important for interaction with PDZ 
domains on membrane scaffolding proteins, for nuclear import and export, as well as for 
specific activation of PLCβ isozymes by GPCRs and G-protein subunits208-210. Unique to 
PLCε are two C-terminal Ras-associating domains and an N-terminal guanine nucleotide 
exchange domain, both believed to be important for the unique regulatory mechanisms 
governing the activity of this isozyme211. Despite the unique domains associated with 
different PLC isozyme families, there is a high degree of conservation among active site 
residues; therefore, it is not surprising that they all act predominantly on just two substrates, 
PIP and PIP2, with some catalytic activity toward PI193. As a result, it is likely that PLC 
isozymes achieve selectivity in their physiological functions by differential regulatory 
mechanisms as well as by different tissue and cellular distribution. 
2. Tissue Distribution and Subcellular Localization 
Differences in tissue distribution provide a mechanism for diversity in the 
physiological functions of PLCs, some of which have been confirmed by transgenic studies 
in knockout mice (Reviewed in section 4). Of the PLCβ isozymes, β1 and β3 are the most 
widely expressed, at particularly high levels in specific regions of the brain197, 212-216, with 
PLCβ3 also reported to be highly expressed in parotid gland and kidney217, 218. PLCβ2 
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appears to be expressed primarily in hematopoeitic cells of the immune system217, 219-221, 
while PLCβ4 expression is restricted to specific regions of the brain, e.g. cerebellum and 
retina222, 223. Of the PLCγ isozymes, PLCγ1 is ubiquitously expressed, particularly high in the 
brain and lungs212, 224, while PLCγ2, although expressed quite widely throughout the body as 
well, appears to be most abundant in cells of hematopoietic origin212, 225, 226. PLCε expression 
is highest in the heart, with expression also high in both the lung and kidney227. Of the PLCδ 
isozymes, δ1 is the most widely expressed, with highest expression in the heart, lung, skeletal 
muscle, brain, and testis212, 228; however, tissue levels of this isozyme appear to be relatively 
low in comparison to PLCβ and PLCγ215. Surprisingly, relatively little is known with respect 
to tissue distribution of PLCδ3 and PLCδ4 isozymes, although their expression has been 
reported in a number of rat tissues229. More recently identified PLCζ has been reported to be 
sperm specific230, 231, while PLCη isozymes have thus far been exclusively found in 
neurons195. 
Differences in subcellular localization of PLC isozymes may also provide perspective 
with respect to diversity in individual functions of different isozyme families. Upon 
activation, every PLC isozyme generates two products, IP3 and DAG. Conventional dogma 
suggests that cytosolic IP3 leads to increased intracellular calcium levels via receptor binding 
at the endoplasmic reticulum, implying little possibility for downstream selectivity. More 
recently however, the identification of IP3 receptors at other cellular locations232, 233, as well 
as the sequential formation of inositol polyphosphates within the cytosol 187-189 implies a 
multitude of diversity for mediating numerous discrete downstream signaling events. DAG 
remains in the membrane and activates conventional and novel PKC isoforms. Activation of 
localized signaling complexes that includes a receptor, a PLC isozyme and an associated 
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PKC isozyme could also produce a mechanism for selective downstream signaling. Very 
recently, a signaling complex including EGF receptor, PLCγ1, and PKCε has been reported, 
providing direct evidence for such a hypothesis234. Therefore, differences in subcellular 
localization are likely a key component for selectivity between isozyme-dependent 
downstream signaling pathways, a hypothesis supported by sequence variability in PLC PH 
domains, which are thought to mediate membrane binding as well as protein-protein 
interactions. The cellular localization of most PLCs has typically been reported to be 
primarily cytosolic in the resting state, and following receptor activation, they are then 
transiently recruited to the cell membrane via isozyme specific interactions of their PH 
domains with lipid membranes206, 235. For example, in wild-type Caco-2 cells PLCγ1 is 
almost exclusively recovered in the cytosolic fraction; however, following EGF treatment 
and PLC activation, PLCγ1 is instead found entirely within the membrane fraction236. PLCγ 
also contains SH3 domains that bind proline-rich motifs on proteins; interestingly, ZO 
proteins contain proline-rich sequences that could bind and localize PLCγ to the tight 
junction. Although no reports exist that specifically colocalize PLCγ with junctional 
complexes, these isozymes have long been reported to colocalize with cortical actin 
filaments207, 237, which line the cell periphery and link the cytoskeleton directly to the tight 
junction and neighboring cells. Recent studies further establish PLCγ interaction with cortical 
actin by demonstrating an SH2 mediated binding with the actin regulatory protein villin238, 
239, a protein expressed exclusively in epithelial tissues, including the intestine. 
Evidence is emerging that PLCβ isozymes may be co-localized to the membrane with 
other signaling components. Most PLCβ isoforms are strongly associated with the 
membrane/particulate fraction, which is interesting since these enzymes bind phospholipids 
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weakly in vitro; therefore, other proteins204 and/or the cytoskeleton240 may organize these 
isozymes with other signaling proteins at the membrane. For example, recent reports suggest 
that scaffolding proteins containing PDZ domains play a significant role in the regulation of 
mammalian PLCβ isozymes. PDZ-containing proteins mediate the clustering of receptors and 
signaling molecules and thereby regulate agonist-induced signal transduction in polarized 
cells241. Interestingly, PDZ domains are found in ZO proteins of the tight junction, and a 
recent study has reported binding of PLCβ3 to ZO-1 in rat fibroblasts209, providing direct 
evidence that PLCβ isozymes may be localized to junctional complexes. Consistent with this 
recent report, another reported component of PLCβ signaling, Gα12, is co-localized with the 
tight junction in Caco-2 and MDCK cells242, providing evidence for the likely presence of 
PLCβ signaling complexes localized in the vicinity of tight junctions. 
An abundance of evidence has also clearly demonstrated localization of PLCβ 
isozymes to the nucleus, likely mediated via a nuclear localization signal sequence in their 
unique carboxy terminal extension208, where they play a key role in cell proliferation and 
differentiation243-246; their presence at the nuclear membrane indicates diverse roles for these 
isozymes that may be mediated by differential regulation, as there is no evidence that G-
protein subunits that regulate these isozymes at the cell membrane are expressed in the 
nuclear compartment. The role of PLCβ isozymes in nuclear signaling has been recently 
reviewed247, 248. While all four members of the PLCβ family have been localized both inside 
and outside the nucleus, the subcellular localization of PLCδ isozymes appears to be more 
specific. PLCδ4 is thought to be primarily nuclear249, while PLCδ1 and PLCδ3 possess and 
nuclear export sequence within the EF-hand domain, implying they may shuttle between the 
nucleus and cytoplasm. Further, PLCδ1 has been reported to be mostly cytoplasmic, while 
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PLCδ3 is found in membrane fractions250-253. Although neither PLCγ isozyme contain a 
known nuclear signal sequence, they too have been reported to be localized to nuclei of 
certain cell types243. 
3. Differential and Overlapping Regulation of PLC Isozymes 
The major differences in the core domain structure of PLC isozyme families are 
primarily reflected in their modes of regulation. A complete picture of how each isozyme 
family is controlled and regulated is far from complete; recent evidence has begun to emerge 
suggesting a higher level of regulation than previously believed, including cross-talk and 
regulation between distinct PLC isozyme families196. 
PLCβ isozymes are regulated via G-protein coupled receptors (GPCR) of the Gq 
family. Upon occupation of GPCR by an agonist, the α-subunit of the heterotrimeric G-
protein exchanges GDP for GTP and dissociates from the βγ-dimer. The α-subunit, and for 
some isozymes the Gβγ dimer, selectively activate PLCβ isozymes without any effect on 
others, such as PLCγ254, 255. PLCβs contain a unique, highly basic CT domain which 
promotes membrane association and is required for activation by Gα subunits210. 
Interestingly, this family of PLCs may contribute to self-regulation of its activation via 
“feedback deactivation” of GPCRs. PLCβs associate with Gαq and function as GTPases 
themselves256, thus controlling the amplitude and duration of their own signaling. 
PLCγ isozymes are regulated through RTKs via binding of hormones such as EGF to 
their corresponding receptors257. Agonist binding leads to dimerization of receptor subunits, 
stimulation of intrinsic tyrosine kinase activity of the receptor, and phosphorylation of 
specific tyrosine residues that serve as high affinity binding sites for src homology 2 (SH2) 
domains of many effector molecules, including PLCγ isozymes. The association of PLCγ 
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isozymes with the activated receptor results in phosphorylation of specific tyrosine residues 
on the lipase itself258, leading to activation of PLCγ and subsequent substrate hydrolysis. 
Conceivably, both the phosphorylation and the physical association to the activated receptors 
are required to target PLCγ isozymes to the membrane198. The complete activation of these 
isozymes require phosphatidylinositol 3,4,5-triphosphate (PIP3) which contributes to 
membrane binding of PLCγ via its PH domain. Interestingly, PLCγ isozymes also appear to 
be directly activated by phosphatidic acid259, 260 a product formed from DAG as a result of 
DAG kinase activity, as well as unsaturated fatty acids such as arachidonic acid261. 
PLCε is uniquely regulated by Gα12/13 or Gβγ subunits of heterotrimeric G-proteins as 
well as by both Ras and Rho GTPases262-265. These findings have increased the awareness of 
potential cross talk between PLC isozymes mediated by heterotrimeric and small monomeric 
GTPase signaling pathways within the cell211. Additionally, stimulation of cells with EGF, 
which increases cellular concentration of GTP-Ras, induces translocation of PLCε from the 
cytosol to the cell membrane264, and presumably stimulates its activity. Thus, receptor 
stimulated PLC activity may include activation of multiple downstream PLCs in discrete 
patterns leading to defined physiological responses via specific downstream effector proteins. 
Regulation of other PLCs is not as well studied. A much higher sensitivity of PLCδ 
isozymes to intracellular calcium concentrations suggests that their activation may occur 
indirectly via increases in intracellular calcium, and they may therefore serve to prolong 
receptor initiated PLC signaling198, 250, 266, 267. In addition, α1-adernergic and oxytocin 
receptors appear to regulate PLCδ1 activity via a GTP binding protein, known as high 
molecular weight G protein (Gh), which was found to form a complex with PLCδ1268. Sperm 
specific PLCζ has also been recognized as highly sensitive to calcium concentrations, and 
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plays a crucial role during fertilization; the third EF hand of this isozyme appears responsible 
for its high sensitivity to calcium (i.e. resting cell concentrations are sufficient for 
activation)230, 269. Injection of this isozyme into the oocyte by sperm initiates calcium 
oscillations that serve as the trigger for initiation of embryonic development230, 231. The most 
recently identified PLCη isozymes are thought to be neuronal specific and serve an important 
role in postnatal brain development195. They have also been recognized as highly sensitive to 
calcium concentrations270, although co-expression of PLCη2 with Gβγ leads to increased 
activity in vitro, implicating GPCRs in the regulation of PLCη as well271; a hypothesis that is 
consistent with the existence of a CT domain in these isozymes, which is thought to be the 
domain responsible for Gβγ-mediated regulation of PLCβ isozymes. Cleary, diverse and 
overlapping regulatory mechanisms provide the potential for diversification in function, as 
well as opportunity for crosstalk, among thirteen PLC isozymes with the same limited set of 
endogenous substrates. 
4. Cellular and Physiological Functions of PLC Isozymes 
Due to the lack of specific chemical inhibitors for the numerous PLC isozymes, 
studies in transgenic mice have provided the most convincing evidence surrounding the 
physiological functions of PLCs. A number of PLCβ1 knockout mice models have been 
reported213, 272-274, each of which has highlighted the importance of this isozyme in the 
maintenance and development of signaling pathways in the cerebral cortex and hippocampus 
via muscarinic and glutamate receptor signaling pathways, with reported phenotypes 
consistent with behavioral abnormalities observed in schizophrenia. Interestingly, mutation 
of this isozyme in mouse sperm reduced both fertilization and embryonic development rate, 
implicating PLCβ1 in reproductive events as well275. Although PLCβ2 is highly expressed in 
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hematopoietic cells, knockout of this isozyme had no impact on hematopoiesis; however, 
studies have demonstrated that PLCβ2 may be important in chemoattractant-induced signal 
transduction responses276. Knockout of the gene coding for PLCβ3, a widely expressed 
isozyme, produced an embryonic lethal on day 2 in which the blastocoel failed to develop277, 
although a second study reporting PLCβ3 deficiency did not lead to embryonic lethality216. 
Instead, these mice demonstrated altered sensitivity to opioids such as morphine, implicating 
these isozymes in opioid mediated responses in the brain, similar to reported effects in one 
study with PLCβ1 deficient mice278. Such dramatic differences in phenotype between these 
two PLCβ3 knockout mice may be related to the differences in constructs used between the 
two studies, i.e. Wang et al. deleted exons 11-17 of the PLCβ3 gene, while Xie et al. only 
partially deleted one exon; this discrepancy needs further evaluation. Similar to knockout of 
PLCβ1, disruption of the gene for PLCβ4 leads to disruption of inhibitory pathways in the 
brain, particularly in the cerebellum, leading to ataxia and severe visual deficiencies213, 223, 
279, consistent with its reported expression in the retina. The extensive body of literature 
regarding knockout studies for PLCβ isozymes implies a critical role for this family in the 
developing brain. 
Knockout of PLCγ1 in mice leads to embryonic lethality by day 9, demonstrating an 
absolute requirement for this isozyme in embryonic development280, in agreement with its 
reported ubiquitous expression197, 212. Consistent with reports that PLCγ2 expression is 
largely restricted to cells of hematopoietic lineage, knockout of this isozyme does not lead to 
embryonic lethality, but rather developmental abnormalities in B cells leading to severe 
immunodeficiency and platelet disfunction226, 281. Specific knockout of PLCδ1 led to 
significant abnormalities in the skin, including progressive hair loss, epidermal hyperplasia, 
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and cyst development, suggesting an important role for this isozyme in epithelial tissue282, 283. 
Combined knockout of PLCδ1 and PLCδ3 was embryonic lethal at day eleven with abnormal 
proliferation and apoptosis of trophoblasts284. Disruption of PLCδ4 indicated roles in calcium 
oscillations in sperm285 as well as in liver regeneration after partial hepatectomy286. 
Consistent with the high reported expression of PLCε in the heart, disruption of this isozyme 
in mice leads to significant abnormalities in cardiac function, specifically related to β-
adrenergic287 and EGF receptor288 stimulation. Interestingly, no mouse knockout models of 
PLC isozymes have reported significant intestinal malfunctions that may implicate these 
isozymes in the regulation of barrier function in this organ, although no investigators have 
specifically assessed changes to any phenotypes related to epithelial barrier function in the 
gut in any of these knockout studies. 
More recent studies in cellular knockdown models using antisense oligonucleotides or 
RNA interference (RNAi) techniques have provided more discrete and specific functional 
detail on the cellular roles of individual isozymes. Early studies with inducible antisense 
oligonucleotides targeting entire PLCβ, PLCγ, or PLCδ isozyme families in rat hepatocytes 
demonstrated differences in the roles of each isozyme family in cell proliferation (i.e. γ > δ > 
β)289. An abundance of additional studies over the last ten years have supported an essential 
role for PLCγ1 in facilitating cell proliferation, adhesion, migration, and motility, in many 
cases via interactions with actin and its binding partners236, 239, 290-294, and consistent with the 
embryonic lethality observed in knockout mice280. Interestingly, knockdown of PLCε in an 
epithelial breast cell line also abrogated cell spreading via Ras dependent mechanisms295 
supporting the hypothesized cross-talk between the regulation of PLCγ and PLCε isozymes 
264. Specific knockdown of PLCζ supports its proposed role as the physiological trigger of 
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calcium oscillations required for the activation of early embryonic development296. Recently, 
RNAi mediated depletion of PLCβ3 in rat fibroblasts revealed a novel function for this class 
of isozymes in cell-cell communication via gap junctions209; thus, knockdown of this 
isozyme abrogated GPCR stimulated closure of gap junctions. It is likely that the continued 
application of genetic knockdown techniques in cell lines derived from various tissues will 
continue to reveal novel and complex functions of each PLC isozyme in different organs. 
5. Role of PLC in the Regulation of Tight Junction Barrier Function 
The PLC-dependent pathway has long been postulated as a regulatory pathway 
involved in the regulation of cellular junctional complexes297-299. Evidence in the literature 
implicates this well known signal transduction cascade in the assembly and biogenesis of 
tight junctions. For example, inhibition of the PLC-dependent pathway attenuates the 
assembly of tight junctions in MDCK cells300, 301, while activation of PLC by thyrotropin-1 
releasing hormone stimulates its assembly in the same cell line297. Activation of the 
downstream effector PKC with 1,2-dioctanoylglycerol, an analog of DAG, also stimulates 
tight junction assembly, while inhibition of this enzyme prevents the assembly297. 
Furthermore, lowering intracellular calcium levels inhibits the assembly of the tight 
junction302. Developmental studies also suggest a role for PLC in the assembly of junctional 
complexes; knockout of both PLCβ3 and PLCγ in mice produces an embryonic lethal mutant 
where development is severely disorganized277, 280. In drosophila, PLCγ is expressed 
predominately in the blastoderm cell303, and lack of this PLC isozyme causes a 
developmental disorder known as small wing304. In general, tight junction formation is 
essential for early embryonic development305, and PLC may play a crucial role in 
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development processes, a hypothesis supported by the numerous developmental defects 
observed in the various knockout mice that have been generated for different PLC isozymes. 
The majority of literature that supports a role for PLC in the regulation of established 
tight junction barrier function is indirect, and often based on modulation of downstream 
effectors of PLCs, i.e. IP3 and ensuing changes to intracellular calcium levels, as well as 
DAG and subsequent activation of PKC isozymes. For example, increased intracellular 
calcium activates the calmodulin-dependent kinase. Both PKC and the calmodulin-dependent 
kinase phosphorylate and alter myosin light chain kinase activity, which subsequently 
phosphorylates myosin light chain and induces contraction of the actin myosin ring, a 
mechanism previously postulated to alter tight junction permeability172, 306. The increase in 
tight junction permeability caused by medium chain fatty acids, such as capric and lauric 
acid, has been attributed to this mechanism, as chelation of cytosolic calcium and inhibition 
of myosin light chain kinase attenuated the observed increase in tight junction permeability 
caused by these two fatty acids298. However, there is conflicting evidence with respect to the 
effect of increased intracellular calcium levels on the tight junction barrier. For example, 
although treatment of T84 cells with the calcium ionophore, A23187, increased the 
permeability of mannitol across the monolayer307, treatment of MDCK cells with the calcium 
ionophore, ionomycin, had no   effect on the permeability of mannitol308. Interestingly 
though, when PKC activators were added to MDCK cells in combination with ionomycin, 
mannitol permeability was significantly increased, implicating a synergistic effect of both 
increased calcium and activated PKC, both the end result of PLC activation, on the 
permeability of tight junctions in MDCK cells. In support of a role for downstream effectors 
of PLC on tight junction barrier function, the type 3 IP3 receptor, generally believed to be 
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localized specifically to the endoplasmic reticulum, has recently been localized to tight 
junctions in polarized MDCK cells, directly implicating IP3, an end product of PLC substrate 
hydrolysis, in tight junction function232, 233. 
The role of PKC in the regulation of tight junction function also seems somewhat 
controversial. Experimental evidence suggests that activated PKC isozymes promote the 
assembly of tight junctions. For example, PKC-specific inhibitors calphostin C177 and 
GF109203X178 prevent TJ formation, while PKC agonists such as 1,2-dioctanoylglycerol and 
phorbol-12-myristate-13-acetate (PMA) induce the formation of tight junction fibrils in 
MDCK cells maintained in low calcium media178, 309. On the other hand, a number of studies 
have suggested that activated PKCs actually impair barrier function, consistent with the 
effects of increased calcium. Prolonged treatment of epithelial cells with PMA results in 
breakdown of the barrier, which can be blocked by the overexpression of kinase-inactive 
mutants of PKCα310. A number of biologically active agents like clostridium difficile toxin 
A311, thrombin312, and tumor necrosis factor-α313 also seem to impair barrier function via 
PKC dependent pathways. Thus, various PKC inhibitors are reported to both impair tight 
junction assembly and function177, 178, 297 as well as to promote tight junction assembly and 
function174. More recent studies have begun to clarify this apparent contradiction. There are 
at least eleven PKC isozymes differing in structure, substrate requirement, and cellular 
localization that are involved in the regulation of numerous cellular functions. PKCs are 
divided into three subfamilies: (i) conventional PKCs (α, βI, βII, γ) which are calcium 
dependent and activated by both phosphatidylserine and diacylglycerol, (ii) novel PKCs (δ, ε, 
η, θ) which are activated by both phosphatidylserine and diacylglycerol, but are not 
dependent on calcium, and (iii) atypical PKCs (ζ, λ, PRK for PKC-related kinases), which 
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are insensitive to both co-factors. Recent evidence suggests that the assembly of tight 
junctions is regulated by opposing actions of novel and conventional PKC isoforms314. 
Conventional PKC isoforms seem to downregulate tight junction assembly and maintenance, 
whereas novel PKC isoforms seem to support tight junction assembly and maintenance. 
Another recent report is in full agreement with these findings, as the novel PKCθ isozyme 
was found to be crucial for the maintenance of a functional tight junction barrier in Caco-2 
cells315. Compelling experimental evidence suggests that atypical PKCs may also directly 
regulate TJ assembly by binding to the proteins PAR3 and PAR6316, which regulate late 
stages of tight junction biogenesis317. However, since atypical PKCs are not directly activated 
by diacylglycerols, it is less likely that they are downstream effectors of PLC action. 
Upstream regulators of PLC activity have also been reported to have effects on tight 
junction barrier function. As described previously, the activity of PLCβ and PLCγ isozymes 
are regulated upstream via GPCRs and RTKs, respectively. A number of studies have 
demonstrated changes to the barrier function of tight junctions in response to a number of 
known agonists of these receptors. For example, treatment of cells with PDGF154, EGF155, 
and vascular endothelial growth factor (VEGF)318-320 have all been shown to modulate tight 
junction proteins and barrier function. Each of these growth hormones are endogenous 
agonists of their respective RTKs, i.e. PDGFR, EGFR, and VEGFR, each of which have been 
previously reported to be coupled to PLCγ isozymes321-324. A recent study has revealed that 
EGFR, PLCγ1, and PKCε may form the basis for a signaling complex at the plasma 
membrane234, consistent with the reported effects of these two effector proteins, both 
upstream and downstream of PLCγ, on tight junction permeability. Another recent study 
found that PKCε phosphorylation of the cytoplasmic tail of claudin-4 was associated 
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increased paracellular permeabililty in ovarian cancer cells179, providing an indirect link 
between PLCγ1 and claudin-4 at junctional complexes. In addition to growth factor 
stimulated changes to tight junction function, another study reported that nucleotides, ATP 
and ADP, substrates of P2Y GPCRs that couple to PLCβ isozymes 325, 326, increase the 
paracellular permeability of excised rat intestine, indirectly implicating PLCβ signal 
transduction in the regulation of tight junction permeability152. Interestingly, two recent 
studies have directly implicated PIP2, the preferred substrate of PLC isozymes, in regulation 
of cell-cell junctions209, 327. A role for PIP2 itself in mediating regulatory signal transduction 
within the cell has begun to emerge and is a rapidly growing area of research. This lipid 
target of PLCs has been shown to be important in actin filament assembly and remodeling, 
including the uncapping of barbed ends and the severing and bundling of filaments328, 329, as 
well as in the regulation of a number of ion channels330-332. Clearly, indirect experimental 
evidence over the last fifteen years suggests a role for PLC signaling in the regulation of both 
the assembly and maintenance of the barrier function of both endothelial and epithelial tight 
junctions. 
Recently, more direct evidence has emerged supporting a role for PLC isozymes in 
regulation of tight junction barrier function333, 334. These studies demonstrated that the 
potency of previously reported PLC inhibitors, i.e. alkylphosphocholines335, 336, U73122337, 
and 3-nitrocoumarin338, is strongly correlated to their potency as paracellular permeability 
enhancers in MDCK cells, implicating inhibition of PLC as a mechanism for increasing 
paracellular permeability. Significant alterations to the actin cytoskeleton were observed 
following specific inhibition of PLCβ by alkylphosphocholines and U73122334. On the other 
hand, increases in the phosphorylation of ZO-1, ZO-2, and occludin were observed 
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concomitantly with increased tight junction permeability following specific inhibition of 
PLCγ by 3-nitrocoumarin333. Significantly, the increase in ZO-2 phosphorylation could be 
reversed, along with an attenuation of the increase in tight junction permeability, by pre-
treating cells with the general serine/threonine kinase inhibitor staurosporine, suggesting a 
potential cause-effect relationship between ZO-2 phosphorylation and changes in tight 
junction function. These results implicate discrete downstream signaling events associated 
with selective inhibition of different PLC isozyme families, and more importantly, provide 
direct evidence for a role for these signaling enzymes in the regulation of epithelial tight 
junction barrier function. 
E. Application to Drug Delivery 
While the intestinal epithelium provides a protective barrier to the entry of intestinal 
pathogens, it also regulates and restricts the absorption of orally administered drugs and 
macromolecules. The ability to dose therapeutics orally confers a number of advantages 
when compared to alternative routes, such as parenteral administration. These advantages 
include easier administration and the avoidance of pain and discomfort associated with 
injectable formulations (which typically leads to increased patient compliance), prevention of 
possible infections due to reuse of needles, as well as less complicated and less expensive 
development strategies for pharmaceutical companies due to the lack of necessary sterile 
formulations.  
For a hydrophilic drug or macromolecule that is not recognized by a carrier, oral 
absorption is poor because the drug cannot partition into the hydrophobic membrane and 
traverse the epithelial barrier via the transcellular pathway, and transport via the paracellular 
pathway is severely restricted by the very low surface area available for transport, as well as 
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the presence of tight junctions (Figure 1.1, page 4)). For example, the broad spectrum 
antibiotic cefoxitin and the antiviral zanamivir, both hydrophilic drug molecules, have oral 
bioavailabilities less than 5%, precluding their use in conventional oral formulations and 
limiting their clinical utility. Strategies to develop oral formulations for hydrophilic drug 
candidates typically include chemical modifications that provide increased lipophilicity to 
promote increased transcellular permeation, or that provide increased affinity for transporters 
to promote carrier mediated absorption (i.e. prodrugs). Unfortunately, structural changes 
often lead to reduced potency towards the intended pharmacological target, necessitating 
complete release of the prodrug moiety from the parent drug, and complicating drug design 
and the drug development process. Furthermore, this strategy is not typically useful for 
macromolecules such as insulin, heparin, or salmon calcitonin, as their polar surface area is 
simply too large to mask with a small chemical modification. An alternative approach to 
improve the oral absorption of hydrophilic drugs is to transiently alter the physical barrier 
imposed by the intestine, through controlled and reversible opening of tight junctions. This 
approach has a distinct advantage over the development of prodrugs, as it would be 
universally applicable to all hydrophilic drugs and macromolecules; however, it has generally 
been met with significant resistance in the pharmaceutical industry. A major concern stems 
from the fact that many intestinal pathological disorders are characterized by leaky epithelia, 
including inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis339, as 
well as intestinal cancers340; therefore, there is a general fear that tight junction modulation is 
an approach to increase paracellular permeability that may lead to pathological outcomes, 
and therefore, should not be considered as a pharmacological approach. This fear is partly 
substantiated by the fact that a number of bacterial enterotoxins have considerable effects on 
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tight junction function. For example, clostridium perfringens enterotoxin (CPE)341 and zonula 
occludens toxin (ZOT)342 cause food poisoning and diarrhea in humans, effects thought to be 
mediated by their specific modulation of tight junctions343, 344. Interestingly however, specific 
amino acid sequences of these two toxins have been shown to be responsible for the observed 
effects on tight junction function (i.e. c-CPE and ΔG respectively), and when administered as 
small peptides, lack the observed toxicity associated with each enterotoxin, suggesting that 
tight junctions can be modulated without significant adverse events. Currently, these two 
peptides represent the most promising PPEs identified to date345, 346. A second major concern 
regarding the use of PPEs in humans stems from a general lack of understanding about how 
mature epithelial tight junctions are formed and regulated; however, in recent years, 
significant advancement in our understanding of how the tight junction is organized and 
regulated physiologically have made this approach to increasing oral absorption an 
achievable reality, and have begun to ameliorate these safety concerns. 
Unfortunately, there has not yet been a safe and effective PPE approved for clinical 
use in humans in the United States. Many of the known PPEs have been found to lack 
selectivity, i.e. there is little separation between their potency as permeability enhancers and 
their potency to cause local intestinal toxicity, suggesting that their enhancement effect may 
be the result of erosion of the intestinal epithelium. The PPEs with these characteristics are 
typically amphiphilic, and their physicochemical properties suggest a propensity to 
accumulate in cell membranes, a characteristic that likely contributes to the lack of separation 
between efficacy and toxicity (Liu et al., 1999). Bile acids347, fatty acids298, acylcarnitines348, 
alkylphosphocholines334, and glyceride analogs349 all fall into this category of PPEs. Most of 
these molecules were identified empirically, and their discovery was not necessarily based on 
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a strategy of rationale drug design, likely due to a lack of validated targets known to regulate 
tight junction function. Recent advances surrounding the biochemistry and physiology of 
junctional complexes have led to renewed interest in these complex subcellular structures, 
and continued research in this area should soon provide a number of pharmacological targets 
to realize the potential for transient and reversible opening of intestinal tight junctions to 
allow increased absorption of orally administered therapeutics. 
F. Rationale for Proposed Research 
The underlying molecular mechanisms regulating the barrier function of epithelial 
tight junctions and paracellular permeability are poorly understood. There exists an 
abundance of literature over the past fifteen years implicating PLC signal transduction as a 
potential component of the regulatory mechanisms governing both the assembly and 
maintenance of tight junction function; however, it is unclear which of the identified thirteen 
PLC isozymes, if any, are important. The majority of evidence supporting a hypothesis for 
PLC involvement has been developed indirectly by modulating upstream receptors and/or 
downstream effectors of these signaling molecules. Further, conflicting evidence exists with 
respect to how PLCs may be involved in regulating cell-cell junctions, i.e. some studies 
suggest that increased activity leads to tight junction modulation, while others imply that 
inhibition of activity alters tight junction function. It may be that different PLC families 
function in concert but with opposing function, akin to the recently proposed action of 
PKCs314, i.e. one family supports assembly of tight junctions while another supports 
disassembly. Nonetheless, additional studies are clearly necessary to further understand the 
importance of PLC in epithelial tight junction regulation.  
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The overall goal of this research was to develop a clearer understanding of the 
molecular mechanisms involved in the regulation of intestinal epithelial tight junctions via 
the PLC catalyzed signal transduction cascade. The proposed research was intended to test 
the following hypothesis: 
Phospholipase C isozymes are involved in the regulation of intestinal epithelial 
paracellular permeability. Inhibition of phospholipase C activity causes an increase in 
paracellular permeability across epithelial tissues via specific modulation of the tight 
junction. 
As little information has been reported with respect to the expression of PLCs in the 
human small intestine, studies were designed in the first aim of this research to address this 
deficiency by evaluating the longitudinal mRNA expression of PLCs in this organ. 
Additional studies were designed to establish a relationship between the catalytic activity of 
PLC and the specific function of intestinal tight junctions by using a well established in vitro 
model for the human intestine, Caco-2 cells. Initially, the expression of PLCs in these cells 
was compared to that in the human small intestine, with the goal of establishing this cell line 
as an appropriate model in which to study the proposed hypothesis. Following this 
assessment, the potency of a homologous series of alkylphosphocholines (APCs) as well as 
U73122, drug molecules previously utilized to implicate PLC in tight junction function in 
MDCK cells, to both inhibit PLC activity and increase paracellular permeability was 
evaluated. The purpose of these studies and intended contribution to the literature was to 
provide direct evidence for a role for PLC in tight junction regulation in the human intestine. 
The rationale for these initial studies was based on recent reports in MDCK cells 
demonstrating a strong relationship between PLC activity and tight junction function using a 
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number of previously reported chemical inhibitors of these isozymes (i.e. APCs and 
U73122). There exists some evidence in the literature suggesting that these purported 
specific inhibitors may exert off-target effects on cultured cells, raising some concern with 
regard to the observed relationship between PLC inhibition and tight junction function. 
Therefore, a second aim of this research was to evaluate the direct interaction of these 
reported inhibitors with specific PLC isozymes in a simple, cell-free system. The purpose of 
these studies was two fold: (1) to confirm that these inhibitors inhibit the catalytic activity of 
PLC, and (2) to obtain a clear understanding of their interaction with PLC at the molecular 
level. These studies would clarify previous reports that have questioned the specificity of 
these compounds towards PLC, and build evidence to support a hypothesis for inhibition of 
PLC activity as a molecular mechanism to increase epithelial paracellular permeability. 
In recent years, the advent of techniques such as RNAi have provided the opportunity 
to more directly assess the functions of cellular proteins with diminished concerns for the 
potential lack of specificity of small drug molecules. The use of a genetic knockdown 
approach was critical for assessing the existence of a direct cause-effect relationship between 
PLC inhibition and increased paracellular permeability. Therefore, the final aim of this 
research was to suppress the expression and activity of individual PLC isozymes alone and in 
combination using RNAi, and to assess the impact of this suppression on the barrier function 
of tight junctions. Studies were designed to independently assess the effect of knockdown on 
both the assembly of tight junctions, as well as on the barrier function of already formed tight 
junctions. This approach allowed a more direct analysis of the role specific PLC isozymes 
play in the regulation of epithelial tight junction function. 
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The overall goal of this dissertation research was to test the hypothesis that a direct 
cause-effect relationship exists between the inhibition of PLC activity and increased 
paracellular permeability via specific modulation of epithelial tight junctions. This goal is of 
considerable interest, as PLC isozymes have been postulated for many years as potential 
regulatory enzymes controlling numerous cellular functions, including tight junction 
function297-299, 333, 334, 350; however, convincing evidence to support such a role for any PLC 
isozyme has yet to be established unequivocally. 
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CHAPTER 2 
 
 
 
 
Phospholipase C Inhibitors U73122 and Alkylphosphocholines Increase Paracellular 
Permeability in a Human Intestinal Epithelial Cell Line 
 
ABSTRACT 
Phospholipase C (PLC) isozymes comprise a large family of key cell signaling proteins that 
hydrolyze inositol containing phospholipids to form two intracellular second messengers, 
diacylglycerol (DAG) and inositol triphosphate (IP3). Recently, PLCβ isozymes have been 
implicated in the regulation of epithelial paracellular permeability in Madin-Darby canine 
kidney (MDCK) cells, identifying these enzymes as potential pharmacological targets for 
increasing the permeability of hydrophilic drugs and macromolecules across epithelial cell 
monolayers, such as those in the small intestine. The specific expression pattern of these 
enzymes in human intestine and their role in regulating cellular signaling processes in this 
organ however, remain largely undefined. The purpose of this study was to evaluate the gene 
expression of phospholipase C isozymes in Caco-2 cells, an in vitro cellular model for the 
human intestinal epithelium, and to compare the expression levels in this cell model to those 
observed in the human gastrointestinal (GI) tract. Further, studies intended to specifically 
implicate PLCβ isozymes in the regulation of human intestinal paracellular permeability 
were performed. mRNA was detected for six different PLCs in Caco-2 cells, including 
PLCβ1, β3, δ3, ε, γ1, and γ2. Western blots confirmed expression of PLCβ1, β3, γ1, and γ2 
proteins in Caco-2 cells, but not of δ3 and ε. Transcripts for all six of these PLCs were 
detected in all regions of the human small intestine. Interestingly, mRNA levels were as 
much as 100-fold lower along the small intestine relative to Caco-2 cells. The potency of a 
series of homologous alkylphosphocholines (APCs) to inhibit PLCβ activity varied forty five 
fold and correlated significantly with potency to enhance paracellular permeability across 
Caco-2 cells, suggesting that inhibition of PLCβ activity is associated with increased 
paracellular permeability in epithelial cells. Further, structurally unrelated PLC inhibitor, 
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U73122, also increased paracellular permeability and inhibited PLCβ activity in Caco-2 cells. 
In summary, the data describe the expression pattern of PLC mRNA in human tissues as well 
as in Caco-2 cells, an in vitro cell line derived from human colon, and results suggest that 
Caco-2 cells represent a suitable model with which to evaluate the role of PLC in regulating 
tight junction barrier function in the human intestine. Further, they support the hypothesis 
that inhibition of PLCβ activity leads to increased paracellular permeability. 
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INTRODUCTION 
 Phospholipase C (PLC) enzymes comprise a family of key proteins involved in the 
cellular turnover of inositol containing phospholipids. These enzymes cleave the polar head 
group from membrane lipids such as phosphatidylinositol 4,5-bisphosphate (PIP2) to generate 
inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG), intracellular second messengers 
that mobilize intracellular calcium and activate protein kinase C enzymes, respectively. To 
date, thirteen human PLC isozymes have been identified comprising six distinct and 
differentially regulated families (β1-4, γ1-2, δ1,3-4, ε, η1-2, and ζ)1-3. They vary in molecular 
size from the ~70kDa PLCζ to the much larger ~250kDa PLCε, and share little sequence 
similarity even within isozyme families. PLC enzymes do share a common core domain 
structure which includes the EF domain, C2 domain, and the highly conserved catalytic core 
made up of two regions, commonly referred to as X and Y domains4, 5. Given the high 
conservation of active site residues within all PLCs, it is not surprising that they all act 
predominantly on just two substrates, PIP and PIP2, with some catalytic activity towards PI6; 
therefore, PLC isozymes likely achieve selectivity in their physiological functions by 
differential regulatory mechanisms. PLC signaling has been implicated in a number of 
critical cellular functions such as motility7, migration8, growth and differentiation9, 10, as well 
as in the assembly and regulation of cell-cell junctions11-13. 
 Neighboring epithelial cells are fused to one another via multi-protein junctional 
complexes near the apical membrane, consisting of tight junctions, adherens junctions, and 
desmosomes. The tight junction, the most apical component of junctional complexes, is 
generally considered the major barrier to the passage of ions, solutes, and water through the 
space between adjacent epithelial cells, as it forms a charge and size selective barrier within 
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the paracellular space. In the human intestine, tight junctions function as a component of the 
barrier limiting the access of luminal contents, including orally administered drugs, to the 
systemic circulation. The ability to selectively and reversibly modulate human intestinal tight 
junctions and increase paracellular permeability would have significant implications in the 
pharmaceutical industry, providing the opportunity to develop oral formulations for 
hydrophilic drugs and macromolecules that are typically very poorly absorbed following an 
oral dose. 
A number of recent studies directly link PLC to specific regulatory components of 
junctional complexes, as PLCβ1 or β3 isozymes bind to Par14, calmodulin15, 16, and ZO-117. 
PLCs have also been implicated in the regulation of established epithelial tight junction 
function in Madin-Darby canine kidney (MDCK) cells, as chemical inhibition of PLCβ 
isozymes correlates with increased paracellular permeability, and with alterations to the 
structural integrity of the cortical actin ring18. Extrapolation of the MDCK data to intestinal 
absorption in humans cannot be assumed however, due to the canine kidney origin of MDCK 
cells. Caco-2 cells, a cell line derived directly from the human colon19 and used extensively 
as an in vitro model for the human intestine20-24, are a more appropriate model in which to 
evaluate pharmacologically based paracellular permeability enhancement for the purposes of 
increasing intestinal absorption. Thus, the purpose of the current study was to evaluate the 
gene and protein expression of phospholipase C isozymes (PLCβ1, PLCβ2, PLCβ3, PLCβ4, 
PLCγ1, PLCγ2, PLCδ1, PLCδ3, PLCδ4 and PLCε) in Caco-2 cells in a quantitative fashion, 
and compare the expression levels to those observed along the human gastrointestinal tract, 
as well as in other organs of drug disposition. Further studies were designed to implicate 
PLCβ isozymes in the regulation of human intestinal tight junction permeability by 
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determining the potency of previously reported PLCβ inhibitors, alkylphosphocholines 
(APCs) and U7312218, to inhibit agonist induced PLCβ activity and increase paracellular 
permeability across Caco-2 cell monolayers. 
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MATERIALS AND METHODS 
Materials. Normalized first-strand cDNA preparations, prepared from pooled poly A+ RNA 
from various human tissues, were purchased from BD Clontech (Palo Alto, CA) as a part of 
the Human Digestive System MTC™ panel and Human MTC™ panel I. The tissue sources 
were free of disease and are presented in Table 2.1. PolyATtract® System 1000 for isolation 
of mRNA directly from cells was obtained from Promega (Madison WI). TaqMan® 
universal PCR master mix and high capacity cDNA archive kit were purchased from Applied 
Biosystems (Foster City, CA). Gene specific pre-designed primer/probes sets for individual 
PLC isozymes and endogenous control, actin, were purchased from Ambion (Foster City, 
CA). Antibodies for PLC isozymes and whole cell lysates used as positive controls were 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). APCs with various alkyl chain 
lengths were synthesized previously18. N-2-hydroxyethylpiperazine-N'-2-ethansulfonic acid 
(HEPES), Hank's Balanced Salt Solution (HBSS), and other cell culture reagents were 
obtained from Invitrogen (Carlsbad, CA). Twelve well Transwells™ were obtained from 
Costar (Cambridge, MA). D-[1-14C]-Mannitol (55 mCi/mmol) and [2-3H(N)]-myo-inositol 
(20 Ci/mmol) were obtained from American Radiolabeled Chemicals (St. Louis, MO). AG1-
X8 formate columns and nitrocellulose membranes were obtained from Bio-Rad Laboratories 
(Hercules, CA). All other compounds and reagents were obtained from Sigma (St. Louis, 
MO). 
Cell Culture. The Caco-2 cell line, clone HTB-37, derived from human colorectal carcinoma 
cells19, was obtained from American Type Tissue Culture at passage 20. Cells were cultured 
at 37°C in minimum essential medium, supplemented with 10% FBS, 1% non-essential 
amino acids, 100 U/ml penicillin, 100 μg/ml streptomycin, and 0.25 μg/ml amphotericin B in 
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an atmosphere of 5% CO2 and 90% relative humidity. Cells (passage number 25 to 35) were 
seeded at a density of 60,000 cells/cm2 in twelve well TranswellsTM. Medium was changed 
the day after seeding, and every other day thereafter (apical volume 0.5 ml, basolateral 
volume 1.5 ml). Cells were grown to confluence for at least 21 days during which time they 
differentiated into epithelial cell monolayers as evidenced by the establishment of a stable 
transepithelial electrical resistance (TEER) between 200-500 Ω*cm2. Cells were used 
between 21-27 days after seeding. 
mRNA Isolation and cDNA Synthesis. mRNA was isolated directly from Caco-2 cells 
using the PolyATtract® System 1000 (Promega, Madison, WI) according to the 
manufacturer’s instructions, and was quantified using Quant-iTTM RiboGreen® RNA Assay 
Kit (Molecular Probes, Eugene, OR). First strand cDNA synthesis was performed with the 
High Capacity cDNA Archive Kit (Invitrogen, Carlsbad, CA) using 1 μg mRNA. cDNA was 
quantified using PicoGreen® dsDNA assay kit (Invitrogen, Carlsbad, CA). 
Real-time RT-PCR. Pre-designed and validated gene-specific primers and 5’-(FAM)-
(TAMRA)-3’ labeled TaqMan® probes for PLC isozymes (Assays on Demand) were 
purchased from Ambion (Foster City, CA). Singleplex or multiplex amplification reactions 
were performed using TaqMan® universal PCR master mix on a 7500 RT-PCR System 
(Applied Biosystems). Amplification was performed at 95ºC for ten minutes, followed by 
forty cycles at 95ºC for fifteen seconds, and 60ºC for sixty seconds.  Reactions were run in a 
volume of 50 μl and contained 5 ng of cDNA. To obtain standard plasmid DNA for PLCβ1, 
β3, γ1, γ2, δ3, and ε, a partial cDNA fragment of each gene, incorporating the region of 
primer and probe recognition sequences, was amplified by RT-PCR from Caco-2 cDNA and 
cloned into the pCR®4-TOPO vector (Invitrogen, Carlsbad, CA). Primers designed for these 
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amplifications are presented in Table 2.2. Standard curves were constructed by plotting Ct 
values obtained from real time PCR reactions versus the logarithm of the initial copy 
number. A 5’-VIC labeled TaqMan® probe and primers set for β-actin was used for  
quantification of β-actin gene expression in each sample, and served as an endogenous 
control where noted. Each reaction was measured in quadruplicate and data reported as mean 
± ranges. 
 Absolute quantification of target genes was achieved by calculating copy numbers of 
individual PLC mRNA transcripts. Calibration curves for each target gene were constructed 
by serial dilution of known amounts of standard plasmid DNA, the concentration of which 
was determined using the PicoGreen® dsDNA assay kit (Invitrogen, Carlsbad, CA). Copy 
numbers were calculated from the mass of standard plasmid DNA and molecular weight of 
DNA as follows: 
pairs base ofnumber  pair) nt/base 2  ng/nmol (330
DNA plasmid ngDNA plasmid nmol ••=  (1) 
where 330 ng/nmol is the average molecular weight of one DNA base. 
nmol/mol 10
copies/mol 10 x 02.6DNA plasmid nmol copies ofnumber 9
23
−•=               (2) 
Western Blotting.  Whole cell lysates were collected by washing cultured Caco-2 cells (day 
21-27) three times with PBS+ (supplemented with 1.8 mM calcium chloride), adding 200 μl 
SDS sample buffer at 55°C, and sonicating each lysate briefly. Lysates were stored at -20°C 
until analysis by immunoblot using standard protocols. Primary antibodies were rabbit anti-
PLCγ1 (1:100), rabbit anti-PLCγ2 (1:100), rabbit anti-PLCβ1 (1:100), and rabbit anti-PLCβ3 
(1:500). Secondary antibodies were Alexa Fluor IRDye 700-conjugated donkey anti-rabbit. 
Imaging of Western blots was performed using an Odyssey detector (LI-COR, Lincoln, NE). 
84 
PLCβ activity by cellular assay.  The activity of PLC in Caco-2 cells was determined by an 
adaptation of previously published methods18, 25. Cell media was aspirated from both 
compartments of Transwell™ inserts and replaced with serum-free media containing [3H]-
myo-inositol at 2 μCi/ml (4 μCi/well; 0.5 ml apical, 1.5 ml basolateral of inositol-free media) 
for 12 hours at 37°C. Cell media was aspirated from both compartments of Transwell™ 
inserts, washed twice with HBSS, supplemented with 10 mM HEPES and 25 mM glucose, 
pH 7.1 (transport buffer), and pre-incubated at 37°C for 30 minutes. Integrity of the tight 
junctions was confirmed with the measurement of TEER prior to the experiment. 
Experiments were initiated by replacing the apical media with 0.5 ml of transport buffer 
containing a test compound or vehicle, and the cells were incubated for indicated times at 
37°C. PLC assays were initiated by replacing transport buffer in both compartments with 
transport buffer containing 50 mM LiCl, with or without adenosine triphosphate (ATP) to 
specifically activate PLCβ activity. The cells were incubated at 37°C for 15 minutes to allow 
accumulation of [3H]-inositol phosphates. Incubations were terminated by aspiration of the 
transport buffer from both compartments and addition of 0.5 ml boiling 10 mM EDTA (pH 
8.0) to the apical compartment. Cell lysates were applied to AG1-X8 formate columns for 
chromatographic isolation of [3H]-inositol phosphates 26. The amount of [3H]-inositol 
phosphates was measured by liquid scintillation counting in a Packard Tri Carb 4000 Series 
spectrophotometer. Data from each inhibition experiment were normalized to the response 
observed with 300 μM ATP and were reported as the mean ± standard deviation performed in 
triplicate. The IC50 (PLCβ), defined as the concentration of test compound that causes a 50% 
decrease in ATP-stimulated PLCβ activity (accumulation of [3H]-inositol phosphates), was 
determined. 
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Measurement of paracellular permeability enhancement. TEER and mannitol transport 
across epithelial cell monolayers are indicators of the paracellular permeability of the 
monolayer18, 27, 28. Tight junctions cause a restriction in the ionic flux across cell monolayers, 
giving rise to an electrical potential difference, measured experimentally as electrical 
resistance. Mannitol, a hydrophilic molecule, cannot readily partition into phospholipid 
membranes and diffuse transcellularly through cells, therefore, it must move across cell 
monolayers via the paracellular pathway. A decrease in TEER and an increase in mannitol 
permeability across Caco-2 cell monolayers were used as parameters to measure the efficacy 
of test compounds as paracellular permeability enhancers (PPEs).   
TEER. Cell media was aspirated from both compartments (apical and basolateral) of 
Transwell™ inserts and replaced with transport buffer. Cell monolayers were pre-incubated at 
37°C for 30 minutes and TEER was measured with an EVOM Epithelial Tissue Voltohmeter 
(World Precision Instruments, Sarasota, FL) and an Endohm-12 electrode to confirm the 
integrity of the monolayer. Experiments were initiated by aspirating transport buffer from the 
apical compartment and replacing it with transport buffer (0.5 ml) containing desired test 
compound or vehicle. Cell monolayers were incubated at 37°C and TEER values were 
measured at indicated timepoints. Data from each experiment were normalized to the 
response from the vehicle and were reported as the mean ± standard deviation of three 
experiments performed in triplicate. The effect of a test compound on TEER was evaluated at 
several concentrations, and its EC50 value, defined as the concentration that caused a 50% 
decrease in TEER with respect to the untreated control, was determined18, 27, 28. 
Mannitol permeability. Cell media was aspirated from both compartments of Transwell™ 
inserts and replaced with transport buffer. Cell monolayers were pre-incubated at 37°C for 
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thirty minutes, and tight junction integrity was confirmed with the measurement of TEER 
prior to the experiment. Transport experiments were initiated by replacing the apical media 
with 0.5 ml of transport buffer containing a test compound or vehicle, and [14C]-mannitol at 
10 μM. Permeability was monitored by the appearance of [14C]-mannitol in the basolateral 
side (1.5 ml) during two thirty minute intervals according to the following equation: 
sec)/101(sec/)/(1*)/(1*/P 70 cmxnmunitsCAdtdQapp
−==                                 (3) 
where dQ/dt is the amount, Q, of mannitol measured in the basolateral compartment at time 
T. A is the membrane surface area and C0 is the initial concentration of mannitol in the apical 
compartment. The amount of [14C]-mannitol transported was measured by liquid scintillation 
counting in a Packard Tri Carb 4000 Series spectrophotometer. All transport experiments 
were conducted under sink conditions (transport experiments were designed such that less 
than 10% of the total amount of [14C]-mannitol was present on the basolateral side at any 
given time). The permeability of [14C]-mannitol in the presence of a test compound was 
normalized to that in the vehicle-treated cells and was reported as the mean ± standard 
deviation performed in triplicate. The EC10x, defined as the concentration of a test compound 
that causes a  ten fold increase in mannitol permeability with respect to the vehicle-treated 
control18, 27, 28, was determined for each enhancer of paracellular permeability. 
Data analysis. Data are expressed as the mean ± standard deviation from three 
measurements unless indicated otherwise. Where indicated, statistical significance was 
assessed using a two sample Student’s t tests. Samples were assumed to have an unequal 
variance; significant differences were assigned at p < 0.05. For determination of EC50 TEER 
values, the relationship between TEER (% Control) and enhancer concentration was fit to a 
three parameter Hill equation by nonlinear least-squares regression (WinNonlin, version 4.1). 
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Estimates were also generated for the sigmoidicity factor (γ) and Emax. For determination of 
EC10X values, the relationship between mannitol permeability and enhancer concentration 
was fit to a four parameter Hill equation by nonlinear least-squares regression. Estimates 
were generated for the sigmoidicity factor (γ), E0, EC50, and Emax. The model output was used 
to estimate the concentration of each enhancer that caused a ten fold increase in the 
permeability of mannitol. For determination of IC50 PLCβ values, the relationship between 
PLCβ activity (% Inhibition) and enhancer concentration was fit to a four parameter Hill 
equation by nonlinear least-squares regression. Estimates were also generated for the 
sigmoidicity factor (γ), un-stimulated PLC activity (E0), and Emax. Relationships between 
parameters estimating paracellular permeability enhancement and PLCβ activity were 
assessed via linear regression analysis, and the correlation was expressed by the Pearson 
correlation coefficient (r). 
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RESULTS 
PLC expression in Caco-2 cells. 
mRNA for six PLC isozymes was detected in Caco-2 cells (Figure 2.1), including 
PLCβ1, β3, γ1, γ2, δ3, and ε, but not PLCβ2, β4, δ1, and δ4. PLCβ3, γ1, and δ3 levels were 
the highest, followed by PLCβ1 and ε, while PLCγ2 was of the lowest expression. 
Expression at the protein level was established by western blot for PLCβ1, β3, γ1, and γ2; 
however, PLCδ3 and ε were not detected (Fig. 2.2). 
PLC mRNA expression in the gastrointestinal tract and other tissues of drug 
disposition. 
 PLCβ1 and β3 mRNA was detected throughout the gastrointestinal (GI) tract with 
highest expression in the ileum and descending colon (Figure 2.3). PLCβ3 levels were 
comparably high in the duodenum and jejunum as well. On the other hand, ileal PLCβ1 
expression was approximately three and five fold higher than that observed in the jejunum 
and duodenum, respectively. Both of these PLCβ isozymes demonstrate broad tissue 
distribution as evidenced by detection of mRNA in all tissues examined. Expression was 
highest in the pancreas for both isozymes, approximately three and five fold higher than any 
other tissue for β1 and β3 respectively.  Notable levels for PLCβ1 were also detected in 
kidney and brain. 
 PLCγ1 and γ2 mRNA was detected throughout the GI tract, with highest expression 
in the stomach, jejunum, and ileum (Figure 2.3). PLCγ isozymes demonstrate broad tissue 
distribution, as mRNA was detected in all tissues examined. Similar to PLCβ1 and β3, 
PLCγ1 mRNA was highest in the pancreas, approximately four fold higher than any other 
tissue. On the other hand, PLCγ2 mRNA was highest in the kidney and liver, although 
amount in the pancreas was also high compared to other tissues examined. PLCγ1 was also 
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identified in the heart and liver at relatively high levels while PLCγ2 was also highly 
expressed in the lung and placenta. 
PLCδ3 and PLCε mRNA was detected throughout the GI tract with highest 
expression in the colon for both isozymes (Figure 2.3). PLCδ3 mRNA was detected in all 
tissues examined with highest expression in the heart, the only tissue with higher levels than 
the colon. PLCε mRNA was also detected in all tissues examined, with highest expression in 
the pancreas. 
Of the six major PLC isozymes identified at the mRNA level in Caco-2 cells (i.e. 
PLCβ1, β3, δ3, ε, γ1, and γ2), each was also found throughout the human GI tract. Major 
differences were observed between Caco-2 cells and human intestine for all six isozymes, as 
Caco-2 mRNA levels were substantially greater than those observed in the human intestine. 
Differences between Caco-2 cells and in vivo small intestinal tissue (i.e. duodenum, jejunum, 
and ileum) ranged from approximately thirteen fold for PLCγ2 to approximately two hundred 
twenty fold for PLCβ3. This result may be related to the fact that the Caco-2 cell line is 
derived from colon carcinoma, as PLC over-expression has often been associated with cancer 
incidence; however, a direct comparison between expression levels is confounded by the 
original source of mRNA for each sample (isolated mRNA for Caco-2 versus purchased poly 
A+ RNA for tissue sources). 
ATP stimulates PLCβ activity in Caco-2 cells. 
To confirm the presence of functionally active PLCβ isozymes in Caco-2 cells, the 
ability of adenosine triphosphate (ATP) to stimulate PLC activity was evaluated. ATP is a 
known ligand for the purinergic P2Y2 receptor that couples to PLCβ isozymes29, 30. ATP 
increased the accumulation of inositol phosphates in a concentration dependent manner 
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confirming the presence of functionally active PLCβ isozymes in Caco-2 cells (Figure 2.4). 
Maximal activation was approximately three fold, and was achieved with concentrations 
greater than or equal to 300 μM; therefore, this concentration was utilized in studies intended 
to assess chemical inhibition of stimulated PLCβ activity by reported inhibitors, U73122 and 
APCs. 
Hexadecylphosphocholine inhibits ATP-stimulated PLCβ activity in Caco-2 cells. 
 Hexadecylphosphocholine (HPC) (Figure 2.5, C16) has previously been reported as 
an inhibitor of PLC isozymes18, 31, 32. The ability of HPC to inhibit ATP-stimulated PLCβ 
activity was evaluated in Caco-2 cells as a model for the human intestine. As shown in 
Figure 2.6, HPC attenuates ATP-stimulated PLCβ activity in a concentration dependent 
manner when applied apically to Caco-2 cells. The concentration of HPC that inhibited PLCβ 
activity by 50% (IC50 PLCβ) was estimated to be 40 ± 19 μM. 
Hexadecylphosphocholine increases paracellular permeability in Caco-2 cells. 
HPC has been shown to increase paracellular permeability across epithelial cell 
monolayers18, 33. When Caco-2 cell monolayers were treated with HPC at various 
concentrations on the apical side, TEER decreased as a function of time over a 90 minute 
period, indicating an increase in paracellular permeability (Figure 2.7.A). When measured at 
a fixed time, i.e. after 30 minutes, the decrease in resistance and the increase in mannitol 
permeability were dependent on concentration (Figure 2.7.B); the concentration that 
decreased TEER by 50% (EC50 TEER) was estimated to be 248 ± 52 μM, and the concentration 
that increased mannitol permeability ten-fold (EC10X) was estimated to be 317 ± 26 μM 
(Table 2.3). HPC is significantly less potent as an enhancer of tight junction permeability in 
Caco-2 cells as compared to MDCK cells18. 
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Alkylphosphocholines increase tight junction permeability and inhibit ATP-stimulated 
PLCβ activity in Caco-2 cells. 
Previous studies have suggested that the ability of phosphocholine containing 
molecules to increase paracellular permeability is dependent on the length of the alkyl 
chain18, 27, 28, 34. When Caco-2 cell monolayers were treated with APCs varying in alkyl chain 
length from ten to twenty carbons (Figure 2.5) on the apical side for thirty minutes, the 
decrease in resistance and increase in mannitol permeability were dependent on 
concentration for all APCs (Figure 2.8). The concentrations that decreased TEER by 50% 
(EC50 TEER) and increased mannitol permeability by ten fold (EC10X) were dependent on alkyl 
chain length and are presented in Table 2.3. The EC50 TEER and EC10X values were strongly 
correlated (data not shown; r > 0.99, p < 0.001), and varied forty six and thirty two fold 
respectively when the alkyl chain length increased from ten to twenty carbons, with the 
maximum potency occurring with fourteen carbons in the alkyl chain. There was a 
substantial drop in potency between twelve and ten carbons. 
To determine if the ability of APCs to increase paracellular permeability across Caco-
2 cells was associated with their ability to inhibit PLC activity in these cells, the effect of all 
APCs on ATP-stimulated PLCβ activity was assessed. All APCs inhibited ATP-stimulated 
PLCβ activity in a concentration dependent manner (Table 2.3); their potency (IC50 PLCβ) 
varied approximately forty five fold and was dependent on chain length. The relationship 
between potency as PLCβ inhibitors and potency as PPEs is depicted in Figure 2.9. The IC50 
(PLC) is linearly related to both EC50 TEER and EC10x ((r > 0.98, p < 0.001) and (r > 0.97, p < 
0.001) respectively). Interestingly, their potency as PLCβ inhibitors was from five to nine 
fold greater than their potency as PPEs. 
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U73122 inhibits ATP-stimulated PLCβ activity in Caco-2 cells. 
 U73122 (Figure 2.5) is a previously reported inhibitor of PLC activity18, 35-38 that is 
structurally distinct from APCs; therefore, its ability to inhibit ATP-stimulated PLCβ activity 
in Caco-2 cells was evaluated. As shown in Figure 2.10, U73122 attenuates ATP-stimulated 
PLCβ activity in a concentration dependent manner when applied apically to Caco-2 cells. 
The concentration of U73122 that inhibited PLCβ activity by 50% (IC50 PLCβ) was not 
determined, as aqueous solubility limited studies to concentrations ≤ 30 μM. U73343, the 
inactive analog of U73122 (Figure 2.10), had no effect of ATP-stimulated PLC activity at 30 
μM (Figure 2.10). 
U73122 increases paracellular permeability in Caco-2 cells. 
U73122 has been reported to increase paracellular permeability across MDCK cells18. 
When Caco-2 cell monolayers were treated with U73122 at various concentrations on the 
apical side, TEER decreased as a function of time over a ninety minute time period, 
indicating an increase in paracellular permeability (Figure 2.11.A). Importantly, the inactive 
analog, U73343, had no effect on paracellular permeability at any concentrations tested. 
When measured at a fixed time, i.e. after 90 minutes, the decrease in resistance and the 
increase in mannitol permeability were dependent on concentration (Figure 2.11.B). The 
concentration that decreased TEER by 50% (EC50 TEER), and the concentration that increased 
mannitol permeability ten-fold (EC10X) were not determined, as solubility limitations 
precluded treatment greater than 30 μM. Similar to APCs, U73122 is less potent as an 
enhancer of paracellular permeability in Caco-2 cells as compared to MDCK cells18. 
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DISCUSSION 
The PLC-dependent pathway has long been postulated to be a regulatory pathway 
involved in the regulation of cellular junctional complexes11, 13, 39-41. Recently, PLCβ 
isozymes have been directly implicated in the modulation of epithelial paracellular 
permeability in MDCK cells18, suggesting that PLC may play an important role in the 
regulation of mature epithelial tight junctions. Although MDCK cells are a useful model for 
evaluating permeability of drugs across an epithelial monolayer, their canine kidney origin 
makes them less than ideal as a model to investigate regulation of paracellular permeability 
for the purposes of improving the oral absorption of hydrophilic drugs and macromolecules 
in humans. Caco-2 cells, a human intestinal cell line, are a more appropriate model in which 
to evaluate the potential role of PLC in the regulation of human intestinal epithelial tight 
junctions. 
 In the present study, RT-PCR was initially utilized to determine the expression 
pattern of PLC isozymes in Caco-2 cells. As shown in Figure 2.1, six isozymes of PLC were 
detectable at the mRNA level, with at least one member of each isozyme family expressed. 
Western blot analysis confirmed expression at the protein level for PLCβ and γ isozymes 
(Figure 2.2), but not for PLCδ3 and PLCε. High levels of PLCβ1 in Caco-2 cells is notable, 
as most cell lines, including many of colon carcinoma origin, fail to express detectable levels 
of this isozyme2, 42. While the two PLCβ isozymes were quite similar in mRNA expression 
with respect to one another (i.e. approximately two fold difference), mRNA expression for 
PLCγ1 was more than six fold higher than that for PLCγ2, suggesting it is the dominant 
isozyme of this family in Caco-2 cells. 
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In order to establish Caco-2 cells as a suitable model in which to evaluate the PLC-
dependent pathway as a potential regulator of intestinal permeability, it was critical to 
establish that PLC isozymes expressed in Caco-2 cells are also expressed in the human small 
intestine. Therefore, the expression profile of the six PLC isozymes found in Caco-2 cells 
was quantitatively compared to that in the human gastrointestinal tract, as well as in other 
organs of drug disposition. There are few reports in the literature evaluating expression of 
PLCs in any segments of the human small intestine. Because PLC over-expression has often 
been associated with cancer incidence, many studies have evaluated differences in expression 
between carcinomas of gastric or colon tissue and their corresponding healthy tissue42-45.  
These studies have provided evidence for several PLC isozymes in gastrointestinal tissues 
(PLCβ, γ, and δ), although none have reported expression in the small intestine. In the 
present study, RT-PCR data revealed that the human small intestine expresses all six PLC 
isozymes detected in Caco-2 cells, although no distinct expression pattern of these PLC 
isozymes in the small intestine was evident (Figure 2.3).   
After confirmation that functionally active PLCβ isozymes are expressed in Caco-2 
cells (Figure 2.4), the ability of known inhibitors to attenuate ATP-stimulated PLCβ activity 
and increase paracellular permeability was evaluated. Because an entire series of APCs was 
available (with variable alkyl chain lengths and variable reported potency towards PLCβ 18), 
this series of inhibitors was evaluated first (Figure 2.5). A concentration dependent decrease 
in PLCβ activity by HPC was observed; the concentration of HPC that inhibited PLCβ 
activity by 50% (IC50 PLCβ) was estimated to be 40 ± 19 μM (Figure 2.6). Within the series of 
APCs, the ability to inhibit PLCβ activity was dependent on alkyl chain length with a 
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maximum potency occurring with fourteen to sixteen carbons in the alkyl chain (Table 2.3), 
similar to their potency in MDCK cells18. 
After developing an understanding of the ability of APCs to inhibit ATP-stimulated 
PLC activity, their ability to increase paracellular permeability across Caco-2 cells was 
evaluated by monitoring the change in TEER, as well as the change in permeability of the 
paracellular marker, mannitol. A time and concentration dependent drop in TEER was 
observed following treatment of Caco-2 cells with varying concentrations of HPC (Figure 
2.7), consistent with previously reported effects in MDCK cells18 and Caco-2 cells33. 
However, several differences were noted between the two cell lines. The EC50 TEER value was 
substantially greater than in MDCK cells. It was also noted that the kinetics of the observed 
effect appeared to be different in Caco-2 cells than in MDCK cells, as the effect in Caco-2 
cells appeared to have two distinct phases, an immediate effect that resulted in a rapid drop in 
TEER (60% of control within ten minutes), followed by a slower phase that led to complete 
abolishment of TEER after approximately sixty minutes of treatment. Following assessment 
of the effect of HPC on TEER, its ability to increase the permeability of mannitol was 
determined. This value was consistent with effects on TEER, and was also less potent than 
the observed effect in MDCK cells18. 
Following studies with HPC, the effects of the APC series (C10 - C20) on both TEER 
and mannitol permeability were evaluated in Caco-2 cells (Figure 2.8, Table 2.3). Within the 
series, EC50 TEER values were similar to EC10X values, and a strong relationship between these 
two parameters was evident (data not shown); therefore, it was possible to utilize an EC50 
TEER value as a marker for increased paracellular permeability of Caco-2 cells to APCs. Their 
potency as PPEs was dependent on chain length, with C14 being the most potent of the 
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series, followed by C16, C18, C20, C12, and C10. Consistent with the reduced efficacy of 
HPC, EC50 TEER and EC10X values were significantly grater than those in MDCK cells for 
most of the series. Interestingly, the effect of C10 and C12 on paracellular permeability was 
similar between the two cell lines; further, the potency of C12 for increasing paracellular 
permeability across Caco-2 cells was similar to that previously reported27. 
Within the series of APCs, the chain length dependence for inhibition of PLCβ 
activity was identical to that for both decreasing TEER and increasing mannitol permeability; 
thus, a relationship between mannitol permeability and PLCβ inhibition was evident in Caco-
2 cells (Figure 2.9). However, the potency of APCs to inhibit PLCβ was significantly greater 
than their potency to increase paracellular permeability; EC10X values were from five to nine 
fold greater than IC50 PLCβ values, obscuring the relationship between these two parameters. 
For example, the concentrations that inhibit PLCβ activity by 50% (i.e. IC50 PLCβ) have little 
to no effect on mannitol permeability; increases in mannitol permeability are only evident 
when PLCβ activity is completed inhibited. Together, these observations suggest that the 
effects of APCs on the two cell lines may be different, and that different permeability 
enhancement mechanisms may be governing the observed effects of APCs on paracellular 
permeability in Caco-2 cells as compared to MDCK cells. Given the amphiphilic nature of 
this series of compounds, direct interaction with the apical cell membrane leading to changes 
in membrane fluidity and lipid composition is a plausible alternative mechanism of 
paracellular permeability enhancement that has been previously postulated34, 46. Additional 
data support this hypothesis47, as a thirty minute treatment of HPC at concentrations close to 
EC50 TEER caused significant redistribution of a fluorescent paracellular probe molecule from 
an almost exclusively paracellular localization to one suggesting ready access to the cytosol 
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of Caco-2 cells. Therefore, differences in the apical membrane phospholipid composition 
between cells lines could explain the differences in the potency of APCs as PPEs between 
MDCK and Caco-2 cells. More studies are warranted to further evaluate the direct impact 
APCs have on apical membranes of Caco-2 cells at concentrations relevant to their potency 
as both PLC inhibitors and PPEs.  
Consistent with the reduced potency of APCs on paracellular permeability in Caco-2 
cells as compared to MDCK cells, the potency of another reported PLC inhibitor, U73122 
(Figure 2.11), as a PPE was also reduced. After a 30 minute treatment of 30 μM U73122, 
PLCβ activity was inhibited approximately 50% (Figure 2.10) and TEER dropped to 80% of 
control (Figure 2.11); however, after an extended treatment of 90 minutes, TEER continued 
to decline to 40% of control cells. After the same 90 minute treatment, mannitol permeability 
was increased approximately ten fold. The inactive analog of U73122, U73343, was unable 
to inhibit PLCβ activity or increase paracellular permeability across Caco-2 cells at similar 
concentrations, implicating the maleimide moiety in U73122 in the observed effects on both 
PLC inhibition and paracellular permeability. Recent studies have suggested that 
nucleophiles present in any experimental test system can have a direct impact on the 
observed effects of U73122 on cellular phenotypic responses48. Therefore, variable 
expression of accessible nucleophiles between MDCK and Caco-2 cell systems may 
contribute to the observed differences in potency of U73122 as a PLC inhibitor and PPE in 
these studies. Further studies are necessary to confirm this hypothesis. 
 Results generated in this study support a role for PLC isozymes in the regulation of 
epithelial paracellular permeability, although notable differences are apparent between the 
effects of tested PLC inhibitors on both MDCK and Caco-2 cell lines from both chemical 
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classes. Further studies are necessary to confirm the role of PLC isozymes in the regulation 
of epithelial paracellular permeability, and to establish PLC as a viable pharmacological 
target for the purposes of increasing the oral absorption of hydrophilic drugs, nutrients, and 
macromolecules. More specific approaches that could selectively inhibit the expression and 
activity of specific PLC isozymes would be beneficial to assess the role of these signal 
transduction enzymes in regulation of cellular functions such as tight junction barrier 
formation and maintenance of paracellular permeability.  
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Table 2.1. Tissue sources for poly A+ RNA Isolation 
Tissue Source * 
esophagus 39 M/F Caucasians, ages 17-72 
stomach 7 M/F Caucasians, ages 20-55 
duodenum 30 M/F Caucasians, ages 17-75 
jejunum 6 M/F Caucasians, ages 20-57 
ileum 8 M/F Caucasians, ages 18-57 
ileocecum 19 M/F Caucasians, ages 24-58 
cecum 29 M/F Caucasians, ages 18-63 
colon, ascending 5 M/F Caucasians, ages 18-50 
colon, descending 7 M/F Caucasians, ages 31-61 
colon, transverse 19 M/F Caucasians, ages 24-59 
rectum 6 M/F Caucasians, ages 24-52 
liver 4 M/F Caucasians, ages 44-50 
heart 3 M Caucasians, ages 33, 55, and 55 
brain (whole) 2 M Caucasians, ages 43 and 55 
placenta 17 Caucasians, ages 19-33 
lung 2 F Caucasians, ages 24 and 32 
skeletal muscle 8 M/F Caucasians, ages 29-60 
kidney 6 M/F Caucasians, ages 28-52 
pancreas 15 M/F Caucasians, ages 22-69 
 
* Abbreviations: M, male; F, female
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Table 2.2. Primers used to generate standard plasmid DNA for quantification of mRNA in 
human tissues. 
Protein 
Forward Primer 
(base pair position) 
Reverse Primer 
(base pair position) 
Accession # 
hPLCβ1*
5’-atgatcacagtggtgtatgggcct 
(307-330) 
5’-aacagagggatcctcatggcaagt 
(3480-3457) 
NM182734 
hPLCβ3 
5’-ggcgcgggagtaagttcatcaaa 
(68-90) 
5’-ctcaaaggctgcaatgcgaagtga 
(2400-2377) 
NM000932 
hPLCγ1 5’-gggcaccgtcatgactttgttcta 
(214-237) 
5’-tcttgcggtatagcgggtgtttct 
(2369-2346) 
NM002660 
NM182811 
hPLCγ2 5’-tctgaacaaagtccgtgagcggat 
(935-958) 
5’-gcagaaatgccaggtttgggtcat 
(3549-3526) 
NM002661 
hPLCδ3 
5’-acatcttcttcgtgcagcacatcg 
(434-457) 
5’-atgcggatttggatgaagagcgtg 
(2471-2448) 
NM133373 
hPLCε 
5’-caaaggcggcatgaagggatttca 
(4222-4245) 
5’-aagtgaacgcggaacagaaactgc 
(6423-6400) 
NM016341 
 
* Reverse primer for PLCβ1 not present in variant with accession number NM015192. 
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Table 2.3. Potency of alkylphosphocholines (APCs) as paracellular permeability enhancers 
(EC50 TEER and EC10X) and as inhibitors of ATP-stimulated PLCβ activity (IC50 PLCβ). 
APC Chain Length EC50 TEER (μM) EC10X (μM) IC50 PLCβ (μM) 
C10 9800 ± 1375 8333 ± 1320 1304 ± 837 
C12 735 ± 62 576 ± 160 123 ± 28 
C14 213 ± 23 261 ± 90 29 ± 13 
C16 248 ± 52 317 ± 26 40 ± 19 
C18 299 ± 19 384 ± 94 70 ± 38 
C20 429 ± 77 481 ± 45 104 ± 8 
 
See Figure 2.5 for chemical structures of compounds in the APC series. 
Results are reported as the mean ± standard deviation of three experiments performed in 
triplicate. 
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Figure 2.1. PLC mRNA expression in Caco-2 cells. Expression levels of PLC mRNA in 
Caco-2 cells were determined by real-time RT-PCR. All data were normalized to the β-actin 
expression level within each sample, and the level of each isozyme is expressed relative to 
PLCγ2, the isozyme with the lowest expression. Data represent mean ± range from triplicate 
determinations. 
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Figure 2.2. PLC protein expression in Caco-2 cells. Expression of PLCβ1, PLCβ3, PLCγ1, 
and PLCγ2 isozymes in Caco-2 cells determined via Western blot. Lanes 1 and 2 represent 
positive controls, i.e. A431 and MCF7 whole cell lysates respectively. Lanes 3 and 4 
represent 1.5 and 15 μg of a Caco-2 whole cell lysate. 
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Figure 2.3. Human tissue distribution of PLC mRNA. Expression levels of PLC mRNA in 
multiple human tissues and Caco-2 cells were determined by quantitative real-time RT-PCR. 
Expression in Caco-2 cells (gray bar), along the small intestine (solid bars), and in other 
organs of drug disposition (open bars) is indicated. Tissue expression data were obtained 
using purchased poly A+ RNA. Caco-2 expression data was obtained from laboratory isolated 
mRNA. Data represent mean ± standard deviation from triplicate determinations. 
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Figure 2.4. Stimulation of PLCβ activity in Caco-2 cells by ATP. Accumulation of inositol 
phosphates was determined by stimulating PLCβ activity with ATP for fifteen minutes. [3H]-
inositol phosphates were isolated by ion exchange chromatography and quantified via liquid 
scintillation counting. Data represent mean ± standard deviation from triplicate 
determinations. 
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Figure 2.5. Structures of alkylphosphocholines, U73122, and U73343. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
112 
[HPC] (μM)
No ATP 0 10 50 150 250 400
PL
C
 In
hi
bi
tio
n 
(%
 C
on
tr
ol
)
0
20
40
60
80
100
120
 
 
 
Figure 2.6. The effect of HPC on ATP-stimulated PLCβ activity in Caco-2 cells. Cells were 
labeled with [3H]-myo-inositol overnight at 37°C, and then treated apically with HPC for 
thirty minutes. The effect of HPC on the accumulation of inositol phosphates was determined 
by stimulating PLCβ activity with 300 μM ATP for fifteen minutes. [3H]-inositol phosphates 
were isolated by ion exchange chromatography and quantified via liquid scintillation 
counting. Data represent mean ± standard deviation from triplicate determinations from one 
representative experiment. 
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Figure 2.7. The effect of HPC on paracellular permeability across Caco-2 cell monolayers. 
(A) Cells were treated apically with HPC at indicated concentrations and TEER was 
measured at ten minute intervals for ninety minutes. (B) Cells were treated apically with 
HPC and TEER was measured after thirty minutes. To evaluate HPC induced changes in 
paracellular permeability, [14C]-mannitol was added to the apical compartment, and the 
amount appearing in the basolateral compartment during the 30-60 minute period post-
treatment was measured. Data represent mean ± standard deviation from triplicate 
determinations from one representative experiment. Asterisks indicate significant difference 
(p < 0.05) for mannitol permeability. 
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Figure 2.8. The effect of alkylphosphocholines (APC) on paracellular permeability across 
Caco-2 cell monolayers. Cells were treated apically with indicated APC at 37°C for thirty 
minutes. (A) TEER (B) The amount of [14C]-mannitol appearing in the basolateral 
compartment during the 30-60 minute period post-treatment. Data represent mean ± standard 
deviation from triplicate determinations from one representative experiment for each APC. 
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Figure 2.9. The relationship between inhibition of PLCβ activity and increase in paracellular 
permeability by APCs in Caco-2 cell monolayers. (A) The relationship between the IC50 PLCβ 
and EC50 TEER (B) the relationship between the IC50 PLCβ and EC10X. 
116 
 [U73122] (μM)
No ATP 0 5 30 U73343
PL
C
 In
hi
bi
tio
n 
 (%
 C
on
tr
ol
)
0
20
40
60
80
100
120
140
*
 
 
Figure 2.10. The effect of U73122 on ATP stimulated PLCβ activity in Caco-2 cells. Cells 
were labeled with [3H]-myo-inositol overnight at 37°C, then treated apically with U73122 at 
indicated concentrations, or with U73343 (30 μM), for thirty minutes. Accumulation of 
inositol phosphates was determined by stimulating PLCβ activity with 300 μM ATP for 
fifteen minutes. [3H]-inositol phosphates were isolated by ion exchange chromatography and 
quantified via liquid scintillation counting. Data represent mean ± standard deviation from 
triplicate determinations from one representative experiment. Asterisks indicate significant 
difference (p < 0.05). 
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Figure 2.11. The effect of U73122 on paracellular permeability across Caco-2 cell 
monolayers. (A) Cells were treated apically with U73122 at indicated concentrations and 
TEER was measured every thirty minutes for two hours. (B) Cells were treated apically with 
U73122 at indicated concentrations, or with U73343 (30 μM), and TEER was measured after 
ninety minutes. To evaluate U73122 induced changes in paracellular permeability, [14C]-
mannitol was added to the apical compartment, and the amount appearing in the basolateral 
compartment during the 90-120 minute period post-treatment was measured. Data represent 
mean ± standard deviation from triplicate determinations from one representative 
experiment. Asterisks indicate significant difference (p < 0.05) for mannitol permeability. 
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CHAPTER 3 
 
 
 
 
RNAi KNOCKDOWN OF PHOSPHOLIPASE C ISOZYMES IN MDCK II CELLS 
HAS NO IMPACT ON ESTABLISHMENT OR MAINTENANCE OF TIGHT 
JUNCTION BARRIER FUNCTION 
 
  
ABSTRACT 
Phospholipase C (PLC) isozymes comprise a large family of key cell signaling proteins that 
hydrolyze inositol containing phospholipids to form two cellular second messengers, 
diacylglycerol (DAG) and inositol triphosphate (IP3). Recently, PLCβ and PLCγ isozymes 
have been implicated in the regulation of epithelial paracellular permeability in both Madin-
Darby canine kidney (MDCK) and Caco-2 cells using previously reported PLC inhibitors, 
implicating this important class of signaling enzymes as potential regulators of epithelial 
tight junction function. To confirm the potential role of these enzymes in the barrier function 
of epithelial tight junctions, RNA interference was used to suppress the expression of specific 
PLC isozymes in MDCK cells, and the effect on tight junction function and structure was 
evaluated. mRNA was detected for two isozymes of these PLC families in MDCK cells, 
PLCβ3 and PLCγ1. Surprisingly, depletion of both enzymes, alone or in combination, had no 
impact on paracellular permeability across cell monolayers, and no clearly detectable effect 
on the subcellular localization of tight junction proteins ZO-1, ZO-2, or occludin. Further, 
RNAi-mediated suppression of these isozymes in combination had no effect on the potency 
of previously reported PLC inhibitors, U73122 and hexadecylphosphocholine, to increase 
paracellular permeability across MDCK cell monolayers, implying that these compounds 
may increase permeability via alternative mechanisms. In addition to the lack of effect on 
mature tight junction function, depletion of both PLC isozymes, alone or in combination, had 
no effect on the assembly of tight junctions that were disrupted by removal of extracellular 
calcium. The present results indicate that PLCβ3 and PLCγ1 are not crucial for the formation 
or maintenance of tight junction barrier function in epithelial cells, and that reported PLC 
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inhibitors, U73122 and alkylphosphocholines, increase the paracellular permeability of 
epithelial cell monolayers via mechanisms independent of their effects on PLC enzymes. 
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INTRODUCTION 
 Phospholipase C (PLC) enzymes have previously been postulated to be involved in 
the regulation of tight junction function in epithelial cell monolayers1-4, although there is 
little direct evidence to support this hypothesis. Reports that have specifically implicated 
PLC in the regulation of tight junction barrier function have demonstrated that chemical 
agents that inhibited PLC in both Madin-Darby canine kidney (MDCK) and Caco-2 cell 
monolayers also increased paracellular permeability (Chapter 2)5-8. Specific downstream 
events have been attributed to this PLC inhibition-mediated increase in paracellular 
permeability, including reorganization of the cortical actin ring8, redistribution of tight 
junction proteins ZO-15 and claudin-16, as well as hyperphosphorylation of tight junction 
protein ZO-27. On the other hand, a number of unrelated reports with these same inhibitors 
indicate they may be non-specific in nature, and exert “off-target” effects on cultured cells9-
12, raising speculation regarding the proposed hypothesis that inhibition of PLC activity 
directly leads to changes in the barrier function of epithelial tight junctions. 
In order to establish a cause-effect relationship between inhibition of PLC activity 
and increased paracellular permeability across epithelial cells, a more specific approach to 
inhibition of individual PLC isozymes was required, as evidence is lacking for chemical 
agents that can specifically inhibit PLC isozymes in cellular systems without affecting other 
cellular functions. RNA interference (RNAi), a process by which exogenous double stranded 
RNA silences homologous genes in whole cells, offers an alternative to the use of chemical 
inhibition for achieving highly specific inhibition of functional proteins in cells and tissues. 
Short interfering RNA (siRNA) molecules homologous to a variety of target genes have been 
transiently transfected with high efficiency into numerous mammalian epithelial cell lines, 
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including both Caco-213, 14 and MDCK cells15, to effectively silence genes with greater than 
80% knockdown efficiency. Thus, in addition to the advantage of increased target specificity 
over chemical inhibitors of PLC, siRNAs provide the opportunity to specifically address the 
role of individual PLC isozymes on epithelial tight junction function independently, and in 
combination. 
Previous reports have specifically implicated isozymes of the PLCβ and PLCγ 
families in the regulation of paracellular permeability (Chapter 2)7, 8; therefore, the purpose 
of the present study was to design oligonucleotides to suppress the expression of individual 
PLCβ and PLCγ isozymes, and examine the subsequent effects on the maintenance of tight 
junction barrier function. This approach should overcome the issues of potential “off-target” 
effects associated with reported PLC inhibitors such as alkylphosphocholines (APCs) and 
U73122. As established in Chapter 2, Caco-2 cells are a suitable, and preferred, in vitro 
model for assessing the role of PLC in epithelial tight junction regulation for the purpose of 
increasing oral absorption in humans; however, they are notoriously difficult to transfect with 
high efficiency, particularly in culture after the establishment of a confluent monolayer. 
MDCK cells on the other hand, although of canine kidney origin, are more amenable to a 
number of well established transfection approaches, and have been widely used as a model 
cell line to evaluate the underlying molecular mechanisms regulating epithelial tight junction 
function. Further, their expeditious growth rate and tendency to rapidly establish confluent 
monolayers, particularly when seeded at high density, offers the unique advantage of 
transfecting these cells in suspension to knockdown targeted proteins, and preserving the 
capability of assessing the effect on the maintenance of an established tight junction barrier15, 
16. Therefore, transient transfection of MDCK cells to specifically knockdown the expression 
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of PLCβ and γ isozymes was used to determine if a cause-effect relationship exists between 
inhibition of PLC and increased paracellular permeability. 
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MATERIALS AND METHODS 
Materials. Dulbecco’s modified eagle media (DMEM), Hanks Balanced Salt Solution 
(HBSS), 4-12% Bis-Tris gels, MOPS running and transfer buffers, antioxidant, as well as all 
other cell culture reagents were purchased from Invitrogen (Carlsbad, CA). Gene specific 
primers were designed using Primer3 and purchased from Fisher. Oligonucleotides targeting 
PLC isozymes, as well as non-sense oligos, were purchased from Dharmacon Inc. (Lafayette, 
CO). Antibodies for PLC isozymes were purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA), and GAPDH antibody was purchased from Imgenex (San Diego, CA). Antibody 
for ZO-1 was generously provided by the laboratory of Dr. James Anderson (Department of 
Cellular and Molecular Physiology, School of Medicine, The University of North Carolina at 
Chapel Hill). Antibodies for ZO-2 and occludin were from Zymed (San Francisco, CA). 
Alexa Fluor IRDye secondary antibodies for western blotting were purchased from Rockland 
(Gilbertsville, PA), while secondary antibodies for confocal microscopy were from Jackson 
ImmunoResearch Inc. (West Grove, PA). RNeasy Mini Kit and QIAamp RNA Blood Mini 
Kit were obtained from Qiagen (Valencia, CA). Six and twelve well Transwells™ and twelve 
and twenty-four well culture dishes were obtained from Costar (Cambridge, MA). D-[2-3H]-
mannitol (20 Ci/mmol) and [2-3H(N)]-myo-inositol (20 Ci/mmol) were purchased from 
American Radiolabeled Chemicals (St. Louis, MO). AG1-X8 formate columns were obtained 
from Bio-Rad Laboratories (Hercules, CA). Hexadecylphosphocholine (HPC) was purchased 
from Avanti Polar Lipids (Alabaster, AL). Nucleofector kit L was purchased from Amaxa 
Biosystems (Gaithersburg, MD). U73122 and all other chemical and reagents were purchased 
from Sigma. 
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Cell Culture and Transfection. MDCK II tet off cells (passage 11) were generously 
provided by the laboratory of Dr. James Anderson (Department of Cellular and Molecular 
Physiology, School of Medicine, The University of North Carolina at Chapel Hill), and were 
cultured at 37°C in an atmosphere of 5% CO2 and 90% relative humidity in DMEM with 
10% fetal bovine serum (FBS), 1% non-essential amino acids, and 1% penicillin-
streptomycin. Subconfluent MDCK cells (passage 11-20) were nucleofected in suspension 
(Amaxa Biosystems, Gaithersburg, MD) using nucleofector kit L according to the 
manufacturer’s protocol and seeded at indicated seeding densities. Media was changed daily. 
Each transfection was performed with 1.0 x 106 cells, indicated amounts of free 
oligonucleotides, and 1 μg of pmaxGFP as a transfection marker. Experiments were typically 
performed three days post-transfection unless indicated otherwise. 
siRNA oligonucleotides. Free oligonucleotide smartpools targeting specific PLC isozymes 
were designed in collaboration with Dharmacon Inc. Four different siRNAs were designed 
and combined as pools to maximize the knockdown efficiency of each targeted protein. A 
pre-designed non-sense oligonucleotide smartpool was also purchased from Dharmacon Inc. 
and served as a negative control where indicated. 
RT-PCR. Tissue collection was performed in accordance with the Institutional Animal Care 
and Use Committee of GlaxoSmithKline, Inc. Following collection, tissues for positive 
controls were stored at -80°C until use. Total RNA was isolated from cells and tissues using 
RNeasy Mini Kit or QIAamp RNA Blood Mini Kit (Qiagen, Valencia, CA) according to the 
manufacturer’s protocols. RNA was treated with TURBO DNase (TURBO DNA-free kit, 
Ambion Inc., Austin, TX) to remove genomic DNA contamination. RNA was quantified by 
UV absorbance at 260 nm on a UV-Vis spectrophotometer (Nanodrop Technologies, 
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Wilmington, DE), and its integrity was verified by an OD260/OD280 ratio greater than 1.8. 
cDNA was synthesized from 5 μg of RNA for each tissue sample or cell lysate using 
Superscript III reverse transcriptase (Invitrogen Corporation, Carlsbad, CA) with an 
equivalent amount of RNA included in a no-RT control for each separate RNA sample. Real-
time PCR was performed with 1:50 dilutions of cDNA as well as no-RT and no template 
reaction controls. Reactions consisted of SYBR Green JumpStartTaq ReadyMix (Sigma-
Aldrich Co., St. Louis, MO), primers at 0.3 μM, and 5 μL of sample (cDNA or control). 
Amplification was performed in a Rotor-Gene 3000 (Corbett Research, Mortlake, Australia) 
thermal cycler at 94°C for 2 minutes followed by 40 cycles at 94°C for 15 seconds, 54°C for 
20 seconds, and 72°C for 25 seconds. Following amplification, a melting curve analysis was 
performed by heating the reactions from 50 to 99°C in 0.2°C intervals while monitoring 
fluorescence. All primer pairs are listed in Table 3.1 and produced amplicons of the predicted 
size on an 8% TBE-PAGE gel. 
Western Blotting. Following transfection, MDCK cells were seeded in twenty four well 
culture dishes with 2.0 x 105 cells per well and cultured for indicated times. Media was 
changed daily. Whole cell lysates were collected at indicated timepoints by washing three 
times with PBS+ (supplemented with 1.8 mM calcium chloride), adding 200 μl SDS sample 
buffer at 55°C, and sonicating each lysate briefly. Lysates were stored at -20°C until analysis 
by immunoblot using standard protocols. Primary antibodies were rabbit anti-PLCγ1 (1:100), 
rabbit anti-PLCβ3 (1:500), and goat anti-GAPDH (1:2500). Secondary antibodies were Alexa 
Fluor IRDye 700-conjugated donkey anti-rabbit and Alexa Fluor IRDye 800-conjugated 
donkey anti-goat. Quantitative analysis of Western blots was performed using Odyssey 
infrared imaging system (LI-COR Inc., Lincoln, NE). 
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PLC activity by cellular assay. The activity of PLC isozymes was determined by an 
adaptation of previously published methods7, 8, 17. Following transfection MDCK cells were 
seeded in twenty four well culture dishes with 4.0 x 105 cells per well and cultured for 
indicated times. Medium was changed daily. On day 2, cells were labeled with [3H]-myo-
inositol (2 μCi/well) in 0.5 ml of serum free media for twelve hours at 37°C prior to assay. 
Assays were initiated by incubating cells with 100 mM LiCl for forty five minutes in either 
HBSS supplemented with 10 mM Hepes and 25 mM glucose or inositol and serum free 
media, to assess adenosine triphosphate (ATP)-stimulated and epidermal growth factor 
(EGF)-stimulated activity, respectively. After forty five minutes, treatment cells were 
supplemented with either ATP (100 μM) or EGF (100 ng/ml) for fifteen minutes to stimulate 
PLCβ and PLCγ activity respectively, and allow accumulation of [3H]-inositol phosphates. 
Assays were terminated by aspirating the media and adding 1.0 ml of boiling 10 mM EDTA 
(pH 8.0) to lyse cells. The lysate was then applied to AG1-X8 formate columns for 
chromatographic isolation of [3H]-inositol phosphates18. The amount of [3H]-inositol 
phosphates was measured by liquid scintillation counting in a Packard Tri Carb 4000 Series 
spectrophotometer. Data from each experiment were normalized to the amount of 
accumulated [3H]-inositol phosphates in MDCK cells in the absence of agonist, were 
compared to both non-transfected and non-sense transfected cells, and were reported as the 
mean ± standard deviation of three replicates. 
Measurement of paracellular permeability. Following transfection, MDCK cells were 
seeded in twelve well TranswellsTM with 4.0 x 105 cells per well, and cultured for indicated 
times. Medium was changed daily. Transepithelial electrical resistance (TEER) and 
permeability of hydrophilic paracellular marker mannitol were used as indicators of the 
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barrier function of epithelial tight junctions. As such, decreases in TEER or increases in 
paracellular permeability were perceived to indicate loss of tight junction barrier function. 
TEER measurements were performed at indicated times using an EVOM Epithelial Tissue 
Voltohmeter and an Endohm-12 electrode (World Precision Instruments, Sarasota, FL). For 
permeability measurements, cell media was first aspirated and cells were rinsed two times 
with pre-warmed transport buffer (HBSS supplemented with 25 mM glucose and 10 mM 
Hepes) and incubated at 37°C for thirty minutes. TEER measurements were performed prior 
to each experiment to confirm tight junction integrity. Permeability experiments were 
initiated by aspirating buffer from the apical compartment and replacing with buffer 
containing [3H]-mannitol, and desired concentrations of PLC inhibitors, U73122 or HPC, 
where indicated, and incubating at 37°C for sixty minutes. Permeability was monitored by 
the appearance of compound in the basolateral side (1.5 ml) during the second 30-minute 
interval (i.e. 30-60 minutes), and was calculated according to the following equation: 
sec)/101(sec/)/(1*)/(1*/P 70 cmxnmunitsCAdtdQapp
−==                                 (1) 
where dQ/dt is the amount, Q, of mannitol measured in the basolateral compartment at time 
T. A is the membrane surface area and C0 is the initial concentration of mannitol in the apical 
compartment. The amount of compound transported was measured by liquid scintillation 
counting in a Packard Tri Carb 4000 Series spectrophotometer. All transport experiments 
were conducted under sink conditions (experiments were designed such that less than 10% of 
the total amount of compound was present on the basolateral side at any given time). The 
permeability of [3H]-mannitol in knockdown cells was compared to that in non-transfected 
and non-sense transfected cells, and was reported as the mean ± standard deviation of three 
replicates. 
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Calcium Switch Assay. Calcium switch assay was performed by an adaptation of previously 
published reports19, 20. Following transfection, MDCK cells were seeded in twelve well 
TranswellsTM with 4.0 x 105 cells per well, and cultured for indicated times. Medium was 
changed daily and TEER was measured prior to the addition of low calcium (LC) medium on 
day two. LC medium was prepared with minimum essential medium containing spinner salts 
(SMEM, Invitrogen, Carlsbad, CA), 5% dialyzed FBS, 10 mM Hepes pH 7.2, glutamine, and 
5 μM CaCl2. FBS was dialyzed at 5°C against a buffer containing 150 mM NaCl and 50 mM 
Na2HPO4 pH 7.2 for twenty four hours, against the same buffer with 0.2 mM EDTA added 
for 24 hours, then again against the same buffer without EDTA two more times for twenty 
four hours each. Dialysis was performed using 32 mM diameter dialysis tubing (molecular 
weight cutoff of 12-14 kD) (Spectrum Laboratories, Irving, TX) against a forty fold volume 
of each buffer. Cells were incubated at 37°C in an atmosphere of 5% CO2 and 90% relative 
humidity for approximately twelve hours in LC media. TEER was measured again to confirm 
loss of barrier function, and normal calcium (NC) medium was then returned to both the 
apical and basolateral compartments. NC medium was prepared by slowly adding an 
appropriate amount of a 0.18 mM CaCl2 stock solution to LC media, with stirring, to reach a 
final concentration of 1.8 mM CaCl2. Formation of tight junction barrier function was 
evaluated by measurement of TEER at indicated times for the next twenty four hours, or until 
resistance had returned to initial levels. 
Confocal Microscopy. Following transfection, MDCK cells were seeded in twenty four well 
culture dishes on top of ethanol sterilized glass coverslips (12 mm diameter) with 2.0 x 105 
cells per well and cultured for indicated times. Media was changed daily. On day three 
following transfection, MDCK cells were rinsed three times with PBS+ prior to fixation with 
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1% paraformaldehyde in PBS+ for 30 minutes. Cells were then washed again three times with 
PBS+, and paraformaldehyde fixed cells were permeabilized with 0.1% Triton X-100 in PBS 
for 15 minutes, followed by three additional washes with PBS. All cells were then blocked 
for one hour at room temperature in 5% normal donkey serum (Jackson ImmunoResearch) 
with 1% BSA to block nonspecific binding, followed by three washes with PBS. Staining 
with appropriate primary and secondary antibodies was performed for one hour at room 
temperature in 1% BSA with three ten minute PBS washes following incubation with each 
antibody. Primary antibodies used were rat anti-ZO-1 (1:25; hybridoma supernatant (R40.76) 
provided by laboratory of Dr. J. Anderson, Cellular & Molecular Physiology, The UNC 
School of Medicine, Chapel Hill, NC), mouse anti-ZO-2 (1:250; Zymed Laboratories), and 
mouse anti-occludin (1:300; Zymed Laboratories). Secondary antibodies were goat anti-rat 
Cy3 and donkey anti-mouse Cy3 (1:1000; Jackson ImmunoResearch Inc.). Cells were 
mounted in Mowiol (Calbiochem, San Diego, CA) with 1.0% n-propyl gallate. 
Confocal microscopy images were collected on a laser scanning Zeiss510 Meta 
Confocal System (Thornwood, NY) with a 63x 1.4NA plan-Panchromatic oil immersion lens 
using an argon (488 nm) and a Hone (543 nm) laser for detection of GFP and Cy3 labeled 
proteins, respectively. The system was operated with a pinhole size of one Airy unit. A series 
of XY images were collected along the Z-axis with a 0.36 am step size. Image projections 
were generated with Zeus LSM Image Browser version 3.2. Contrast adjustment was 
generated using Adobe Photoshop for consistent presentation of morphology (version 6.0; 
San Jose, CA). 
Data analysis. Data are expressed as the mean ± standard deviation (SD) from three 
measurements unless indicated otherwise. Where indicated, statistical significance was 
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assessed using a two sample Student’s t tests. Samples were assumed to have an unequal 
variance; significant differences were assigned at p < 0.05. 
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RESULTS 
Knockdown of PLCβ3 and PLCγ1 expression in MDCK cells 
In order to unambiguously establish which PLC isozymes are expressed at significant 
levels in the MDCK II cells used for these studies, primers were designed for each PLCβ and 
PLCγ isozyme (Table 3.1), excluding PLCβ4, because the expression of this isozyme has 
been reported to be restricted to specific regions of the brain and retina21, 22, and thus, would 
be unlikely to be expressed in a canine kidney epithelial cell line. Other isozyme families 
were not evaluated in this study, because there is no direct evidence to suggest that they are 
involved in the regulation of epithelial tight junctions. mRNA for PLCβ3 and PLCγ1 
isozymes was clearly detected in MDCK cells via RT-PCR, while mRNA for PLCβ1, 
PLCβ2 and PLCγ2 was not (Figure 3.1), suggesting that PLCβ3 and PLCγ1 are the dominant 
receptor regulated PLCs expressed in these cells. Western blots further confirmed the protein 
expression of these two isozymes in MDCK cells (Figures 3.2.B and 3.3.B). 
In order to directly investigate the role of individual PLC isozymes in the regulation 
of epithelial tight junction function, the expression of both PLCβ3 and PLCγ1 was 
suppressed using RNAi. MDCK cells were transiently transfected with free oligonucleotides 
using Amaxa nucleofection to knockdown expression of both proteins individually. Four 
siRNAs targeting either PLCβ3 or PLCγ1 were combined and used as pools in order to 
maximize knockdown efficiency. Efficiency of knockdown was quantified from 
immunoblots of cell lysates for up to five days post-transfection (Figures 3.2.A and 3.3.A). 
Both pools efficiently depleted targeted PLC isozymes in MDCK cells without affecting the 
expression levels of the non-targeted PLC. Depletion of PLCβ3 was more efficient than 
PLCγ1 with respect to both time and siRNA concentration (Figure 3.2 and Figure 3.3). 
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Maximum knockdown of PLCβ3 was achieved by day 3 (approximately 80%), was similar 
for all siRNA concentrations tested, and was maintained out to five days (Figure 3.2). 
Maximum knockdown of PLCγ1 was achieved by day 2 (approximately 70%), was more 
efficient with siRNA concentrations ≥ 5 μM, but interestingly, was not maintained 
throughout the five day test-period. Instead, protein expression returned to near control levels 
by day 5 (approximately 30% knockdown for all tested concentrations) (Figure 3.3). 
Subsequent experiments intended to evaluate the effect of PLC isozyme depletion on tight 
junction barrier function were performed on day 3 post-transfection using 2 and 5 μM siRNA 
for PLCβ3 and PLCγ1, respectively. One μg of pmaxGFP was co-transfected in all 
experiments to assess transfection efficiency. Notably, the transfection efficiency was 
determined to be approximately 70-80% (data not shown but consistent with reported 
transfection efficiency for MDCK II cells by Amaxa Inc. (Gaithersburg, MD)), suggesting 
that silencing in transfected cells approached 100% for each isozyme. 
Knockdown of PLCβ3 and PLCγ1 expression in MDCK cells attenuates agonist 
induced PLC activation. 
To confirm that specific knockdown of both PLCs leads to an isozyme specific 
reduction in PLC catalytic activity, the ability of known agonists for both isozymes (i.e. ATP 
for PLCβ and EGF for PLCγ) to stimulate PLC activity was assessed in knockdown cells, 
and compared to non-transfected and non-sense transfected cells. Specific knockdown of 
each isozyme resulted in almost complete abolishment of PLC activation by their respective 
agonists (Figure 3.4), confirming that the observed reduction in protein expression had 
functional consequences on the ability of exogenous agonists to stimulate the activity of the 
respective isozyme. 
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Maintenance of tight junction barrier function following PLC isozyme knockdown. 
 Chemical inhibition of PLC activity has previously been shown to increase 
paracellular permeability across both MDCK and Caco-2 cell monolayers (Chapter 2)7, 8. To 
address the possibility that either PLCβ3 or PLCγ1 is specifically involved in regulating 
epithelial tight junction function in MDCK cells, paracellular permeability was evaluated in 
knockdown cells and compared to non-transfected and non-sense transfected cells. Sub-
confluent MDCK cells were transfected in suspension and over-seeded in order to rapidly 
establish a confluent monolayer16. This seeding density and subsequent rapid tight junction 
formation provides the opportunity to assess the importance of each PLC isozyme on the 
maintenance of barrier function. On each day following transfection and seeding, TEER was 
measured to assess barrier function. Depletion of either PLCβ3 or PLCγ1 had no effect on the 
resistance across MDCK cell monolayers, suggesting that epithelial tight junction function is 
unaffected by knockdown of either enzyme (Figure 3.5.A). To further confirm that tight 
junction barrier function is maintained in knockdown cells, the permeability of paracellular 
marker mannitol was determined on day three, or the point of maximal knockdown. 
Consistent with TEER data, the permeability of [3H]-mannitol was unchanged in knockdown 
cells (Figure 3.5.B), confirming the lack of effect of PLC isozyme knockdown on tight 
junction barrier function in MDCK cells. 
Establishment of tight junction barrier function following PLC isozyme knockdown. 
 To evaluate the effects of PLC isozyme depletion on the assembly of tight junctions, 
knockdown cells were subjected to a calcium switch assay (see Materials and Methods) and 
compared to non-transfected and non-sense transfected cells (Figure 3.5.C). Following the re-
addition of normal calcium medium to cells, both control cells and knockdown cells 
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established tight junctions within two hours, as indicated by the initial increase in TEER. 
Further, the TEER profile over the following twenty four hour period was identical in all 
conditions, and returned to initial levels by twenty four hours. This result suggests that 
neither PLCβ3 nor PLCγ1 is necessary for the formation of epithelial tight junctions in 
MDCK cells. 
Maintenance and establishment of tight junction barrier function following 
simultaneous knockdown of both PLCβ3 and PLCγ1. 
 The individual knockdown of PLCβ3 and PLCγ1 isozymes had no impact on either 
the maintenance of already established tight junctions, or on the biogenesis of tight junctions 
following calcium switch. To assess the possibility that the function of these two isozymes is 
redundant in MDCK cells, and that one isozyme can compensate for the reduced or 
eliminated function of the other, the expression of both isozymes was depleted 
simultaneously using RNAi for up to five days post-transfection (Figure 3.6). Consistent with 
individual knockdown studies, the knockdown of PLCβ3 was more efficient than the 
knockdown of PLCγ1. Maximum knockdown of PLCγ1 was achieved by day one 
(approximately 60%), but again was not maintained throughout the five day test-period, as 
protein expression returned to near control levels by day 5. Knockdown of PLCβ3 was again 
maximized at day three (approximately 80%); interestingly though, the knockdown of PLCβ3 
was not maintained throughout the five day test-period as it was when depleted alone. On the 
other hand, expression increased at day four compared to day three and had returned to 50% 
of control by day five. Subsequent experiments intended to evaluate the effect of combined 
knockdown on tight junction barrier function were performed on day 3 post-transfection 
using 2 and 5 μM siRNA oligonucleotides for PLCβ3 and PLCγ1, respectively. 
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 Consistent with individual knockdown studies, simultaneous depletion of both PLCβ3 
and PLCγ1 had no effect on TEER (Figure 3.7.A), or on the permeability of paracellular 
marker mannitol across MDCK cell monolayers (Figure 3.7.B), suggesting that epithelial 
paracellular permeability is unaffected by simultaneous depletion of both enzymes. In 
addition, the combined knockdown had no impact on the establishment of TEER following 
calcium switch (Figure 3.7.C). These results further suggest that neither PLCβ3 nor PLCγ1 
isozymes are required for the maintenance or formation of stable epithelial tight junctions; in 
addition, the results exclude the possibility that PLC isozyme function is redundant. 
Subcellular localization of tight junction proteins following knockdown of PLCβ3 and 
PLCγ1. 
 Despite the absence of functional consequences to tight junction barrier function in 
MDCK cells following RNAi-mediated depletion of specific PLC isozymes, the effects of 
knockdown on the subcellular localization of tight junction proteins was examined. As 
previously indicated, specific downstream events have been associated with the PLC 
inhibition-mediated increase in paracellular permeability, including redistribution of tight 
junction proteins ZO-15 and claudin-16, as well as hyperphosphorylation of ZO-1, ZO-2, and 
occludin7. To examine the possibility that these observed events are a result of PLC 
inhibition, but not related to changes in tight junction barrier function, the subcellular 
localization of ZO-1 and ZO-2, as well as transmembrane protein occludin, was assessed in 
combination knockdown cells and compared to non-sense transfected cells. As previously 
reported, both ZO-1 and occludin were expressed exclusively at cell-cell junctions in control 
cells23-27, while ZO-2 demonstrated junctional staining, as well as some speckled cytosolic 
and nuclear staining28-31. As shown in Figures 3.8, 3.9, and 3.10, the subcellular localization 
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of these three tight junction associated proteins was unaffected when PLCβ3 and PLCγ1 
were depleted in combination. 
The potency of hexadecylphosphocholine and U73122 as paracellular permeability 
enhancers in PLCβ3 and PLCγ1 depleted MDCK cells. 
 Because the specific knockdown of PLCβ3 and PLCγ1 in MDCK cells did not cause 
changes to the barrier function of tight junctions, the effects of previously established PLC 
inhibitors and paracellular permeability enhancers, U73122 and HPC (Figure 3.11), on 
paracellular permeability in knockdown cells was explored. The rationale for this study is as 
follows: if U73122 and HPC increase paracellular permeability via direct inhibition of PLC, 
their potency as paracellular permeability enhancers should be significantly reduced in 
knockdown cells due to the absence of their proposed pharmacological target. As shown in 
Figures 3.12 and 3.13, the ability of both HPC and U73122 to increase paracellular 
permeability (i.e. decrease TEER and increase mannitol permeability) was unchanged in 
knockdown cells as compared to non-transfected and non-sense transfected cells. This result 
is consistent with the effect of RNAi-mediated PLC depletion on paracellular permeability, 
and further suggests that inhibition of PLC activity does not lead to an increase in 
paracellular permeability across MDCK cell monolayers. 
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DISCUSSION 
The tight junction forms a charge and size-selective barrier between adjacent 
epithelial cells restricting the passage of ions, water, and non-charged solutes through the 
intercellular space. This intricate protein complex consists of both transmembrane proteins 
that combine to form the physical barrier of the tight junction by spanning the intercellular 
space and interacting with transmembrane proteins on neighboring cells (e.g. claudins and 
occludin), as well as membrane scaffolding proteins that link the transmembrane proteins to 
the actin cytoskeleton and arrange them adjacent to important cytosolic regulatory proteins 
(e.g. ZO-1, ZO-2, ZO-3). An abundance of data has emerged in recent years implying that 
the function of these intercellular structures is influenced by numerous physiological and 
pathophysiological stimuli32, 33, suggesting that their barrier properties can be manipulated by 
pharmacological intervention of regulatory signal transduction pathways34-36. One such 
pathway implicated in the regulation of tight junction barrier function is the PLC-mediated 
signal transduction cascade. Chemical inhibition of PLC enzymes has been strongly 
associated with increased tight junction permeability in two models of epithelia, MDCK and 
Caco-2 cells (Chapter 2)7, 8. In the present study, RNA interference was employed to 
specifically inhibit the functional activity of PLC isozymes in MDCK cells, in an attempt to 
provide direct evidence for a cause-effect relationship between reduced PLC activity and loss 
of tight junction barrier function. 
The expression profile of specific PLCβ and PLCγ isozymes in MDCK cells has not 
been clearly defined. One report suggests that PLCβ1, β2, and β3 isozymes are all expressed 
at the protein level37, and although β1 and β3 tissue expression is reported to be widespread, 
the expression of β2 appears restricted to cells of hematopoietic origin38, making their 
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presence in kidney cells a surprise. A recent report has clearly demonstrated the expression 
of PLCγ1 in MDCK cells39, although little evidence supporting the expression of PLCγ2 in 
these cells has surfaced. Therefore, RT-PCR was initially utilized to establish the presence of 
individual PLCβ and PLCγ isozymes in MDCK cells. As shown in Figure 3.1, two isozymes 
were highly expressed at the mRNA level, one from each family (i.e. PLCβ3 and PLCγ1), 
while no PLCβ1, PLCβ2 or PLCγ2 were detected, implying that PLCβ3 and PLCγ1 are the 
only isozymes of their respective families expressed in MDCK II cells. Western blot analysis 
confirmed expression at the protein level for both isozymes (Figures 3.2.B and 3.3.B). 
After establishing which individual isozymes of these two PLC families are viable 
targets in MDCK II cells, siRNA oligonucleotide pools were used to specifically deplete the 
expression of each isozyme alone, and in combination. Complete suppression of PLC 
expression was not achieved for either isozyme, nor was it expected given the transient 
transfection methodology utilized to deliver siRNA to cells; therefore, it is conceivable that 
residual protein would be sufficient to maintain their respective functional roles and 
responsibilities within the entire population of cells. Because transfection efficiency was 
determined to be approximately 70%, silencing in transfected cells was assumed to approach 
100%. Complete suppression of each isozyme in such a high percentage of cells seems 
sufficient to expect global changes to the functional behavior of each with respect to the 
hypothesized changes to paracellular permeability across a monolayer of transfected cells. 
Hence, the ability of known agonists for each isozyme to stimulate PLC catalytic activity in 
knockdown cells was evaluated. Exogenously administered ATP and EGF have been 
previously reported to increase the production of inositol phosphates in epithelial cells, end-
products of PLC catalytic action, via activation of cell surface receptors specifically linked to 
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PLCβ and PLCγ isozymes, respectively (Chapter 2)7, 8, 40-42. As shown in Figure 3.4, the 
ability of ATP and EGF to stimulate the activity of their respective isozymes was almost 
completely abolished in knockdown cells, implying that the achieved knockdown efficiency 
via siRNA is substantial enough to expect global changes to the functional consequences of 
PLC action within the entire population of cells. In further support of this hypothesis, it was 
noted that the suppression of PLCγ1 was not maintained throughout the five day test period 
as it was for PLCβ3; instead, expression returned to near control levels by day five (Figure 
3.3.A). A recent study in MDCK cells reports that RNAi mediated suppression of PLCγ1 
leads to reduced cell migration39; therefore, the inability to maintain stable knockdown of 
PLCγ1 for extended periods in the present study may be due to the following scenario: the 
knockdown cells were unable to grow and migrate at typical rates following transfection; 
however, the small percentage of non-transfected cells maintaining normal growth properties 
continued to grow normally, and (increasingly) overcame the suppressed growth function of 
the initial population of transfected cells as time in culture progressed, leading to an apparent 
recovery of expression levels for PLCγ1. This observation implies that a known functional 
consequence of PLCγ1 suppression (i.e. cell migration) was reduced in transfected cells in 
the present study. If so, it could be argued that other functions of this isozyme should also be 
adversely affected, including regulation of paracellular permeability. Interestingly, when both 
PLC isozymes were depleted simultaneously, the knockdown of PLCβ3 was not maintained 
throughout the five day period as it was when this isozyme was suppressed alone. Instead, its 
expression returned to 50% of control by day five, suggesting that the PLCγ1 phenotype (i.e. 
reduced cell migration) affects the knockdown efficiency of other suppressed proteins. To 
unequivocally reach this conclusion however, cells lines stably expressing siRNA targeting 
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each PLC isozyme would need to be generated in order to achieve complete knockdown of 
each isozyme, and unambiguously assess functional consequences. 
Once sufficient knockdown of each isozyme was achieved, the impact of PLC 
depletion on tight junction barrier properties in MDCK cells was evaluated. When plated at 
sufficiently high density, MDCK cells begin to form junctions within a few hours, and are 
completely polarized within twenty four hours16. On the other hand, maximal suppression of 
PLCs was not achieved until day two, after mature tight junctions have already been formed. 
This temporal separation allows the opportunity to address the hypothesis that PLC isozymes 
are required for the maintenance of an established tight junction barrier and are involved in 
regulating paracellular permeability across cell monolayers. Data presented in Figure 3.5 and 
3.7 suggest that depletion of both PLC isozymes, either alone or in combination, has no 
impact on either the maintenance or assembly of tight junctions in MDCK cells, as assessed 
by the permeability of paracellular marker mannitol and by TEER formation following 
calcium switch. These results contradict previous reports using chemical inhibitors of PLC 
that have demonstrated significant increases in paracellular permeability across cell 
monolayers following treatment with these inhibitors (Chapter 2)5-8. 
Because specific changes in either the subcellular localization or phosphorylation 
status of ZO-1, ZO-2, and occludin have all been previously associated with increased 
paracellular permeability, presumably resulting from chemical inhibition of PLC activity5, 7, 
the subcellular localization of each of these tight junction associated proteins was evaluated 
in control and knockdown cells. Despite the fact that PLC knockdown had no apparent effect 
on the maintenance of barrier function, it was possible that depletion of PLC enzymes could 
lead to altered localization and function of tight junction proteins without measurable 
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changes to paracellular permeability, as there is no definitive evidence that the observed 
changes to these proteins in previous studies was the ultimate cause of the increased 
permeability. More recently, evidence for direct binding of PLCβ3 to the PDZ3 domain of 
ZO-1 has been reported43, confirming a direct interaction of PLC with tight junction 
scaffolding proteins, and supporting a hypothesis that this isozyme regulates the function of 
ZO-1. As shown in Figures 3.8, 3.9, and 3.10, depletion of PLCβ3 and PLCγ1 alone or in 
combination had no visibly significant impact on the subcellular localization of ZO-1, ZO-2, 
or occludin. These results imply that previously observed changes to specific tight junction 
proteins is not likely related to inhibition of PLC activity, although the phosphorylation status 
of each protein was not evaluated in the current study. Further, these results imply that 
neither PLCβ3 nor PLCγ1 play a role in maintaining the subcellular localization of these 
proteins once mature tight junctions have been established. However, as indicated earlier, in 
order to unequivocally reach this conclusion, cells lines stably expressing siRNA targeting 
each PLC isozyme should be used to achieve complete knockdown of each isozyme before 
completely ruling out a role for PLC isozymes in the subcellular localization of these 
proteins. 
One explanation for the apparent contradiction between the present study and 
previous studies with chemical inhibitors could be that purported specificity of reported PLC 
inhibitors was overestimated, and that their effects on paracellular permeability are mediated 
by effects unrelated to PLC. As indicated earlier, some literature reports with these 
compounds have suggested that they may be non-specific in nature, and exert “off-target” 
effects on cultured cells9-12, consistent with a hypothesis that their ability to inhibit PLC 
activity is not related to the observed effects on tight junction barrier properties. To provide 
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additional evidence to support the current findings (i.e. PLC inhibition has no impact on tight 
junction barrier properties), the effect of HPC and U73122 (Figure 3.11) on paracellular 
permeability was evaluated in cells depleted of both PLCβ3 and PLCγ1, and directly 
compared to non-transfected and non-sense transfected cells. If the effects of these two PLC 
inhibitors on tight junctions are mediated via their interaction with PLC, their potency as 
permeability enhancers should be reduced or eliminated in cells lacking PLC isozymes. As 
shown in Figure 3.12 and Figure 3.13, the potency of both U73122 and HPC as paracellular 
permeability enhancers was unchanged in knockdown cells, providing further evidence that 
inhibition of PLC does not lead to increase paracellular permeability in epithelial cells. In 
addition, this result implies that U73122 and HPC cause increased paracellular permeability 
by mechanisms other than inhibition of PLC activity; although additional studies are required 
to confirm this hypothesis. 
The results presented in this study provide evidence to suggest that neither PLCβ3 nor 
PLCγ1 isozymes are required for the maintenance, or formation, of tight junction barrier 
function in MDCK cells. However, as isozymes from other PLC families that may also be 
expressed in MDCK cells were not suppressed, these results do not rule out the possibility 
that inhibition of other PLCs leads to changes in paracellular permeability; a report that HPC 
inhibits the activity of PLCδ1 provides support for such a hypothesis44. Further, these results 
do not completely rule out a potential role for PLCβ and PLCγ isozymes in the regulation of 
tight junction function. A number of studies have indirectly suggested that PLC activation 
may lead to changes in the function of junctional complexes. For example, a number of 
agonists of receptors known to couple to PLCs have been reported to affect the functional 
integrity of tight junctions45-48. Further, increase in intracellular calcium levels49, 50, activation 
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of specific PKC isozymes51, 52, as well as non-PLC-mediated depletion of membrane PIP2 
content43, 53, all downstream effects of PLC activation, have been demonstrated to increase 
paracellular permeability or alter the barrier function of junctional complexes in a number of 
systems. Clearly, further study is warranted to probe this hypothesis. 
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Table 3.1. Designed primer sequences for canine PLCs. 
 
Protein 
Forward Primer 
(base pair position) 
Reverse Primer 
(base pair position) 
Accession # 
Product 
Size 
(bp) 
PLCβ1 
5’-tcggtcaccggatcttgccagt 
(2252-2273) 
5’-agctggaagcatcagaggctggt 
(2346-2324) 
XM542896 95 
PLCβ2 
5’-cggtggatcgcattgacgtggt 
(2015-2036) 
5’-aggtgcgcacactgcgttca 
(2104-2085) 
XM544615 90 
PLCβ3* 
5’-ggccattgcagaaaccgcct 
(1292-1311) 
5’-ttggcctgctgcttcgctga 
(1381-1362) 
XM533243 90 
PLCγ1 
5’-atgcgcctttcagagccggt 
(1831-1850) 
5’-acgcatcagcatgtgctcgg 
(1932-1913) 
XM542998 102 
PLCγ2 
5’-cgacgtcgtgcaggccatcaaa 
(1156-1177) 
5’-tgctgctccacgcaacagtg 
(1248-1229) 
XM546812 93 
 
All primers were designed using Primer3 software 54. 
 
PLCβ4 has been reported to be specifically localized to regions of the brain and retina21, 22; 
therefore, its expression in MDCK cells was not assessed. 
 
* Eleven splice variants are reported in Pubmed for canine PLCβ3. The designed forward 
primer sequence is present in all eleven, however, the amino acid position is different in 
variant 3 (XM861950). The designed reverse primer sequence is present in only nine of the 
eleven reported variants, excluding variant 4 (XM861961) and 5 (XM861973); in addition, 
the amino acid position is different in variant 3. 
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Figure 3.1. PLC mRNA expression in MDCK cells by qualitative RT-PCR. Products of RT-
PCR amplification reactions were run on an 8% TBE-PAGE gel and visualized via Sybr-
green fluorescence. (A) Expression of PLCβ isozymes in MDCK cells. Lanes 1, 4, and 7, 
represent negative controls, i.e. non-reverse-transcribed mRNA from MDCK cells. Lanes 2, 
5, and 8 represent positive control tissues, i.e. reverse transcribed mRNA isolated from 
canine intestine, whole blood, and canine intestine respectively. Lanes 3, 6, and 9 represent 
MDCK cells, i.e. reverse transcribed mRNA isolated from MDCK cells. (B) Expression of 
PLCγ isozymes in MDCK cells. Lanes 1 and 4 represent negative controls, i.e. non-reverse-
transcribed mRNA from MDCK cells. Lanes 2 and 5 represent positive control tissues, i.e. 
reverse transcribed mRNA isolated from canine intestine and whole blood, respectively. 
Lanes 3 and 6 represent MDCK cells, i.e. reverse transcribed mRNA isolated from MDCK 
cells. 
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Figure 3.2. RNAi-mediated knockdown of PLCβ3 in MDCK cells. MDCK cells were 
transfected with siRNA oligonucleotides targeting PLCβ3 and expression was compared to 
non-transfected cells (NT). GAPDH served as loading control. (A) Expression of PLCβ3 
with respect to days in culture and siRNA concentration. (B) Expression of PLCβ3and 
PLCγ1 on day three post-transfection with respect to siRNA concentration.  
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Figure 3.3. RNAi-mediated knockdown of PLCγ1 in MDCK cells. MDCK cells were 
transfected with siRNA oligonucleotides targeting PLCγ1 and expression was compared to 
non-transfected cells (NT). GAPDH served as loading control. (A) Expression of PLCγ1 with 
respect to days in culture and siRNA concentration. (B) Expression of PLCγ1and PLCβ3 on 
day three post-transfection with respect to siRNA concentration. 
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Figure 3.4. The effect of RNAi-mediated knockdown of PLCβ3 and PLCγ1 on agonist 
induced PLC activation in MDCK cells. Cellular accumulation of [3H]-inositol phosphates 
was determined during a fifteen minute treatment period with either (A) 100 μM ATP or (B) 
100 ng/ml EGF, to stimulate PLCβ and PLCγ activity respectively, and was compared to 
non-transfected (NT) and non-sense transfected (NS) cells. Data represent mean ± standard 
deviation from triplicate determinations. Error bars are omitted from control cells in both 
figures to simplify data presentation, as each tested condition was compared to its own set of 
un-stimulated cells that served as control. Asterisks (*) indicate significant difference (p < 
0.05) compared to control. Number sign (#) indicates significant difference (p < 0.05) 
compared to NT. 
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Figure 3.5. The effect of RNAi-mediated knockdown of PLCβ3 and PLCγ1 on tight junction 
barrier function in MDCK cells. Knockdown cells were compared to both non-transfected 
(NT) and non-sense transfected (NS) cells. (A) TEER was measured every twenty four hours 
for five days following transfection. (B) On day three, paracellular marker mannitol was 
added to the apical compartment and absorptive permeability during the 30-60 minute 
interval post-dose was determined. (C) On day two following transfection, low calcium 
media was applied to cells for twelve hours. Following the twelve hour treatment period, 
normal calcium media was returned to cells and TEER was measured for twenty for hours to 
assess tight junction formation. Data represent mean ± standard deviation from triplicate 
determinations. 
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Figure 3.6. RNAi-mediated knockdown of PLCβ3 and PLCγ1 alone and together in MDCK 
cells. MDCK cells were transfected with siRNA oligonucleotides targeting both cPLCβ3 (2 
μM) and cPLCγ1 (5 μM) and expression was compared to non-transfected (NT) cells. Non-
sense transfected cells (NS) served as an additional control. GAPDH served as loading 
control. (A)  Expression of both isozymes with respect to days in culture during simultaneous 
knockdown. (B) Expression of both isozymes on day three post transfection alone and in 
combination. 
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Figure 3.7. The effect of simultaneous RNAi-mediated knockdown of PLCβ3 and PLCγ1 on 
tight junction barrier function in MDCK cells. Knockdown cells were compared to non-
transfected (NT) and non-sense transfected (NS) cells. (A) TEER was measured every twenty 
four hours for five days following transfection. (B) On day three, paracellular marker 
mannitol was added to the apical compartment and absorptive permeability during the 30-60 
minute interval post-dose was determined. (C) On day two following transfection, low 
calcium media was applied to cells for twelve hours. Following the twelve hour treatment 
period, normal calcium media was returned to cells and TEER was measured for twenty for 
hours to assess tight junction formation. Data represent mean ± standard deviation from 
triplicate determinations. 
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Figure 3.8. The effect of simultaneous RNAi-mediated knockdown of PLCβ3 and PLCγ1 on 
the subcellular localization of tight junction protein ZO-1. Knockdown cells were compared 
to non-sense transfected cells (NS). Cells were fixed with 1% paraformaldehyde and stained 
with appropriate antibodies on day three post-transfection. GFP was used to identify 
transfected cells. Cell populations were selected that contained a mixed population of 
transfected and non-transfected cells. Arrows indicate cell borders of transfected cells. 
Images were collected using a Zeiss510 Meta confocal microscope with a 63x plan-
Apochromat oil immersion lens. Maximum XY projections were generated with Zeiss LSM 
Image Browser version 3.2 and processed using Adobe Photoshop. Individual staining of 
ZO-1 and GFP are presented in black and white to provide increased contrast and clarity 
while merged image is presented in color. 
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Figure 3.9. The effect of simultaneous RNAi-mediated knockdown of PLCβ3 and PLCγ1 on 
the subcellular localization of tight junction protein ZO-2. Knockdown cells were compared 
to non-sense transfected cells (NS). Cells were fixed with 1% paraformaldehyde and stained 
with appropriate antibodies on day three post-transfection. GFP was used to identify 
transfected cells. Cell populations were selected that contained a mixed population of 
transfected and non-transfected cells. Arrows indicate cell borders of transfected cells. 
Images were collected using a Zeiss510 Meta confocal microscope with a 63x plan-
Apochromat oil immersion lens. Maximum XY projections were generated with Zeiss LSM 
Image Browser version 3.2 and processed using Adobe Photoshop. Individual staining of 
ZO-2 and GFP are presented in black and white to provide increased contrast and clarity 
while merged image is presented in color. 
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Figure 3.10. The effect of simultaneous RNAi-mediated knockdown of PLCβ3 and PLCγ1 
on the subcellular localization of tight junction protein occludin. Knockdown cells were 
compared to non-sense transfected cells (NS). Cells were fixed with 1% paraformaldehyde 
and stained with appropriate antibodies on day three post-transfection. GFP was used to 
identify transfected cells. Cell populations were selected that contained a mixed population 
of transfected and non-transfected cells. Arrows indicate cell borders of transfected cells. 
Images were collected using a Zeiss510 Meta confocal microscope with a 63x plan-
Apochromat oil immersion lens. Maximum projections were generated with Zeiss LSM 
Image Browser version 3.2 and processed using Adobe Photoshop. Individual staining of 
occludin and GFP are presented in black and white to provide increased contrast and clarity 
while merged image is presented in color. 
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Figure 3.11. Structures of U73122 and hexadecylphosphocholine (HPC). 
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Figure 3.12. The effect of simultaneous RNAi-mediated knockdown of PLCβ3 and PLCγ1 
on the potency of HPC and U73122 as paracellular permeability enhancers in MDCK cells. 
Cells were treated apically with either (A) HPC or (B) U73122 at indicated concentrations 
for thirty minutes and TEER was measured. Data represent mean ± standard deviation from 
triplicate determinations from one representative experiment. 
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Figure 3.13. The effect of simultaneous RNAi-mediated knockdown of PLCβ3 and PLCγ1 
on the potency of HPC and U73122 as paracellular permeability enhancers in MDCK cells. 
Cells were treated apically with either (A) HPC or (B) U73122 at indicated concentrations 
for thirty minutes and the absorptive permeability of mannitol was determined during the 30-
60 minute period post-treatment. Data represent mean ± standard deviation from triplicate 
determinations from one representative experiment. 
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CHAPTER 4 
 
 
 
 
DIRECT ACTIVATION OF HUMAN PHOSPHOLIPASE Cβ3 BY U73122 IN 
DODECYLMALTOSIDE MIXED MICELLES VIA ALKYLATION AT CYSTEINE 
RESIDUES 
 
   
ABSTRACT 
Phospholipase C (PLC) enzymes hydrolyze the polar head group from inositol-containing 
membrane phospholipids, and are a key family of regulatory proteins involved in numerous 
cellular functions. U73122 is one of only a few small molecules reported to inhibit the 
activity of these enzymes in cellular and non-cellular systems, and has been broadly applied 
as a pharmacological tool to implicate PLC in observed experimental phenotypes. The 
purpose of the present study was to develop a better understanding of the molecular 
interaction between U73122 and PLC by evaluating the effects of U73122 on human PLCβ3 
(hPLCβ3) in a simple, cell free system. PLC activity was assessed by measuring changes in 
[3H]-inositol phosphate formation following incubation of hPLCβ3 with [3H]-
phosphatidylinositol-4,5-bisphosphate (PIP2) in a dodecylmaltoside micellar system. It was 
hypothesized that the maleimide-containing U73122 would irreversibly inhibit the activity of 
PLC via covalent binding to cysteine residues. Surprisingly, U73122 was found to increase 
the activity of hPLCβ3 in DDM mixed micelles in a concentration and time dependent 
manner (EC50 = 13.6 ± 5 µM). Activation was attenuated by thiol containing nucleophiles, L-
cysteine and glutathione, suggesting that covalent modification of cysteine residues on the 
enzyme is essential for the activation. Mass spectrometric analysis of U73122-activated 
hPLCβ3 confirmed alkylation at up to eight cysteine residues, specifically identified by 
LC/MS/MS peptide sequencing.  This study is the first to report direct activation of PLC via 
a mechanism involving cysteine alkylation. 
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INTRODUCTION  
U73122 (1-(6-((17β-3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-
2,5-dione) (Figure 4.1) is an aminosteroid first reported as an inhibitor of PLC dependent 
processes in 19891. Many reports have since demonstrated that several isozymes of PLC are 
inhibited by U73122, but not by U73343, a close structural analog of U73122 containing N-
alkylsuccinimide instead of N-alkylmaleimide moiety2-4, establishing U73122 as the 
prototypical inhibitor of PLC enzymes. These reports have been previously substantiated in 
both MDCK and Caco-2 cells as U73122, but not U73343, inhibits ATP-stimulated PLCβ 
activity in both cells lines in a concentration dependent manner, while U73343 does not 
(Chapter 2)5. In addition to its effects on PLC, U73122 at similar concentrations has been 
found to increase the permeability of epithelial cell monolayers to the paracellular marker 
mannitol, implicating PLC isozymes in the modulation of paracellular permeability (Chapter 
2)5. However, recent studies (Chapter 3) contradict this hypothesis, as RNAi-mediated 
knockdown of both PLCβ3 and PLCγ1 in MDCK cells has no effect on the assembly or 
maintenance of tight junction barrier function. Therefore, the observed increase in 
paracellular permeability following treatment of epithelial cells with U73122 likely occurs 
via an alternative mechanism. Several laboratories have demonstrated that U73122 is not 
selective for PLC, as effects on a variety of other proteins have been reported including 
telomerase6, 5-lipoxygenase7, histamine H1 receptor8, calcium channels9, and 
phosphatidylinositol (PI)-dependent as well as PI-independent exocytic processes10. These 
studies provide examples of alternative cellular targets that may be affected by U73122 
treatment; however, none have been directly linked to regulation of tight junction function. 
Interestingly, although U73122 clearly inhibits receptor-mediated activation of PLC, indirect 
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evidence for activation of PLC activity has also been reported1, 11, implying complex effects 
of this compound on the activity of these enzymes in whole cell systems. 
Consistent with the numerous reports identifying alternative cellular targets for 
U73122, recent studies have questioned the use of this compound as a truly selective 
modulator of PLC, specifically addressing the presence of the electrophilic maleimide moiety 
that is replaced by a succinimide moiety in the inactive analog, U73343 (Figure 4.1)11, 12. 
Maleimides are inherently reactive and readily react with cellular thiols and amines, 
providing a likely mechanism for the observed off-target effects. Despite the numerous 
studies reporting U73122 as an inhibitor of PLC, as well as it’s widespread use as a probe 
molecule to implicate the involvement of PLC in signaling pathways and phenotypic cellular 
response, little work has been done to understand the interaction of this molecule with PLC at 
the molecular level. In the present study, the ability of U73122 to inhibit the catalytic activity 
of hPLCβ3 in a simple, cell free, mixed micellar system was investigated. Surprisingly, these 
studies revealed that U73122 activates, not inhibits, the activity of hPLCβ3 in a concentration 
dependent manner. 
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MATERIALS AND METHODS 
Materials. Dodecylmaltoside (DDM) was purchased from Fluka. [3H]-PIP2 
(phosphatidylinositol 4,5-bisphosphate, [myo-inositol-2-3H(N)]) (20 Ci/mmol) was 
purchased from American Radiolabeled Chemicals. PIP2 and hexadecylphosphocholine were 
purchased from Avanti Polar Lipids. 3-nitrocoumarin was synthesized as described 
previously13. U73122, U73343, N-ethylmaleimide, fatty acid free bovine serum albumin 
(BSA), and all other reagents were purchased from Sigma unless otherwise indicated. 
Purified hPLCβ3 was generously provided by the laboratory of Dr. T. K. Harden 
(Department of Pharmacology, School of Medicine, University of North Carolina at Chapel 
Hill). Trypsin, thermolysin, and endoproteinase GluC for digestion of hPLCβ3 were from 
Promega, Fluka, and Roche respectively. 
Mixed Micellar PLC Assay. The activity of hPLCβ3 in a cell free system was evaluated by 
an adaptation of previously published methods14, 15.  Briefly, [3H]-labeled and unlabeled PIP2 
(5 nmol), was reconstituted in a 1 mM DDM solution and mixed with assay buffer containing 
40 mM Hepes (pH 7.4), 480 mM KCl, 40 mM NaCl, 8 mM EGTA, 4 mM MgCl4, and 7.6 
mM CaCl2. Compounds at desired concentrations, and purified hPLCβ3 in 1% fatty acid-free 
BSA and 10 mM Hepes (pH 7.0), were subsequently added to the mixture. To initiate assays, 
samples were moved to a 37°C water bath and incubated for 2-10 minutes such that less than 
fifteen percent total substrate was hydrolyzed. At designated times, reactions were stopped 
by addition of 750 μl CHCl3:MeOH:HCl (40:80:1), followed by the addition of 100 μl water, 
250 μl CHCl3, and 250 μl 0.1 M HCl. Samples were vortexed and centrifuged at 3000 rpm 
for 10 minutes at 4°C. The amount of [3H]-inositol phosphates formed was measured by 
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liquid scintillation counting of 500 μl of the upper phase in a Packard Tri Carb 4000 Series 
spectrophotometer. 
Data analysis. Data are expressed as the mean ± standard deviation (SD) from three 
measurements unless indicated otherwise. Where indicated, statistical significance was 
assessed using a two sample Student’s t tests. Samples were assumed to have an unequal 
variance; significant differences were assigned at p < 0.05. 
EC50 PLCβ3 Estimation.  To accurately quantify the potency of U73122 for activating PLCβ3 
in DDM mixed micelles, concentration-effect profiles were generated for each experiment 
(n=4). Catalytic activities were converted to the percentage of the maximum effect (E(%)) 
according to Equation 1, where Eobs is the observed activity, E0 is control activity in the 
absence of U73122, and Emax is the maximum activity attained with 100 μM U7312216. The 
relationship between E(%) for PLCβ3 activity and U73122 concentration (C) was fit to a 
standard Hill equation by nonlinear least-squares regression (WinNonlin, version 4.1) to 
recover estimates for EC50 PLCβ3 for each concentration-effect profile (Equation 2). Estimates 
were also generated for the sigmoidicity factor (γ); however, 100% was substituted for Emax. 
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Mass Spectrometry. Mass spectrometry of intact PLCβ3 was performed using reversed-
phase chromatography17 coupled to an Agilent Technologies (Santa Clara) 6210 LC-MSD-
TOF mass spectrometer. Ionization was achieved using electrospray ionization with a spray 
voltage of -4.0 kV with heated nitrogen (350°C) serving as both a nebulizing (25 psi) and 
drying (12 L/min) gas. The fragmentor was set at 280 V and the instrument was set to detect 
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ions from mass/charge 500 to mass/charge 2500. The mass-to-charge data were transformed 
to the mass domain using BioConfirm software from Agilent. For peptide sequencing, 
solutions of unmodified and modified hPLCβ3 were reduced using DTT, alkylated with 
iodoacetamide, and incubated in an ammonium bicarbonate buffer with trypsin, thermolysin, 
or endoproteinase GluC (enzyme:substrate = 1:20) overnight at 37°C18. The tryptic peptides 
were subsequently analyzed by nano-LC/MS/MS on a Dionex UltiMate nano LC (Sunnyvale, 
CA) coupled to ABI-Sciex (Toronto, ON) Q-Star Pulsar i mass spectrometer using both a 
trapping cartridge column (0.3 x 5 mm) and a pepmap (0.075 x 150 mm, 3 μM particle size) 
C18 columns (Dionex). Mobile phase A contained 2% acetonitrile and mobile phase B 
contained 95% acetonitrile, both with 0.2% formic acid. Following a six minute load of 
sample onto the trapping cartridge at a flow rate of 25 μl/min with a mobile phase ratio of 
95:5, flow was then switched to backflush off the trapping cartridge and onto the nano-LC 
column at 0.2 μl/min. The percentage of mobile phase B was changed over one hour from 
5% to 40% with a linear gradient to adequately separate peptides, followed by a second linear 
gradient from 40% to 99% over the next seven minutes. The results were processed using 
MASCOT (Matrix Sciences, London, UK) protein database that had the mass of U73122 
modification created as a variable modification. 
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RESULTS 
Activity of human PLCβ3 in phospholipid-detergent mixed micelles 
Rates of PIP2 hydrolysis catalyzed by several PLCβ isozymes in DDM/PIP2 mixed 
micelles have been shown to be linear when substrate mole fraction is <0.3 and ≤10% of total 
substrate is utilized14, 15. hPLCβ3 activity with respect to time at a substrate mole fraction of 
0.1 is presented in Figure 4.2. Consistent with previous studies, two distinct phases of 
activity were observed, an initial burst of activity linear when ≤15% of PIP2 is utilized, 
followed by a second, slower phase of hydrolysis. Additional studies were performed at fixed 
calcium and PIP2 concentrations, and were designed such that ≤15% of total substrate was 
utilized in all cases when substrate consumption was linear with respect to time. 
U73122, but not U73343, increases human PLCβ3 activity in a concentration dependent 
manner. 
 In DDM mixed micelles, U73122 unexpectedly increased the activity of hPLCβ3 in a 
concentration-dependent manner with a maximum increase of approximately eight fold with 
respect to control. Application of a modified Hill equation, as described in Materials and 
Methods, estimated an EC50 value of 13.6 ± 5 μM (n=4) for the observed activation (Figure 
4.3). The estimated EC50 from these data should be interpreted within the context of the 
current set of results, as solubility limitations of U73122 in DMSO stock solutions prevented 
assessment of activation at concentrations greater than 100 μM. U73343, a close structural 
analog of U73122 containing N-alkylsuccinimide instead of N-alkylmaleimide moiety, 
(Figure 4.1) had a small but significant effect on activity at 40 μM (Figure 4.4), implicating 
the maleimide moiety in the observed activation of hPLCβ3 by U73122. 
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Thiol-containing nucleophiles, glutathione and cysteine, attenuate the U73122-mediated 
activation of human PLCβ3 in DDM mixed micelles. 
 Thiol containing compounds, glutathione and cysteine, targets for reaction with 
electrophilic functional groups such as maleimide, attenuated the U73122-mediated 
activation of hPLCβ3 in a concentration-dependent manner (Figure 4.5). The ability of thiols 
to prevent the increase in PLC activity caused by U73122 suggests that U73122 alkylates 
hPLCβ3 by reacting with nucleophiles, likely protein sulfhydryl groups (i.e. cysteine 
residues) leading to an irreversible modification of the enzyme. 
U73122-mediated activation of human PLCβ3 is rapid and irreversible. 
 To further investigate the hypothesis that activation of hPLCβ3 by U73122 involves 
covalent alkylation of the enzyme, the effect of pre-incubation time on the observed 
activation was evaluated. Thus, hPLCβ3 was pre-incubated with U73122 in the absence of 
substrate and detergent, excess U73122 was removed with the addition of 1 mM glutathione. 
PIP2, re-suspended in DDM, was then added to initiate the assay. Pre-incubation of hPLCβ3 
with U73122 increased activity compared to control, suggesting that activation of the enzyme 
was caused by direct interaction of U73122 with the enzyme, likely irreversible covalent 
modification of one or more sulfhydryl groups. Increased activity was observed with minimal 
pre-incubation time, and reached a maximum increase of five fold within thirty seconds 
(Figure 4.6). Separate studies established that addition of 1 mM glutathione to 40 μM 
U73122 results in the immediate disappearance of U73122 as measured via LC/MS (data not 
shown). It was further confirmed that the preformed U73122-glutathione conjugate had no 
direct effect on the activity of hPLCβ3 in this system (data not shown). 
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U73122, but not U73343, alkylates human PLCβ3. 
 In order to unequivocally establish that alkylation of hPLCβ3 by U73122 is a 
requirement for its activation, mass spectra were obtained of intact hPLCβ3 alone and after 
incubation with either 40 μM U73122 or 40 μM U73343 for various time intervals. Mass 
spectra of hPLCβ3 revealed a complex protein of approximately 138kD (Figure 4.7.A); 
however, when incubated with 40 μM U73122, spectra revealed the presence of protein 
species with discrete increases in mass consistent with covalent addition of up to eight 
molecules of U73122 (Figure 4.7.B and 4.7.C). Extended incubation times did not lead to 
more than eight U73122 additions, although shorter incubation times revealed the presence 
of proteins with less than eight molecules of U73122 covalently attached, i.e. two to eight 
additions of U73122 were observed, and even at the shortest incubation times, protein 
species with a single addition of U73122 were not detected. One minute incubation revealed 
up to four covalently attached U73122 molecules (Figure 4.7.B) in conjunction with the near 
maximal activation of the protein by U73122 in DDM mixed micelles (Figure 4.6). This 
observation implies that not all eight U73122 molecules are required to achieve maximal 
activation of the enzyme. Interestingly, increasing incubation times also led to a shift in 
chromatographic retention time of intact hPLCβ3 (data not shown). With increasing 
incubation times, the observed peak began to split, and as time progressed the later half of the 
observed split peak became the dominant peak. This downstream shift in chromatographic 
retention is likely due to increased lipophilicity of intact hPLCβ3 as a result of the increased 
addition of the highly lipophilic U73122. Mass spectra of hPLCβ3 incubated with U73343 
for extended time periods was unchanged (Figure 4.7.D), suggesting that the maleimide 
moiety in U73122 is responsible for the alkylation. 
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U73122 alkylates specific cysteine residues of human PLCβ3.  
hPLCβ3 contains fourteen cysteine residues (Figure 4.8). LC/MS/MS peptide 
mapping of protease-digested hPLCβ3 identified peptides containing twelve of the fourteen 
cysteines. Following incubation of hPLCβ3 with U73122 for thirty minutes, eight of the 
twelve detectable cysteines were found alkylated by U73122, consistent with the observed 
mass changes to intact hPLCβ3 when incubated with U73122 for the same time period. The 
following cysteines were identified as alkylated: Cysteine (Cys)193, Cys221, Cys360, 
Cys516, Cys614, Cys892, Cys1176, and Cys1207. 
Effect of N-ethylmaleimide (NEM) on human PLCβ3 activity, and on U73122-mediated 
activation and alkylation of human PLCβ3. 
 NEM is a small water soluble maleimide-containing compound lacking the long alkyl 
chain and steroid backbone present in U73122 (Figure 4.9.A). At concentrations up to 400 
μM, NEM had no effect on the activity of hPLCβ3 in DDM mixed micelles (Figure 4.9.B). 
Despite this lack of activation by NEM in DDM mixed micelles, mass spectra of intact 
hPLCβ3 incubated with 400 μM NEM for extended time periods revealed protein species of 
increasing mass consistent with the covalent addition of up to eight NEM molecules (Figure 
4.9.C). Due to the low molecular weight of NEM compared to U73122, it was not possible to 
distinguish discrete additions of NEM to hPLCβ3. Together, these data demonstrate that 
although NEM alkylates hPLCβ3, it is unable to increase its activity. On the other hand, 
NEM was able to attenuate the ability of U73122 to activate hPLCβ3 in a concentration 
dependent manner (Figure 4.9.D). Therefore, NEM blocks the U73122-mediated activation 
of hPLCβ3, but does not activate the protein itself. Interestingly, NEM, at concentrations as 
high as 1 mM, was unable to completely inhibit the U73122-mediated activation, unless 
hPLCβ3 was pre-incubated with NEM prior to the addition of U73122 (Figure 4.9.D). To test 
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the hypothesis that NEM alkylates the same cysteine residues as U73122, NEM-modified 
hPLCβ3 was subsequently incubated with U73122. Mass spectra of this sample revealed no 
further additions of U73122 to hPLCβ3 (Figure 4.9.E). Together, these data suggest that 
NEM attenuates the U73122-mediated activation of hPLCβ3 via alkylation at the same 
cysteine residues, and prevents alkylation by U73122. 
PLC inhibitors 3-nitrocoumarin (3-NC) and hexadecylphosphocholine (HPC) have no 
effect on human PLCβ3 activity in DDM mixed micelles. 
 Previously reported PLC inhibitors 3-NC13, 19 and HPC5, 20, 21 were tested for their 
ability to inhibit hPLCβ3 in DDM mixed micelles. Contrary to numerous reports 
demonstrating inhibition of PLC by both molecules, neither had any effect on hPLCβ3 
activity in DDM mixed micelles at concentrations as high as 500 μM (Figure 4.11). 
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DISCUSSION 
U73122 has long been regarded as a prototypical inhibitor of PLC, while its inactive 
analog, U73343, has served as a negative control. Structurally, the difference between these 
two compounds is simply the substitution of a maleimide moiety in U73122 for a 
succinimide moiety in U73343, suggesting that the highly electrophilic maleimide is 
responsible for the observed effects in experimental systems, including inhibition of PLC 
activity. Recent studies have questioned the use of U73122 as a specific inhibitor of PLC by 
uncovering its “off-target” interactions, likely due to covalent modification of nucleophiles 
by the maleimide moiety10-12. These findings point to the likely complication of using 
U73122 as a tool to study PLC function in complex cellular systems, and suggest the need 
for a clearer understanding of how U73122 interacts with PLC at the molecular level. 
PLCs are water soluble enzymes that hydrolyze poorly soluble phospholipids present 
in cell membranes. Enzymatic activity is tightly regulated in whole cells via both cell 
membrane and intracellular mechanisms. For example, the activity of PLCβ isozymes is 
tightly regulated via specific G-protein coupled receptors at the cell membrane; further, novel 
intracellular feedback mechanisms have recently been identified that control the amplitude 
and duration of PLCβ stimulation22. Due to the complexity of how PLC functions inside the 
cell, it is difficult to assess whether an observed inhibition of PLC activity is by directly 
interacting with the enzyme, by indirectly interfering with PLCs interaction with its 
substrates in the cell membrane, or by indirectly interfering with receptors and other 
cofactors involved in regulating its activity. In the present study, the interaction of U73122 
with hPLCβ3 was investigated in a cell-free system to elucidate the mechanism by which it 
inhibits the enzyme in cellular systems. 
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In order to study PLC in cell-free systems, the presence of a suitable interface 
between the hydrophilic enzyme and the hydrophobic substrate is required in order to 
achieve measurable enzymatic activity. The enzyme must first partition between the aqueous 
phase and the substrate interface prior to acting on its substrate. A number of useful 
experimental systems have been described for assessing lipase activity, although most are 
unable to measure both of these discrete steps simultaneously, complicating data 
interpretation and kinetic analysis. The use of liposomes, vesicle based co-expression 
systems, membrane bilayers and monolayers, as well as mixed micellar systems have been 
reported, each with a unique set of advantages and limitations14, 15, 23-25. Perhaps the simplest 
of systems in which to present the substrate to PLC is a mixed micellar system, which 
eliminates the complexities of receptor activation that must be considered in more complex 
systems; on the other hand, lamellar structure is not necessarily maintained in a mixed 
micellar system, a characteristic that makes it less representative of physiologic cell 
membranes. As the purpose of the present study was to assess the direct interaction between 
U73122 and hPLCβ3 in the absence of confounding components that may act as nucleophilic 
targets for U73122, the simplest system available, i.e. mixed micelles, was employed. DDM 
is a non-ionic surfactant previously reported to be a useful inert diluent to establish an 
interface for presentation of insoluble substrate, PIP2, to PLC in the absence of a 
phospholipid bilayer14, 15, and was therefore utilized as detergent to form micelles in these 
studies. 
The expectation was that U73122 would irreversibly inhibit lipase activity via a 
mechanism involving covalent modification of the nucleophilic residues on PLC (i.e. 
cysteines). Surprisingly, U73122 actually increased hPLCβ3 activity in a concentration 
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dependent manner in DDM mixed micelles (Figure 4.3), while U73343 had a minimal effect 
(Figure 4.4). As previously indicated, U73122 has almost exclusively been reported as a 
potent inhibitor of PLC action, although a recent study in whole cells observed weak and 
transient activation effects in addition to the expected potent inhibition11, providing both 
precedence and potential relevance to cellular systems for the current observations. 
The activation observed in mixed micelles reached maximal effect rapidly, and was 
irreversible (Figure 4.6). Furthermore, activation could be attenuated with competing 
nucleophiles, glutathione and cysteine (Figure 4.5). These results, along with the inactivity of 
succinimide containing analog U73343, strongly implicated the maleimide in the observed 
activation. Maleimides are inherently reactive and readily interact with thiols, such as 
cysteine residues, on cellular proteins. To determine if protein alkylation at cysteine residues 
on hPLCβ3 was a likely mechanism for the U73122-mediated activation, mass spectra of 
intact hPLCβ3 in the presence and absence of U73122 were collected. With increasing 
incubation times, the addition of up to eight U73122 molecules could easily be detected 
based on increases in mass/charge of intact hPLCβ3 by multiples of the molecular weight of 
U73122 (approximately 0.5 kDa) (Figure 4.7). These data demonstrate that U73122 reacts 
covalently with as many as eight distinct sites on hPLCβ3, and provides an underlying 
molecular mechanism for modulation of PLC activity in experimental systems. 
The importance of cysteine residues in protein function is well established. Specific 
protein cysteine residues are required for activation of the ion channel, TRPA126, 27, are 
important for enzymatic activity of caspases 28, 29 as well as other lipases30, are crucial for 
regulating the activity of cellular phosphatases such as PTEN31, and are used as 
palmitoylation sites for integral membrane proteins such as claudin32 and signaling proteins 
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like H-ras33, 34. There are fourteen cysteine residues in hPLCβ3 (Figure 4.8). In order to 
confirm cysteines as the site of alkylation by U73122, as well as to identify particular 
residues as specific targets, LC/MS/MS was used for peptide mapping of protease digested 
hPLCβ3. Intact protein was digested overnight with three different proteases (trypsin, 
thermolysin, and endoproteinase GluC) in order to provide greater sequence coverage of the 
high molecular weight hPLCβ3. Peptides containing twelve of the fourteen cysteines were 
detected in unmodified hPLCβ3, excluding Cys669 and Cys834. When hPLCβ3 was 
incubated with U73122, eight specific cysteine residues were alkylated, including Cys360 
and Cys614 located in the so called ‘X’ and ‘Y’ boxes that make up the highly conserved 
catalytic domain of all PLCs, Cys516 in the less conserved linker region between the ‘X’ and 
‘Y’ boxes, as well as Cys193, Cys221, Cys892, Cys1176, and Cys1207 outside of the 
catalytic domain. Interestingly, Cys193 and Cys221 are located within the PH domain, a 
region thought to be critical for the membrane recruitment of PLCβ isozymes, and recently 
implicated in the interaction of PLCβ2 with Rac1 during substrate catalysis35. Time-
dependent activation studies (Figure 4.6) demonstrating maximum activation with very short 
pre-incubation of U73122 with hPLCβ3 (i.e. less than one minute), together with time-
dependent alkylation studies (Figure 4.7.B and Figure 4.7.C) imply that incomplete 
alkylation (i.e. less than eight modifications) is sufficient to achieve the observed activation. 
In other words, maximal activation was observed within one minute of pre-incubation of 
U73122 with hPLCβ3; however, after one minute of incubation, mass spectra of intact 
hPLCβ3 revealed only four additions of U73122. Despite the apparent lack of specificity of 
U73122 for alkylating hPLCβ3, it is conceivable that alkylation at one specific residue is 
primarily responsible for the activation. Site-directed mutagenesis of each alkylated cysteine 
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residue would be useful to explore the role of individual cysteine residues in the observed 
activation. At this point, the question remaining to be addressed was whether the covalent 
modification was responsible for the activation, and if so, how? 
NEM (Figure 4.9) is a small water soluble maleimide capable of modifying sulfydryl 
groups on proteins, and served as a useful tool to further probe the interaction between PLC 
and U73122. A number of interesting observations were noted in studies performed with 
NEM: (1) NEM alone had no effect on the activity of hPLCβ3 in DDM mixed micelles at 
concentrations as high as 400 μM, despite the fact that mass spectra of intact hPLCβ3 
incubated with NEM identified protein species with mass/charge consistent with the addition 
of up to eight NEM molecules. This result indicates that although the maleimide moiety is 
required for the activation of PLC, it is not sufficient by itself, suggesting an important role 
for the hydrophobic backbone of U73122 in the mechanism of activation. This result further 
suggests that the eight cysteine residues alkylated by NEM are not crucial for maintaining the 
catalytic activity of hPLCβ3 in this system. (2) The combined treatment of NEM and U73343 
had no effect on activity (data not shown), implying that the maleimide moiety and the 
hydrophobic backbone must be chemically bound to observe PLC activation. It would be 
interesting to investigate structure-activity relationships between the observed activation of 
PLC activity and the length of the N-alkyl chain that links the maleimide moiety to the 
steroid moiety of U73122. (3) Although NEM was unable to activate PLC alone, it was able 
to attenuate the U73122-mediated activation in a concentration dependent manner. 
Interestingly though, the inhibition was not complete up to concentrations as high as 1 mM, 
unless NEM was incubated with the enzyme prior to the addition of U73122. This result 
suggests a common mechanism of interaction for both molecules with hPLCβ3, and implies 
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that NEM alkylates the same cysteine residues. (4) To confirm that NEM alkylates the same 
cysteine residues, mass spectra of NEM-treated hPLCβ3 were collected before and after 
incubation with U73122. This study indicated that once hPLCβ3 had been exposed to NEM, 
U73122 was not able to react with the protein. Together, studies with NEM demonstrate that 
NEM alkylates hPLCβ3 at cysteine residues but does not increase its lipase activity; 
however, the alkylation by NEM can completely block covalent reaction of hPLCβ3 with 
U73122 and its subsequent activation. 
The results presented herein are consistent with the following hypothesis for 
activation of hPLCβ3: U73122 irreversibly binds to multiple cysteine residues on hPLCβ3 
and serves as either a lipid anchor or interfacial recognition site for the enzyme, facilitating 
adsorption to the substrate interface (i.e. the micelle surface), subsequently increasing the 
rate of lipase activity by keeping the enzyme in close proximity to multiple substrates (Figure 
4.10). 
The molecular mechanism of cellular PLC activation and subsequent substrate 
hydrolysis is not completely understood. It is interesting to speculate about the potential role 
of a cysteine residue in conformational changes that may occur during lipase activation and 
subsequent substrate hydrolysis. Conformational changes exposing the active site and 
increasing activity have been reported at substrate interfaces for a number of lipases (i.e. the 
opening of the lid providing access to the active site)23, 36-42, and have recently been 
hypothesized for PLCβ isozymes35; although the molecular mechanisms associated with 
these changes have not yet been elucidated. Post-translational modifications, such as 
phosphorylation, have clearly been shown to trigger rapid conformational changes in many 
proteins leading to significant alterations in protein function43-46. In recent years, studies have 
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rapidly emerged implicating reversible cysteine modifications (e.g. S-nitrosation) in changes 
to protein function47-49. For example, nitrosation of caspase 3 by nitric oxide at a specific 
cysteine residue was reported to be critical for promotion of apoptosis28, 29. S-nitrosothiols 
have also been shown to oxidatively modify phosphatases such as PTEN, a PIP3 phosphatase, 
leading to a reversible inhibition of its phosphatase activity31 and supporting a hypothesis for 
cysteine-dependent changes in protein function. Further, S-nitrosation has been postulated as 
a regulatory mechanism for Ras superfamily GTPases (i.e. Ras and RhoA)50, 51, two enzymes 
known to be directly involved in the regulation of specific PLC isozymes52. Perhaps a 
reversible modification of a cysteine residue in hPLCβ3 occurs during receptor mediated 
activation that leads to a protein conformational change promoting interaction with cell 
membranes, akin to the reported activation and conformation change of hypoxia inducible 
factor 1 by S-nitrosation53. Interestingly, a recent report suggests that low concentrations of 
the reactive oxygen species, H2O2, generates intracellular calcium oscillations in rat 
astrocytes by activating PLCγ1 via a sulfydryl-dependent oxidation mechanism54. 
Even more interesting are reports implicating PLC activation, not inhibition, in tight 
junction barrier function, as a number of agonists of receptors known to couple to PLCs have 
been reported to affect the functional integrity of tight junctions55-58. Further, increase in 
intracellular calcium levels59, activation of specific PKC isozymes60, as well as non-PLC-
mediated depletion of membrane PIP2 content61, 62, all downstream actions resulting from 
PLC activation, have been demonstrated to increase paracellular permeability or alter the 
barrier function of junctional complexes. These studies imply that PLC activation, not 
inhibition, may lead to an increase in paracellular permeability due to modulation of cell-cell 
junctions. This hypothesis, in conjunction with current evidence suggesting U73122 may 
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activate PLC, provides an alternative mechanism for the observed effects of U73122 on 
paracellular permeability in both MDCK and Caco-2 cells (Chapter 2)5, and explains the 
discrepancy between results from studies using chemical inhibitors of PLC (Chapter 2) 
versus results from studies employing RNAi suppression of PLC (Chapter 3). Further studies 
are necessary to evaluate this hypothesis and to understand why PLC activity measured in 
whole cell systems appears to be inhibited by U73122. 
The present results also support recent evidence suggesting that U73122 is highly 
reactive and capable of rapidly alkylating nucleophiles12, including cysteine residues on 
hPLCβ3 and BSA (data not shown). The effects of U73122, particularly in cell-based assays, 
will be complex and dependent on the presence of free nucleophiles in the media, in the cell 
membrane, and in the cytosol. Care should be taken when making conclusions based on the 
effects of U73122 in cellular, and non-cellular, assays. Studies intended to implicate PLC 
enzymes in cellular phenotypes should avoid using this compound as a probe molecule, as its 
reactivity with other cellular nucleophiles may lead to off-target effects that could be 
mistakenly attributed to PLC involvement. 
As the studies reported here were carried out in a well defined cell free system, the 
cellular relevance of the observed activation requires further study. Interestingly, other 
reported inhibitors of PLC (i.e. 3-NC and HPC) also failed to inhibit lipase activity in this 
system (Figure 4.11), implying that the effects of these compounds on PLC activity in whole 
cells may not be mediated via direct interaction with the enzyme. In order to acquire a more 
complete understanding of the interaction between PLC and its reported inhibitors, and to 
confirm the unexpected enzymatic activation by U73122, studies should be performed in 
multiple assay systems to develop a more clear understanding of how purported PLC 
185 
inhibitors actually modulate the catalytic activity of this important class of regulatory signal 
transduction enzymes. The data reported herein provide an underlying molecular mechanism 
for modulation of PLC activity by U73122, whether the end-result in cellular systems is 
enzymatic activation or inhibition. 
186 
ACKNOWLEDGEMENTS 
I would like to gratefully acknowledge Drs. David M. Bourdon, T. Kendall Harden, John 
Sondek, and Jason Snyder (Department of Pharmacology, School of Medicine, University of 
North Carolina, Chapel Hill, NC) for hPLCβ3 and helpful discussions regarding cell free 
PLC assays. Further, I would like to acknowledge the important contributions of Dr. Jon 
Williams, Craig Wagner, and Wendy White (GlaxoSmithKline Inc.) with all aspects of mass 
spectrometry. I would also like to thank Rick Graham (Genentech Inc.) for helpful 
discussions with EC50 PLCβ3 modeling. 
187 
REFERENCES 
1. Bleasdale, J.E., et al., Inhibition of phospholipase C dependent processes by U-73, 
122. Adv Prostaglandin Thromboxane Leukot Res, 1989. 19: p. 590-3. 
 
2. Carvou, N., et al., Signalling through phospholipase C interferes with clathrin-
mediated endocytosis. Cell Signal, 2007. 19(1): p. 42-51. 
 
3. Hou, C., et al., In vivo activity of a phospholipase C inhibitor, 1-(6-((17beta-3-
methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole -2,5-dione (U73122), in 
acute and chronic inflammatory reactions. J Pharmacol Exp Ther, 2004. 309(2): p. 
697-704. 
 
4. Smith, R.J., et al., Receptor-coupled signal transduction in human polymorphonuclear 
neutrophils: effects of a novel inhibitor of phospholipase C-dependent processes on 
cell responsiveness. J Pharmacol Exp Ther, 1990. 253(2): p. 688-97. 
 
5. Ward, P.D., H. Ouyang, and D.R. Thakker, Role of phospholipase C-beta in the 
modulation of epithelial tight junction permeability. J Pharmacol Exp Ther, 2003. 
304(2): p. 689-98. 
 
6. Chen, Y.J., et al., Potent inhibition of human telomerase by U-73122. J Biomed Sci, 
2006. 13(5): p. 667-74. 
 
7. Feisst, C., et al., The aminosteroid phospholipase C antagonist U-73122 (1-[6-[[17-
beta-3-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrro le-2,5-dione) 
potently inhibits human 5-lipoxygenase in vivo and in vitro. Mol Pharmacol, 2005. 
67(5): p. 1751-7. 
 
8. Hughes, S.A., W.J. Gibson, and J.M. Young, The interaction of U-73122 with the 
histamine H1 receptor: implications for the use of U-73122 in defining H1 receptor-
coupled signalling pathways. Naunyn Schmiedebergs Arch Pharmacol, 2000. 362(6): 
p. 555-8. 
 
9. Pulcinelli, F.M., et al., Evidence for separate effects of U73122 on phospholipase C 
and calcium channels in human platelets. Biochem Pharmacol, 1998. 56(11): p. 1481-
4. 
 
10. Gloyna, W., F. Schmitz, and J. Seebeck, Inhibition of phospholipase C-independent 
exocytotic responses in rat peritoneal mast cells by U73122. Regul Pept, 2005. 125(1-
3): p. 179-84. 
 
11. Horowitz, L.F., et al., Phospholipase C in living cells: activation, inhibition, Ca2+ 
requirement, and regulation of M current. J Gen Physiol, 2005. 126(3): p. 243-62. 
 
188 
12. Wilsher, N.E., et al., The phosphoinositide-specific phospholipase C inhibitor 
U73122 (1-(6-((17beta-3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrol 
e-2,5-dione) spontaneously forms conjugates with common components of cell 
culture medium. Drug Metab Dispos, 2007. 35(7): p. 1017-22. 
 
13. Ward, P.D., et al., Phospholipase C-gamma modulates epithelial tight junction 
permeability through hyperphosphorylation of tight junction proteins. J Biol Chem, 
2002. 277(38): p. 35760-5. 
 
14. James, S.R., et al., Kinetic analysis of phospholipase C beta isoforms using 
phospholipid-detergent mixed micelles. Evidence for interfacial catalysis involving 
distinct micelle binding and catalytic steps. J Biol Chem, 1995. 270(20): p. 11872-81. 
 
15. James, S.R., et al., Time-dependent inhibition of phospholipase C beta-catalysed 
phosphoinositide hydrolysis: a comparison of different assays. Biochem J, 1996. 314 ( 
Pt 3): p. 917-21. 
 
16. Graham, R.A., et al., Temporal kinetics and concentration-response relationships for 
induction of CYP1A, CYP2B, and CYP3A in primary cultures of beagle dog 
hepatocytes. J Biochem Mol Toxicol, 2006. 20(2): p. 69-78. 
 
17. Wagner, C.D., et al., Automated mass correction and data interpretation for protein 
open-access liquid chromatography-mass spectrometry. J Mass Spectrom, 2007. 
42(2): p. 139-49. 
 
18. Current Protocols in Protein Science. Section 11.1: Enzymatic digestion of proteins 
in solution. 1996-curent, Brooklyn: John Wiley and Sons, Inc. 
 
19. Perrella, F.W., et al., Phospholipase C inhibitors: a new class of cytotoxic agents. J 
Med Chem, 1994. 37(14): p. 2232-7. 
 
20. Berkovic, D., et al., Hexadecylphosphocholine inhibits phosphatidylinositol and 
phosphatidylcholine phospholipase C in human leukemia cells. J Exp Ther Oncol, 
1996. 1(5): p. 302-11. 
 
21. Pawelczyk, T. and J.M. Lowenstein, Inhibition of phospholipase C delta by 
hexadecylphosphorylcholine and lysophospholipids with antitumor activity. Biochem 
Pharmacol, 1993. 45(2): p. 493-7. 
 
22. Litosch, I., Novel mechanisms for feedback regulation of phospholipase C-beta 
activity. IUBMB Life, 2002. 54(5): p. 253-60. 
 
23. Aloulou, A., et al., Exploring the specific features of interfacial enzymology based on 
lipase studies. Biochim Biophys Acta, 2006. 1761(9): p. 995-1013. 
 
189 
24. Ghosh, M. and A.V. Smrcka, Assay for G protein-dependent activation of 
phospholipase C beta using purified protein components. Methods Mol Biol, 2004. 
237: p. 67-75. 
 
25. Myung, C.S., et al., Development of an assay for phospholipase C using column-
reconstituted, extruded phospholipid vesicles. Anal Biochem, 1999. 270(2): p. 303-13. 
 
26. Hinman, A., et al., TRP channel activation by reversible covalent modification. Proc 
Natl Acad Sci U S A, 2006. 103(51): p. 19564-8. 
 
27. Macpherson, L.J., et al., Noxious compounds activate TRPA1 ion channels through 
covalent modification of cysteines. Nature, 2007. 445(7127): p. 541-5. 
 
28. Mitchell, D.A. and M.A. Marletta, Thioredoxin catalyzes the S-nitrosation of the 
caspase-3 active site cysteine. Nat Chem Biol, 2005. 1(3): p. 154-8. 
 
29. Tannenbaum, S.R. and J.E. Kim, Controlled S-nitrosation. Nat Chem Biol, 2005. 1(3): 
p. 126-7. 
 
30. Saario, S.M., et al., Characterization of the sulfhydryl-sensitive site in the enzyme 
responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes. 
Chem Biol, 2005. 12(6): p. 649-56. 
 
31. Yu, C.X., S. Li, and A.R. Whorton, Redox regulation of PTEN by S-nitrosothiols. 
Mol Pharmacol, 2005. 68(3): p. 847-54. 
 
32. Van Itallie, C.M., et al., Palmitoylation of claudins is required for efficient tight-
junction localization. J Cell Sci, 2005. 118(Pt 7): p. 1427-36. 
 
33. Hancock, J.F., et al., All ras proteins are polyisoprenylated but only some are 
palmitoylated. Cell, 1989. 57(7): p. 1167-77. 
 
34. Hancock, J.F. and R.G. Parton, Ras plasma membrane signalling platforms. Biochem 
J, 2005. 389(Pt 1): p. 1-11. 
 
35. Jezyk, M.R., et al., Crystal structure of Rac1 bound to its effector phospholipase C-
beta2. Nat Struct Mol Biol, 2006. 13(12): p. 1135-40. 
 
36. Berg, O.G., et al., Interfacial activation of triglyceride lipase from Thermomyces 
(Humicola) lanuginosa: kinetic parameters and a basis for control of the lid. 
Biochemistry, 1998. 37(19): p. 6615-27. 
 
37. Egloff, M.P., et al., Crystallographic study of the structure of colipase and of the 
interaction with pancreatic lipase. Protein Sci, 1995. 4(1): p. 44-57. 
 
190 
38. Roussel, A., et al., Crystal structure of human gastric lipase and model of lysosomal 
acid lipase, two lipolytic enzymes of medical interest. J Biol Chem, 1999. 274(24): p. 
16995-7002. 
 
39. Roussel, A., et al., Crystal structure of the open form of dog gastric lipase in complex 
with a phosphonate inhibitor. J Biol Chem, 2002. 277(3): p. 2266-74. 
 
40. Thomas, A., et al., Role of the lid hydrophobicity pattern in pancreatic lipase activity. 
J Biol Chem, 2005. 280(48): p. 40074-83. 
 
41. Winkler, F.K., A. D'Arcy, and W. Hunziker, Structure of human pancreatic lipase. 
Nature, 1990. 343(6260): p. 771-4. 
 
42. Yang, Y. and M.E. Lowe, The open lid mediates pancreatic lipase function. J Lipid 
Res, 2000. 41(1): p. 48-57. 
 
43. Canagarajah, B.J., et al., Activation mechanism of the MAP kinase ERK2 by dual 
phosphorylation. Cell, 1997. 90(5): p. 859-69. 
 
44. Goldsmith, E.J., et al., Domain separation in the activation of glycogen phosphorylase 
a. Science, 1989. 245(4917): p. 528-32. 
 
45. Ohki, S., et al., Solution NMR structure of the myosin phosphatase inhibitor protein 
CPI-17 shows phosphorylation-induced conformational changes responsible for 
activation. J Mol Biol, 2001. 314(4): p. 839-49. 
 
46. Ohki, S., et al., Distinctive solution conformation of phosphatase inhibitor CPI-17 
substituted with aspartate at the phosphorylation-site threonine residue. J Mol Biol, 
2003. 326(5): p. 1539-47. 
 
47. Handy, D.E. and J. Loscalzo, Nitric oxide and posttranslational modification of the 
vascular proteome: S-nitrosation of reactive thiols. Arterioscler Thromb Vasc Biol, 
2006. 26(6): p. 1207-14. 
 
48. Konorev, E.A., B. Kalyanaraman, and N. Hogg, Modification of creatine kinase by S-
nitrosothiols: S-nitrosation vs. S-thiolation. Free Radic Biol Med, 2000. 28(11): p. 
1671-8. 
 
49. Miersch, S. and B. Mutus, Protein S-nitrosation: biochemistry and characterization of 
protein thiol-NO interactions as cellular signals. Clin Biochem, 2005. 38(9): p. 777-
91. 
 
50. Raines, K.W., M.G. Bonini, and S.L. Campbell, Nitric oxide cell signaling: S-
nitrosation of Ras superfamily GTPases. Cardiovasc Res, 2007. 75(2): p. 229-39. 
 
191 
51. Zuckerbraun, B.S., et al., Nitric oxide-induced inhibition of smooth muscle cell 
proliferation involves S-nitrosation and inactivation of RhoA. Am J Physiol Cell 
Physiol, 2007. 292(2): p. C824-31. 
 
52. Harden, T.K. and J. Sondek, Regulation of phospholipase C isozymes by ras 
superfamily GTPases. Annu Rev Pharmacol Toxicol, 2006. 46: p. 355-79. 
 
53. Yasinska, I.M. and V.V. Sumbayev, S-nitrosation of Cys-800 of HIF-1alpha protein 
activates its interaction with p300 and stimulates its transcriptional activity. FEBS 
Lett, 2003. 549(1-3): p. 105-9. 
 
54. Hong, J.H., et al., Critical role of phospholipase Cgamma1 in the generation of 
H2O2-evoked [Ca2+]i oscillations in cultured rat cortical astrocytes. J Biol Chem, 
2006. 281(19): p. 13057-67. 
 
55. Antonetti, D.A., et al., Vascular endothelial growth factor induces rapid 
phosphorylation of tight junction proteins occludin and zonula occluden 1. A 
potential mechanism for vascular permeability in diabetic retinopathy and tumors. J 
Biol Chem, 1999. 274(33): p. 23463-7. 
 
56. Fischer, S., et al., Simultaneous activation of several second messengers in hypoxia-
induced hyperpermeability of brain derived endothelial cells. J Cell Physiol, 2004. 
198(3): p. 359-69. 
 
57. Harhaj, N.S., A.J. Barber, and D.A. Antonetti, Platelet-derived growth factor 
mediates tight junction redistribution and increases permeability in MDCK cells. J 
Cell Physiol, 2002. 193(3): p. 349-64. 
 
58. Kinoshita, N., et al., Activation of P2Y receptor enhances high-molecular compound 
absorption from rat ileum. J Pharm Pharmacol, 2006. 58(2): p. 195-200. 
 
59. Tai, Y.H., et al., Regulation of tight junction resistance in T84 monolayers by 
elevation in intracellular Ca2+: a protein kinase C effect. J Membr Biol, 1996. 149(1): 
p. 71-9. 
 
60. Andreeva, A.Y., et al., Assembly of tight junction is regulated by the antagonism of 
conventional and novel protein kinase C isoforms. Int J Biochem Cell Biol, 2006. 
38(2): p. 222-33. 
 
61. Mason, D., et al., Alteration of epithelial structure and function associated with 
PtdIns(4,5)P2 degradation by a bacterial phosphatase. J Gen Physiol, 2007. 129(4): p. 
267-83. 
 
62. van Zeijl, L., et al., Regulation of connexin43 gap junctional communication by 
phosphatidylinositol 4,5-bisphosphate. J Cell Biol, 2007. 177(5): p. 881-91. 
 
192 
 
 
 
 
O NH
NO
O
O
NH
NO
O
U73122 U73343  
 
Figure 4.1. Structures of U73122 and U73343. The box highlights the only structural 
difference between the two compounds (i.e. maleimide in U73122 versus succinimide in 
U73343). 
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Figure 4.2. Time course of PIP2 hydrolysis by hPLCβ3 in DDM mixed micelles. PIP2, 
reconstituted in DDM, was combined with assay buffer and hPLCβ3 in a final volume of 100 
μl. Assays were initiated by moving samples to a 37°C water bath and incubating for 
indicating times. Data represent mean ± SD from triplicate determinations from one 
representative experiment. 
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Figure 4.3. Concentration dependent activation of hPLCβ3 by U73122 in DDM mixed 
micelles. PIP2, reconstituted in DDM, was combined with assay buffer and hPLCβ3 in a final 
volume of 100 μl. U73122, at indicated concentrations, was added to the assay mixture prior 
to the addition of enzyme. Assays were initiated by moving samples to a 37°C water bath. 
Incubation times were adjusted to ensure that less than 15% PIP2 was hydrolyzed in all cases. 
U73343 at 40 μM had not effect (data not shown). Data represent mean ± SD from triplicate 
determinations from one representative experiment. EC50 PLCβ3 was determined as described 
in Materials and Methods and was found to be 19.2 μM in this experiment. The estimated 
EC50 from these data should be interpreted within the context of the current set of results, as 
solubility limitations of U73122 in DMSO stock solutions prevented assessment of activation 
at concentrations greater than 100 μM. 
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Figure 4.4. Effect of U73122 (40 μM) and U73343 (40 μM) on hPLCβ3 activity in DDM 
mixed micelles. PIP2, reconstituted in DDM, was combined with assay buffer and hPLCβ3 in 
a final volume of 100 μl. U73122 or U73343, at indicated concentrations, was added to the 
assay mixture prior to the addition of enzyme. Assays were initiated by moving samples to a 
37°C water bath. Incubation times were adjusted to ensure that less than 15% PIP2 was 
hydrolyzed in all cases. Data represent mean ± SD from triplicate determinations from one 
representative experiment. Asterisks indicate significant difference (p < 0.05). 
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Figure 4.5. The effect of glutathione and cysteine on the U73122-mediated activation of 
hPLCβ3 in DDM mixed micelles. PIP2, reconstituted in DDM, was combined with assay 
buffer, thiol at indicated concentration, and hPLCβ3 in a final volume of 100 μl. U73122 (40 
μM) was added to the assay mixture prior to the addition of enzyme. Assays were initiated by 
moving samples to a 37°C water bath. Incubation times were adjusted to ensure that less than 
15% PIP2 was hydrolyzed in all cases. Data represent mean ± SD from triplicate 
determinations from one representative experiment. 
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Figure 4.6. The effect of pre-incubation time (hPLCβ3 with U73122) on the U73122-
mediated activation of hPLCβ3 in DDM mixed micelles. U73122 was pre-incubated with 
hPLCβ3 at 40 μM in assay buffer (50 μl total volume) for indicated times in the absence of 
PIP2 and DDM. Pre-incubation was quenched with the addition of 1 mM glutathione. Assays 
were initiated with the addition of pre-incubated enzyme to mixed micelles in a final volume 
of 100 μl, and incubation times were adjusted to ensure that less than 15% PIP2 was 
hydrolyzed in all cases. Data represent mean ± SD from triplicate determinations from one 
representative experiment. 
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Figure 4.7. Mass spectra of intact hPLCβ3 following incubation with either U73122 or 
U73343. Both compounds were incubated with hPLCβ3 at 40 μM for various time intervals 
in assay buffer at 37°C in the absence of substrate and detergent. Incubations were 
terminated with the addition of 1 mM glutathione, and an aliquot was analyzed via LC/MS. 
(A) hPLCβ3 alone, (B) hPLCβ3 following incubation with U73122 for one minute, (C) 
hPLCβ3 following incubation with U73122 for fifteen minutes, or (D) hPLCβ3 following 
incubation U73343 for fifteen minutes. Note the differences in the x-axis between figures 
representing recapitulated protein mass. See material and methods for details. 
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1     MAGAQPGVHALQLEPPTVVETLRRGSKFIKWDEETSSRNLVTLRVDPNGFFLYWTGPNME 
61    VDTLDISSIRDTRTGRYARLPKDPKIREVLGFGGPDARLEEKLMTVVSGPDPVNTVFLNF 
121   MAVQDDTAKVWSEELFKLAMNILAQNASRNTFLRKAYTKLKLQVNQDGRIPVKNILKMFS 
181   ADKKRVETALESCGLKFNRSESIRPDEFSLEIFERFLNKLCLRPDIDKILLEIGAKGKPY 
241   LTLEQLMDFINQKQRDPRLNEVLYPPLRPSQARLLIEKYEPNQQFLERDQMSMEGFSRYL 
301   GGEENGILPLEALDLSTDMTQPLSAYFINSSHNTYLTAGQLAGTSSVEMYRQALLWGCRC 
361   VELDVWKGRPPEEEPFITHGFTMTTEVPLRDVLEAIAETAFKTSPYPVILSFENHVDSAK 
421   QQAKMAEYCRSIFGDALLIEPLDKYPLAPGVPLPSPQDLMGRILVKNKKRHRPSAGGPDS 
481   AGRKRPLEQSNSALSESSAATEPSSPQLGSPSSDSCPGLSNGEEVGLEKPSLEPQKSLGD 
541   EGLNRGPYVLGPADREDEEEDEEEEEQTDPKKPTTDEGTASSEVNATEEMSTLVNYIEPV 
601   KFKSFEAARKRNKCFEMSSFVETKAMEQLTKSPMEFVEYNKQQLSRIYPKGTRVDSSNYM 
661   PQLFWNVGCQLVALNFQTLDVAMQLNAGVFEYNGRSGYLLKPEFMRRPDKSFDPFTEVIV 
721   DGIVANALRVKVISGQFLSDRKVGIYVEVDMFGLPVDTRRKYRTRTSQGNSFNPVWDEEP 
781   FDFPKVVLPTLASLRIAAFEEGGKFVGHRILPVSAIRSGYHYVCLRNEANQPLCLPALLI 
841   YTEASDYIPDDHQDYAEALINPIKHVSLMDQRARQLAALIGESEAQAGQETCQDTQSQQL 
901   GSQPSSNPTPSPLDASPRRPPGPTTSPASTSLSSPGQRDDLIASILSEVAPTPLDELRGH 
961   KALVKLRSRQERDLRELRKKHQRKAVTLTRRLLDGLAQAQAEGRCRLRPGALGGAADVED 
1021  TKEGEDEAKRYQEFQNRQVQSLLELREAQVDAEAQRRLEHLRQALQRLREVVLDANTTQF 
1081  KRLKEMNEREKKELQKILDRKRHNSISEAKMRDKHKKEAELTEINRRHITESVNSIRRLE 
1141  EAQKQRHDRLVAGQQQVLQQLAEEEPKLLAQLAQECQEQRARLPQEIRRSLLGEMPEGLG 
1201  DGPLVACASNGHAPGSSGHLSGADSESQEENTQL 
 
Figure 4.8. Primary sequence of hPLCβ3 (NP000923). Cysteine residues are highlighted in 
gray. The following cysteines were found alkylated by U73122: Cys193, Cys221, Cys360, 
Cys516, Cys614, Cys892, Cys1176, and Cys1207. 
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Figure 4.9. The effects of N-ethylmaleimide (NEM) on hPLCβ3 in DDM mixed micelles. 
(A) Structure of NEM. (B) The effect of NEM on hPLCβ3 activity in DDM mixed micelles. 
PIP2, reconstituted in DDM, was combined with assay buffer and hPLCβ3 in a final volume 
of 100 μl. NEM or U73122, at indicated concentrations, were added to the assay mixture 
prior to the addition of enzyme. Assays were initiated by moving samples to a 37°C water 
bath. Incubation times were adjusted to ensure that less than 15% PIP2 was hydrolyzed in all 
cases. Data represent mean ± S.D. from triplicate determinations. (C) Mass spectra of intact 
202 
hPLCβ3 following incubation with NEM. NEM was incubated with hPLCβ3 at 400 μM for 
fifteen minutes in assay buffer at 37°C in the absence of substrate and detergent. Incubations 
were terminated with the addition of 1 mM glutathione, and an aliquot was analyzed via 
LC/MS. (D) The effect of NEM on the U73122-mediated activation of hPLCβ3 in DDM 
mixed micelles. PIP2, reconstituted in DDM, was combined with assay buffer and hPLCβ3 in 
a final volume of 100 μl. NEM, at indicated concentrations, and U73122 (40 μM) were added 
to the assay mixture prior to the addition of enzyme. * indicates that NEM was pre-incubated 
with enzyme prior to adding the enzyme to the assay mixture. Assays were initiated by 
moving samples to a 37°C water bath. Incubation times were adjusted to ensure that less than 
15% PIP2 was hydrolyzed in all cases. Data represent mean ± SD from triplicate 
determinations from one representative experiment. (E) Mass spectra of intact hPLCβ3 
following sequential incubation with NEM and U73122. NEM was incubated with hPLCβ3 
at 400 μM for fifteen minutes in assay buffer at 37°C in the absence of substrate and 
detergent, followed by the addition of U73122 at 40 μM for an additional fifteen minutes. 
Incubations were terminated with the addition of 1 mM glutathione, and an aliquot was 
analyzed via LC/MS. Treatment of hPLCβ3 with NEM (400 μM)  followed by treatment 
with U73122 (40 μM) does not further modify hPLCβ3, consistent with almost complete 
inhibition of U73122-mediated activation by NEM at concentrations greater than 250 μM. 
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Fig. 4.10. Proposed model for the observed activation of hPLCβ3 in DDM mixed micelles. 
Open circles in micelle represent detergent (DDM) while closed circles represent substrate 
(PIP2). Ribbon structure of PLCδ1 reproduced with permission from Harden and Sondek 
(2006). (A) Representative alkylation of PLC at multiple sites by U73122 prior to micelle 
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interaction. (B) A U73122-modified PLC anchored to the micelle via the steroid backbone of 
U73122 that facilitates enzyme interaction with substrate. Points of attachment of four 
representative U73122 molecules are not necessarily representative of identified alkylation 
sites in hPLCβ3. 
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Figure 4.11. The effect of hexadecylphosphocholine (HPC) and 3-nitrocoumarin (3-NC) on 
hPLCβ3 activity in DDM mixed micelles. (A) Structures, (B) PIP2, reconstituted in DDM, 
was combined with assay buffer and hPLCβ3 in a final volume of 100 μl. Both compounds 
(500 μM) were added to the assay mixture prior to the addition of enzyme. Assays were 
initiated by moving samples to a 37°C water bath. Incubation times were adjusted to ensure 
that less than 15% PIP2 was hydrolyzed in all cases. Data represent mean ± SD from 
triplicate determinations. 
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CHAPTER 5 
 
 
 
 
ALKYLPHOSPHOCHOLINES INCREASE PARACELLULAR PERMEABILITY 
VIA A MECHANISM INVOLVING MEMBRANE PERTURBATION 
 
ABSTRACT 
Phospholipase C (PLC) isozymes comprise a large family of key cell signaling proteins that 
hydrolyze inositol containing phospholipids to form two cellular second messengers, 
diacylglycerol (DAG) and inositol triphosphate (IP3). Recently, PLCβ isozymes have been 
implicated in the regulation of epithelial tight junction permeability in both MDCK and 
Caco-2 cells based on the observed relationship between the potency of a series of 
alkylphosphocholines (APCs) as PLC inhibitors, and as PPEs. Evidence exists in the 
literature suggesting that APCs may be potent modulators of membrane fluidity and stability. 
The purpose of the present study was to determine whether APCs cause increased tight 
junction permeability via direct inhibition of PLCβ, or by perturbing cell membrane integrity. 
Hence, potency of amphiphilic APCs in a homologous series to partition into Caco-2 cell 
membranes and cause release of intracellular LDH was determined. Further, the ability of 
APCs to directly inhibit PLC activity was assessed in a phospholipid-detergent mixed 
micellar system. The ability of APCs to perturb cell membranes was dependent on the length 
of the alkyl chain, and was correlated to their potency as both enhancers of paracellular 
permeability and PLC inhibitors in Caco-2 cells. Further, although they all inhibited hPLCβ1 
activity in a concentration dependent manner, their potency as inhibitors was inconsistent 
with their potency as PPEs. Finally, the ability of hexadecylphosphocholine to inhibit 
hPLCβ3 in mixed micelles was detergent dependent, with no observable inhibition when 
non-ionic dodecylmaltoside was used as detergent. Collectively, these data suggest that the 
ability of APCs to increase paracellular permeability may not be the direct result of PLC 
inhibition, but instead may be related to their ability to partition into cell membranes. 
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INTRODUCTION 
 Alkylphosphocholines (APCs) containing a polar zwitterionic head group attached to 
a variable length lipophilic alkyl chain have been reported to increase the permeability of the 
paracellular marker mannitol across epithelial monolayers of both MDCK and Caco2 cells 
(Chapter 2)1-3, as well as across rat ileum in situ4. It has been suggested that these 
compounds, with structural similarities to membrane phospholipids, may be potential 
intestinal absorption enhancing agents for hydrophilic drugs and macromolecules in humans1, 
3, 5, 6. 
Hexadecylphosphocholine (HPC), a prototypical APC with a sixteen carbon alkyl 
chain, was initially hypothesized to be an inhibitor of phospholipase C (PLC) more than 
fifteen years ago7, with subsequent studies confirming this hypothesis8, 9. Recent studies have 
extended this hypothesis and demonstrated that APCs of variable chain length inhibited 
PLCβ in MDCK and Caco-2 cell monolayers with different potencies, and that a strong 
relationship existed between their potency as PLCβ inhibitors and as enhancers of 
paracellular permeability across these cell monolayers (Chapter 2)3. These observations 
implicated PLC in the regulation of epithelial tight junction barrier function. Specific 
downstream events have been attributed to this PLC inhibition-mediated increase in 
paracellular permeability by APCs, including reorganization of the cortical actin ring3 and 
redistribution of tight junction proteins ZO-110 and claudin-11. On the other hand, a more 
recent study contradicts the hypothesis that PLC isozymes regulate epithelial paracellular 
permeability, as RNAi mediated knockdown of both PLCβ3 and PLCγ1 in MDCK cells had 
no effect on the assembly of tight junctions, or on the permeability function of established 
tight junctions (Chapter 3). Therefore, the observed increase in paracellular permeability 
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following treatment of epithelial cells with APCs may occur via a mechanism other than PLC 
inhibition. 
Changes to the structure of phospholipid membranes can lead to indirect effects on 
the catalytic activity of membrane associated enzymes11-14. Furthermore, tight junctions form 
between adjacent cells in specialized apical membrane microdomains called lipid rafts15, and 
serve to separate the distinctly different lipid and protein composition of apical and 
basolateral membranes. Therefore, it is reasonable to hypothesize that alterations to the 
stability and integrity of the apical membrane may adversely affect both the activity of 
membrane associated PLC isozymes, as well as the barrier function of apically directed tight 
junctions. For example, depletion of cholesterol from the membrane of Caco-2 cells leads to 
a loss of barrier function, presumably by altering the distribution of specific tight junction 
proteins as a result of changes to the composition of the membrane16. Additional evidence 
suggests that APCs may disrupt the integrity of the apical membrane in Caco-2 cells1, 5, 10, 17 
at concentrations similar to those that have been shown to increase paracellular permeability 
(Chapter 2).  
The purpose of this study was to evaluate the ability of APCs to inhibit PLCβ activity 
in a cell free system to determine if the inhibition was caused by direct interaction with the 
protein, or indirectly by perturbation of the substrate/enzyme interface (e.g. the cell 
membrane). Further, the ability of APCs to perturb integrity of the apical membrane in Caco-
2 cells was quantified. Together, these studies would yield an improved understanding about 
the mechanism underlying the paracellular permeability enhancement by APCs. 
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MATERIALS AND METHODS 
Materials. Purified cholate, as well as purified phospholipase Cβ1 and β3, were generously 
provided by the laboratory of Dr. T. K. Harden (Department of Pharmacology, School of 
Medicine, UNC Chapel Hill). Dodecylmaltoside was purchased from Fluka. APCs with 
various alkyl chain lengths were synthesized as previously described3. N-2-
hydroxyethylpiperazine-N'-2-ethansulfonic acid (HEPES), Hank's Balanced Salt Solution 
(HBSS), and other cell culture reagents were obtained from Invitrogen (Carlsbad, CA). 
Twelve well Transwells™ were obtained from Costar (Cambridge, MA). CytoTox-ONETM 
Homogeneous Membrane Integrity Assay was purchased from Promega Corporation 
(Madison, WI). [3H]-PIP2 (phosphatidylinositol 4,5-bisphosphate, [myo-inositol-2-3H(N)]) 
(20 Ci/mmol) was purchased from American Radiolabeled Chemicals. PIP2 was purchased 
from Avanti Polar Lipids. U73122, fatty acid free bovine serum albumin (BSA), and all other 
reagents were purchased from Sigma unless otherwise indicated.  
Cell Culture. The Caco-2 cell line, Caco-2 cell clone HTB-37 was obtained from American 
Type Tissue Culture at passage 20. Caco-2 cells, derived from human colorectal carcinoma 
cells18, were cultured at 37°C in minimum essential medium, supplemented with 10% FBS, 
1% NEAA, 100 U/ml penicillin, 100 μg/ml streptomycin, and 0.25 μg/ml amphotericin B in 
an atmosphere of 5% CO2 and 90% relative humidity. Caco-2 cells (passage number 25 to 
35) were seeded at a density of 60,000 cells/cm2 in TranswellsTM. Medium was changed the 
day after seeding, and every other day thereafter (apical volume 0.5 ml, basolateral volume 
1.5 ml). Cells were grown to confluence for at least 21 days during which time they 
differentiated into epithelial cell monolayers as evidenced by the establishment of a stable 
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transepithelial electrical resistance (TEER) between 200-500 Ω*cm2. Cells were used 
between 21-27 days after seeding in TranswellsTM. 
Determination of lactate dehydrogenase leakage. Leakage of lactate dehydrogenase 
(LDH) into extracellular compartments is a measure often used as an indicator of cell 
membrane integrity. The CytoTox-ONETM Homogeneous Membrane Integrity Assay was 
used to assess the leakage of intracellular LDH from Caco-2 cells into the apical 
compartment. Cell media was aspirated from both compartments of Transwell™ inserts, 
replaced with transport buffer, and cells were pre-incubated at 37°C for 30 minutes. Integrity 
of the tight junctions was confirmed with the measurement of TEER prior to the experiment. 
Experiments were initiated by aspirating transport buffer from the apical compartment and 
replacing it with pre-warmed transport buffer (0.5 ml) containing test compound or vehicle. 
Cells were incubated at 37°C and TEER values were measured after 30 minutes. At the 
conclusion of the treatment period, an aliquot was removed from the apical compartment of 
each well, diluted ten fold with transport buffer, and assayed for LDH according to the 
manufacturer’s instructions. Briefly, the diluted sample was transferred to a 96-well plate, 
mixed with an equal volume of reagent, and incubated for 10 minutes at room temperature. 
The reaction was stopped with 50 μl of stop solution and the fluorescent end product, 
resorufin, was detected with a Cytofluor fluorescent plate reader (Applied Biosystems, Foster 
City, CA) using an excitation wavelength of 530 nm and an emission wavelength of 590 nm. 
Fluorescence readings of samples obtained from treated monolayers were normalized to the 
maximum amount of LDH released from monolayers, and reported as % LDH leakage ± SD 
of three experiments performed in triplicate. The maximal LDH leakage was determined by 
treating the monolayers with 0.18% (2.9 mM) Triton-X 100, as specified by the 
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manufacturer. The effect of test compounds on LDH leakage was evaluated at several 
concentrations, and EC50 LDH values, defined as the concentration causing half maximal 
leakage of LDH from Caco-2 cell monolayers, were determined. 
Mixed Micellar PLC Assays.  The activity of hPLCβ1 and hPLCβ3 in a cell free system 
was evaluated by an adaptation of previously published methods19, 20. Briefly, [3H]-labeled 
and unlabeled PIP2 (5 nmol) was reconstituted in a 1% cholate, or 1 mM dodecylmaltoside 
(DDM) solution, and mixed with assay buffer containing 40 mM Hepes (pH 7.4), 480 mM 
KCl, 40 mM NaCl, 8 mM EGTA, 23.2 mM MgSO4, and 8.4 mM CaCl2. For assays in DDM, 
4 mM MgCl4, and 7.6 mM CaCl2 were used in lieu of 23.2 mM MgSO4, and 8.4 mM CaCl2. 
Compounds at indicated concentrations, and purified enzyme in 1% fatty acid-free BSA and 
10 mM Hepes (pH 7.0), were subsequently added to the mixture. To initiate assays, samples 
were moved to a 37°C (or 30°C for studies in DDM) water bath and incubated for 2-10 
minutes such that less than ten percent total substrate was hydrolyzed. At designated times, 
reactions were stopped by addition of either 200 μl trichloroacetic acid and 100 μl of 10 
mg/ml fatty acid free BSA. For cholate assays, 750 μl CHCl3:MeOH:HCl (40:80:1), 100 μl 
water, 250 μl CHCl3, and 250 μl 0.1M HCl were added for precipitation instead. Samples 
were vortexed and centrifuged at 3000 rpm for 10 minutes at 4°C. The amount of formed 
[3H]-inositol phosphates was measured by liquid scintillation counting of the supernatant in a 
Packard Tri Carb 4000 Series spectrophotometer. The IC50 (PLCβ), defined as the concentration 
causing a 50% decrease in the formation of inositol phosphates, was determined. 
Data analysis. Data are expressed as the mean ± standard deviation (SD) from three 
measurements unless indicated otherwise. Where indicated, statistical significance was 
assessed using a two sample Student’s t tests. Samples were assumed to have an unequal 
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variance; significant differences were assigned at p < 0.05. For determination of EC50 LDH 
values, the relationship between LDH leakage (% Cytotoxicity) and enhancer concentration 
was fit to a four parameter Hill equation by nonlinear least-squares regression (WinNonlin, 
version 4.1). Estimates were also generated for the sigmoidicity factor (γ), E0, and Emax. For 
determination of IC50 PLCβ1 values, the relationship between hPLCβ1 activity (% Inhibition) 
and enhancer concentration was fit to a three parameter Hill equation by nonlinear least-
squares regression. Estimates were also generated for the sigmoidicity factor (γ) and Emax. 
Relationships between parameters estimating paracellular permeability enhancement and 
LDH release were assessed via linear regression analysis, and the correlation was expressed 
by the Pearson correlation coefficient (r). 
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RESULTS 
Activity of human PLCβ1 in phospholipid-detergent mixed micelles. 
 hPLCβ1 activity with respect to time (using PIP2 as substrate) was measured using 
cholate as a surfactant to establish an interface for presentation of the insoluble substrate to 
the enzyme in the absence of a cell membrane phospholipid bilayer (Figure 5.1). Consistent 
with previous studies with dodecylmaltoside as detergent (Chapter 4), two distinct phases of 
activity were observed, an initial burst of activity linear when ≤ 10% PIP2 is utilized, 
followed by a second, slower phase of hydrolysis. Additional studies were performed at fixed 
PIP2 concentrations and were designed such that ≤ 10% of total substrate was utilized in all 
cases. 
Alkylphosphocholines inhibit hPLCβ1 activity in cholate mixed micelles. 
In cholate mixed micelles, HPC (Figure 5.2) inhibited the activity of hPLCβ1 in a 
concentration-dependent manner (Figure 5.3). The concentration of HPC that caused 50% 
inhibition of activity was estimated from a plot of % inhibition versus concentration and is 
reported in Table 5.1. The IC50 hPLCβ1 determined in cholate mixed micelles was similar to the 
IC50 PLCβ determined in Caco-2 cells (Table 5.1), and therefore, the potency of HPC for 
inhibiting PLC in both systems is greater than its potency as a PPE in Caco-2 cells 
(quantified using EC50 TEER and EC10X). 
Because HPC inhibited hPLCβ1 in cholate mixed micelles, the ability of all APCs 
(Figure 5.2) to inhibit hPLCβ1 activity in this cell free system was evaluated. All APCs 
inhibited hPLCβ1 activity in a concentration dependent manner (Figure 5.4). IC50 hPLCβ1 
values are reported in Table 5.1. The potency of APCs for inhibiting the activity of hPLCβ1 
activity was dependent on chain length and increased with the length of the alkyl chain, with 
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maximum potency occurring at a chain length of twenty carbons. This chain length 
dependent potency of APCs as inhibitors of hPLCβ1 is different than the relationship 
between chain length of APCs and potency as both PLCβ inhibitors and PPEs in Caco-2 
cells, where a maximum potency was achieved with approximately fourteen to sixteen 
carbons in the alkyl chain (Table 5.2). 
Hexadecylphosphocholine inhibition of hPLCβ3 in phospholipid-detergent mixed 
micelles is detergent dependent. 
To further assess the interaction between APCs and PLC isozyme activity, the ability 
of HPC, as a representative APC, to inhibit hPLCβ3 activity was assessed in both cholate and 
DDM mixed micelles, systems composed of detergents with (cholate) or without (DDM) a 
net charge. The ability of HPC to inhibit hPLCβ3 activity was detergent dependent (Figure 
5.5), as it was unable to inhibit hPLCβ3 activity in DDM mixed micelles at concentrations as 
high as 500 μM, yet it inhibited hPLCβ3 activity in cholate mixed micelles in a concentration 
dependent manner. 
Alkylphosphocholines cause leakage of lactate dehydrogenase from Caco-2 cells. 
 To evaluate the effect of APCs on Caco-2 cell membranes, the ability of HPC, as a 
representative APC, to disrupt the barrier function of cell membranes and cause release of 
intracellular LDH was evaluated (Figure 5.6). Apical HPC treatment led to a concentration 
dependent release of LDH from Caco-2 cell monolayers into the apical compartment. The 
concentration that caused 50% of total LDH leakage (EC50 LDH) was estimated from the plot 
of % LDH release versus HPC concentration, and is reported in Table 5.2. The potency of 
HPC for causing LDH leakage (EC50 LDH) was approximately three-fold higher than its 
potency for increasing paracellular permeability (EC50 TEER and EC10X) in Caco-2 cells. 
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Similar to HPC, all APCs caused release of LDH from Caco-2 cells in a concentration 
dependent manner (Figure 5.7). EC50 LDH values are reported in Table 5.2. Interestingly, 
increasing concentrations of C10 never released more than approximately 30% of the total 
cytosolic LDH. Control studies were performed to ensure that this result was not due to 
interference with the LDH assay at the high concentrations of C10 required to observe LDH 
release (data not shown). 
The relationship between the potency of APCs as cytolytic agents and their potency 
as both PLC inhibitors and PPEs was evaluated (Figure 5.8). The EC50 LDH is linearly related 
to both EC50 TEER a (r > 0.99, p < 0.0001) and EC10x (r > 0.99, p < 0.0001). Interestingly, their 
potency as PPEs was approximately 2.5 fold greater than their potency as cytolytic agents in 
Caco-2 cells. 
 Non-amphiphilic PPE and PLC inhibitor, U73122 (Chapter 2) (Figure 5.9), did not 
cause any increase in LDH leakage into the apical compartment after up to ninety minutes of 
exposure to Caco-2 cells at concentrations that also increase paracellular permeability (i.e. up 
to 30 μM), suggesting that the release of LDH caused by APCs is not the direct results of 
PLC inhibition. 
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DISCUSSION 
The PLC-dependent pathway has long been postulated to be involved in the 
regulation of epithelial tight junctions6, 21-23. More recent studies have directly implicated this 
important class of signaling molecules in the regulation of epithelial paracellular 
permeability (Chapter 2)3, 24. However, results from Chapter 3 show that suppression of the 
expression of both PLCβ3 and PLCγ1 in MDCK cells by RNAi had no effect on either the 
assembly of tight junctions, or on the permeability of established tight junctions. These 
results cast some doubt on the involvement of PLC enzymes in the regulation of tight 
junctions, although they cannot rule out the possibility that PLC isozymes other than PLCβ3 
and PLCγ1 may be involved. Clearly, these results raised questions about whether inhibition 
of PLCβ by APCs in both Caco-2 cells and MDCK cells was responsible for their activity as 
enhancers of paracellular permeability in these cell systems, and suggested that the observed 
increase in paracellular permeability following APC treatment may occur via a mechanism 
other than PLC inhibition.  
HPC (miltefosine) is the first orally effective treatment for visceral leishmaniasis and 
has proven to be highly effective in phase III clinical trials25. The major side effects 
associated with oral administration of miltefosine include frequent but mild nausea, 
vomiting, and diarrhea26. These local gastrointestinal side effects may be due to the reported 
ability of APCs to effectively partition into phospholipid membranes27-29, a characteristic 
exploited in cancer therapy, where their anti-neoplastic properties are believed to be related 
to their interaction with cell membranes rather than DNA30. This is supported by the finding 
that the rate of HPC oral absorption is extremely slow, and an unusually high percentage of 
HPC is recovered from intestinal tissue as much as twenty four hours after oral 
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administration to mice31-34. Additional evidence has established the ability of APCs to alter 
the fluidity and barrier function of apical membranes in Caco-2 cells1, 5, 10, 17. Thus, an 
alternative hypothesis is considered in this study that the observed increase in paracellular 
permeability following APC treatment is due to disruption of tight junctions caused by 
alteration in cell membrane fluidity or integrity. Therefore, the inhibition of PLC enzymes 
caused by the APC treatment may not necessarily have a cause-effect relationship with the 
enhancement of paracellular permeability. 
As discussed in Chapter 4, PLCs are water soluble enzymes that hydrolyze poorly 
soluble membrane phospholipids. In the absence of whole cells, these proteins require the 
presence of a suitable interface between hydrophilic enzyme and hydrophobic substrate to 
achieve measurable enzymatic activity. A number of useful experimental systems have been 
described for assessing lipase activity, perhaps the simplest of which is a mixed micellar 
system. The potency of APCs to inhibit hPLCβ1 activity was evaluated in cholate mixed 
micelles to assess their direct interaction with PLC. A concentration dependent effect of HPC 
on hPLCβ1 activity was observed. The IC50 PLCβ was estimated to be 95 ± 9 μM, similar to its 
potency as a PLCβ inhibitor in Caco-2 cells, 40 ± 19 μM (Table 5.1). The ability of the entire 
APC series to inhibit hPLCβ1 activity was determined in triplicate and IC50 hPLCβ1 values 
were determined. Within the series of APC, the ability to inhibit hPLCβ1 activity was clearly 
dependent on alkyl chain length with a maximum potency exhibited by APC containing 
twenty carbons in the alkyl chain (Table 5.1), inconsistent with the reported relationship 
between chain length of APCs and their potencies as PLCβ inhibitors in both MDCK and 
Caco-2 cells, where a chain length of fourteen to sixteen carbons achieved maximum 
inhibitory potency. Interestingly, their potency as hPLCβ1 inhibitors in mixed micelles was 
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more closely related to their reported critical micelle concentrations (Table 5.1), implying 
that their ability to inhibit PLC activity in this system may be dependent on the micellar form 
of APCs causing the disruption of the detergent/substrate mixed micelles. To further probe 
this hypothesis, the non-ionic detergent, dodecylmaltoside (DDM), was used instead of 
cholate, a negatively charged detergent, in the mixed micellar system. Previous reports have 
established the use of DDM as a suitable inert diluent to assess PLC activity in lipid-
detergent mixed micelles (Chapter 4)19, 20. In cholate mixed micelles, HPC inhibited the 
activity of hPLCβ3 in a concentration dependent manner; however, in DDM mixed micelles, 
HPC was unable to inhibit hPLCβ3 activity at concentrations up to 500 μM (Figure 5.5). This 
result supports the hypothesis that APC inhibition of PLC activity is indirect, and dependent 
on the ability of APCs to perturb the interface between water soluble enzyme and lipid 
soluble substrate. However, this hypothesis contradicts the observation that PLC can 
metabolize HPC in mice, as well as in vitro with purified enzyme, hydrolyzing HPC as if it 
were a glycerophospholipid composed of phosphocholine and hexadecanol31, and implying 
that inhibition of PLC activity by HPC may be via competitive binding to the enzyme active 
site. Additional studies are required to further address this apparent contradiction. 
Due to the inconsistency between the potency of APCs to inhibit PLC in a cell free 
system as compared to the whole cells systems (i.e. MDCK and Caco-2 cells), the potency of 
APCs to cause release of LDH into the apical compartment of cultured Caco-2 cell 
monolayers was evaluated. Within the series of APCs, their ability to cause release of LDH 
was dependent on chain length; this dependence followed the order C14, C16, C18, C20, 
C12, and C10, identical to the chain length dependence for both increasing paracellular 
permeability and inhibiting PLCβ activity (Figure 5.7 and Table 5.2). The potency of APCs 
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to cause membrane disruption was approximately 2.5 fold less than the potency for 
increasing paracellular permeability, consistent with previous studies reporting a narrow 
window (i.e. two to three fold) between the efficacy and cytotoxicity of APCs in cultured 
cells1, 4, 10. Notably, small but significant amounts of LDH release from Caco-2 cell 
monolayers were apparent at concentrations that had minimal effect on TEER (i.e. 100 μM) 
(Figure 5.6), demonstrating that the increase in permeability and release of LDH occur at 
similar concentrations, and may be related events. Further, there is a strong correlation 
between the potency of APCs for causing LDH release and for increasing paracellular 
permeability (Figure 5.8), similar to the correlation between their potency as paracellular 
permeability enhancers and PLCβ inhibitors. These established relationships between the 
three measurable effects of APCs on Caco-2 cells cloud any cause-effect interpretation 
between any two of the effects, namely PLC inhibition and paracellular permeability 
enhancement. The results from Chapter 3, demonstrating that specific suppression of PLC 
expression by RNAi has no impact on tight junction barrier function further raise questions 
regarding the role of PLC enzymes in regulating tight junction permeability. The initial 
pharmacological effect of APCs on epithelial cell monolayers may be disruption of the 
integrity of the apical membrane, followed by two dependent downstream events: (1) loss of 
tight junction barrier function and (2) indirect inhibition of membrane associated PLC. This 
hypothesis is not without precedent, as the absorption enhancing effect of other amphiphilic 
PPEs, such as acylcarnitines, has been shown to be dependent on the length of the lipophilic 
carbon chain and the ability of this series of amphiphiles to interact with cell membranes35. In 
this regard, specific membrane composition of different cell types may dictate the potency of 
APCs as PLC inhibitors, or as PPEs, in different models of epithelia and in different tissues. 
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It is worth noting that non-amphiphilic PPE and PLC inhibitor, U73122 (Figure 2.10), did 
not release LDH from Caco-2 cells at concentrations that increased paracellular permeability 
(Figure 5.9), implying potentially different mechanisms of action for these structurally 
distinct PPEs (i.e. U73122 and HPC). 
Given the damage to Caco-2 cell membranes at increasing concentrations of APCs 
allowing the release of relatively large intracellular proteins such as LDH, the observed 
increase in transport of the paracellular marker mannitol could be due an increase in 
transcellular transport rather than paracellular transport, particularly at higher concentrations 
of APCs. Consistent with this hypothesis, HPC has previously been shown to dramatically 
alter the cellular distribution of a fluorescent paracellular probe from a strictly paracellular 
localization to one with an extensive transcellular as well as paracellular localization17. 
However, a more extensive evaluation of the effects of apically dosed APCs on the integrity 
of the basolateral membrane would need to be assessed, as the basolateral membrane serves 
as an additional barrier to the transcellular transport of hydrophilic molecules such as 
mannitol, and could prevent the movement of mannitol into the basolateral compartment via 
the transcellular route. Therefore, the increased mannitol permeability induced by APCs 
could be strictly paracellular, as the apical membrane perturbation could lead to de-
stabilization of the tight junction barrier allowing increased paracellular transport across the 
monolayer as well as increased access to the cytosol from the apical compartment, but not 
increased transcellular permeability. 
Collectively, these data suggest that APCs may not directly interact with the active 
site of PLC, but instead may indirectly inhibit lipase activity by interfering with the quality of 
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the enzyme/substrate interface via a process referred to as “competitive interfacial 
inhibition”36.  
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Table 5.1. Potency of alkylphosphocholines (APCs) as inhibitors of hPLCβ1 in cholate 
mixed micelles, reported critical micelle concentrations37, and potency as inhibitors of ATP-
stimulated PLCβ activity in Caco-2 cells. 
 
APC 
IC50 PLCβ1 (μM) 
(cell free) 
CMC (μM) 
IC50 PLCβ (μM) 
(Caco-2) * 
C10 507 ± 137 10930 ± 2890 1304 ± 837 
C12 288 ± 51 1278 ± 171 123 ± 28 
C14 176 ± 32 110 ± 11 29 ± 13 
C16 95 ± 9 13 ± 2.8 40 ± 19 
C18 112 ± 21 1.4 ± 0.099 70 ± 38 
C20 58 ± 24 0.14 104 ± 8 
 
* Reproduced from Table 2.3. Specific details surrounding the determination of these 
parameters are also provided in Material and Methods, Chapter 2. 
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Table 5.2. Potency of alkylphosphocholines (APCs) as paracellular permeability enhancers 
(EC50 TEER and EC10X), as inhibitors of PLCβ activity (IC50 PLCβ), and as compounds that 
cause LDH leakage and damage to the apical cell membrane (EC50 LDH) in Caco-2 cells. 
 
APC EC50 LDH (μM) EC50 TEER (μM) * EC10X (μM) * IC50 PLCβ (μM) * 
C10 ND 9800 ± 1375 8333 ± 1320 1304 ± 837 
C12 1494 ± 126 735 ± 62 576 ± 160 123 ± 28 
C14 685 ± 86 213 ± 23 261 ± 90 29 ± 13 
C16 745 ± 44 248 ± 52 317 ± 26 40 ± 19 
C18 1093 ± 51 299 ± 19 384 ± 94 70 ± 38 
C20 1254 ± 28 429 ± 77 481 ± 45 104 ± 8 
 
* Reproduced from Table 2.3. Specific details surrounding the determination of these 
parameters are also provided in Material and Methods, Chapter 2. 
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Figure 5.1. Time course of PIP2 hydrolysis by hPLCβ1 in cholate mixed micelles. PIP2, 
reconstituted in cholate, was combined with assay buffer and hPLCβ3 in a final volume of 
100 μl. Assays were initiated by moving samples to a 30°C water bath and incubating for 
indicating times. Data represent mean from duplicate determinations from one representative 
experiment. 
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Figure 5.2. Structures of alkylphosphocholines. 
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Figure 5.3. Concentration dependent inhibition of hexadecylphosphocholine (HPC) on 
hPLCβ1 in cholate mixed micelles. PIP2, reconstituted in DDM, was combined with assay 
buffer and hPLCβ1 in a final volume of 100 μl. HPC, at indicated concentrations, was added 
to the assay mixture prior to the addition of enzyme. Assays were initiated by moving 
samples to a 30°C water bath. Incubation times were adjusted to ensure that less than 10% 
PIP2 was hydrolyzed in all cases. Data represent mean ± SD from triplicate determinations 
from one representative experiment. 
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Figure 5.4. Concentration dependent inhibition of alkylphosphocholines (APCs) on hPLCβ1 
in cholate mixed micelles. PIP2, reconstituted in DDM, was combined with assay buffer and 
hPLCβ1 in a final volume of 100 μl. APCs, at indicated concentrations, was added to the 
assay mixture prior to the addition of enzyme. Assays were initiated by moving samples to a 
30°C water bath. Incubation times were adjusted to ensure that less than 10% PIP2 was 
hydrolyzed in all cases. IC50 PLCβ1 values are reported in Table 5.1. Data represent mean from 
duplicate determinations from one representative experiment for each APC. 
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Figure 5.5. Concentration dependent inhibition of hexadecylphosphocholine (HPC) on 
hPLCβ3 in cholate mixed micelles and in DDM mixed micelles. PIP2, reconstituted in 
detergent, was combined with assay buffer in a final volume of 100 μl. HPC, at indicated 
concentrations, was added to the assay mixture prior to the addition of enzyme. Assays were 
initiated by moving samples to a 30°C or 37°C water bath for cholate and DDM assays 
respectively. Incubation times were adjusted to ensure that less than 10% PIP2 was 
hydrolyzed in all cases. Data represent mean ± SD from triplicate determinations from one 
representative experiment. 
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Figure 5.6. Concentration dependent effect of hexadecylphosphocholine (HPC) on LDH 
release from Caco-2 cells. Cells were treated apically with HPC at indicated concentrations 
for thirty minutes and the amount of LDH released into the apical compartment was 
determined. Data represent mean ± SD from triplicate determinations from one representative 
experiment. Asterisks indicate significant difference (p < 0.05) for LDH release. 
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Figure 5.7. Concentration dependent effect of alkylphosphocholines (APCs) on LDH release 
from Caco-2 cells. Cells were treated apically with APCs at indicated concentrations for 
thirty minutes and the amount of LDH released into the apical compartment was determined. 
Data represent mean ± SD from triplicate determinations from one representative experiment 
for each APC. 
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Figure 5.8. The relationship between LDH release and increase in paracellular permeability 
by alkylphosphocholines in Caco-2 cell monolayers. (A) The relationship between the EC50 
LDH and EC50 TEER, and (B) the relationship between the EC50 LDH and EC10X. See Table 5.2 
for data. The correlation is expressed by the Pearson correlation coefficient (r). 
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Figure 5.9. Concentration dependent effect of U73122 on LDH release from Caco-2 cells. 
(A) Structure of U73122, and (B) Cells were treated apically with U73122 at indicated 
concentrations for ninety minutes and the amount of LDH released into the apical 
compartment was determined. Data represent mean ± SD from triplicate determinations from 
one representative experiment. 
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CHAPTER 6 
 
 
 
 
CONCLUSIONS 
 
  
 The overarching goal of this dissertation research was to develop a clearer 
understanding of the molecular mechanisms involved in the regulation of intestinal epithelial 
tight junctions via the PLC-catalyzed signal transduction cascade. Specifically, the goal was 
to explore whether a cause-effect relationship exists between the inhibition of PLC activity 
and increased paracellular permeability via specific modulation of epithelial tight junctions. 
The outcome of this investigation is of considerable interest, as PLC isozymes have been 
postulated for many years as potential regulatory enzymes of tight junction function1-4; 
however, unequivocal evidence to support such a role for any PLC isozyme has yet to be 
established. A cause-effect relationship between the activity of specific PLC isozymes and 
tight junction permeability would allow mechanism based approaches to selectively and 
reversibly increase the permeability of intestinal tight junctions. Such a technology would 
have significant implications in the pharmaceutical industry, leading to the development of 
novel formulations for hydrophilic drugs, including small to midsize peptides and 
oligonucleotides that are typically very poorly absorbed following an oral dose. The search 
for a safe and effective paracellular permeability enhancer (PPE) for clinical use in humans 
has not yet yielded success, partly due to the lack of a mechanistic understanding of how 
mature epithelial tight junctions are regulated. Therefore, an improved understanding of the 
underlying molecular mechanisms governing tight junction barrier function would make the 
attainment of this goal an achievable reality. 
Recent studies using chemical inhibitors have, for the first time, provided direct 
evidence supporting a role for PLCs as regulators of epithelial tight junction function5, 6; 
however, other recent studies have questioned the alleged specificity of these PLC inhibitors 
in cellular systems7-11. Therefore, an additional aim of this research was to determine whether 
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these putative specific PLC inhibitors interact directly with PLC at the molecular level. This 
was an important objective, as these inhibitors (e.g. U73122) have repeatedly been utilized in 
the literature as pharmacological probes to implicate the activity of PLC isozymes in cellular 
phenotypes. If these molecules are not specifically inhibiting the catalytic activity of PLCs, 
their interactions with other cellular proteins may lead to off-target effects that could be 
mistakenly attributed to PLC, confounding our understanding of the cellular roles of this 
important class of signaling molecules. 
Validation of Caco-2 Cell Monolayers as a Model to Study PLC-mediated Modulation 
of Tight Junction Permeability in the Human Intestinal Epithelium 
 Caco-2 cells are an in vitro cell culture model routinely used to assess the absorption 
potential of new drug candidates12-16. This cell line has also often been used to assess the 
potency of candidate PPEs in vitro17-20. In fact, a recent study has described novel adaptations 
to this model that provide increased predictability of the in vivo efficacy for certain classes of 
PPEs, depending on their physicochemical properties21. Results generated in this dissertation 
(Chapter 2) have characterized the expression profile of PLC isozyme mRNA in Caco-2 
cells, and notably, determined that these specific PLCs are also expressed in the human small 
intestine. Thus, this work has established Caco-2 cell monolayers as an appropriate in vitro 
model in which to assess the role of PLC as a potential pharmacological target for increasing 
intestinal absorption in humans. These findings provide support for the previously published 
hypothesis that sodium caprate increases paracellular permeability in Caco-2 cells via 
modulation of PLC-dependent signaling2, 3, 22. 
Mechanisms Underlying PLC Inhibition and Paracellular Permeability Enhancement 
by Alkylphosphocholines 
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As Caco-2 cells were originally derived from a human colon adenocarcinoma, they 
were further utilized to specifically establish PLC inhibition as a viable mechanism for 
increasing paracellular permeability across the human intestine. Results from Chapter 2 
demonstrated the existence of a significant correlation between the potency of a series of 
homologous APCs as PLCβ inhibitors and as paracellular permeability enhancers in the 
Caco-2 cell culture model. The relationship was dependent on the length of the alkyl chain, 
and was similar to the previously established relationship in MDCK cells6. However, a five 
to nine fold reduction in PPE potency was observed in Caco-2 cells as compared to MDCK 
cells, despite the fact that their potency as PLCβ inhibitors was comparable between the two 
cell culture models. This observation suggested several possibilities: (1) that different 
mechanisms regulate paracellular permeability between the two cell lines, (2) that additional 
regulatory mechanisms are present in Caco-2 cells, or (3) that the observed paracellular 
permeability enhancement was mediated via a mechanism independent of PLC inhibition. 
Given the amphiphilic nature of this series of compounds, direct interaction with the 
apical cell membrane leading to changes in membrane fluidity and lipid composition 
presented a plausible alternative mechanism to explain the observed increase in paracellular 
permeability10, 23, 24. Therefore, differences in the apical membrane phospholipid composition 
between cells lines could explain the observed differences in the potency of APCs as PPEs. 
Indeed, apical cell membranes in the intestine have been reported to contain 
glycosphingolipids25, 26 that serve to increase the stability of the apical membrane facing the 
intestinal lumen through increased intermolecular hydrogen bonds27-29. Therefore, Caco-2 
cell membranes, derived from the human intestine, may be more resistant to membrane 
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perturbing effects of APCs than are MDCK cell membranes, a cell line derived from canine 
kidney. 
Evidence in the literature has suggested that changes to the structure of phospholipid 
membranes can lead to indirect effects on the catalytic activity of membrane associated 
enzymes30-33. This is certainly likely for enzymes in the PLC family since the interactions 
between the cytosolic enzyme and the substrate embedded in the cell membrane must occur 
for catalysis. Thus, one explanation for the observed inhibition of PLC activity  by APCs in 
both cell lines is the disruption of the structural integrity of the apical membrane and 
interference with the quality of the enzyme/substrate interaction via a process referred to as 
“competitive interfacial inhibition”34. Relatively little difference observed between cell lines 
with respect to the potency of APCs as PLCβ inhibitors, in contrast to the substantial 
difference between cells lines with respect to the potency of APCs as PPEs, may be due to  
the possibility that the activity of membrane bound enzymes is more sensitive to membrane 
destabilization events than is paracellular permeability. Clearly, further studies will be 
required to test this hypothesis. 
In Chapter 5, the validity of the above hypothesis was tested by evaluating the ability 
of APCs to directly inhibit PLC in the absence of whole cells. Although all APCs inhibited 
the activity of hPLCβ1 in a concentration dependent manner, the chain length dependence for 
inhibiting PLC in the cell free system was not entirely consistent with the chain length 
dependence for inhibiting PLC in whole cells. In addition, the ability of HPC to inhibit 
hPLCβ3 in the cell free system was dependent on the detergent used in the assay, i.e. HPC 
inhibited the activity of hPLCβ3 in cholate mixed micelles, but had no effect on activity in 
dodecylmaltoside mixed micelles, implying that the inhibition was not via a direct interaction 
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with the enzyme in these assays, but instead was dependent on the environment in which the 
substrate was presented to the enzyme. Additional results presented in Chapter 5 confirmed 
the hypothesis that APCs disrupt apical cell membranes in Caco-2 cells, as each APC caused 
a concentration dependent leakage of the intracellular enzyme LDH across the apical 
membrane. Interestingly, a strong relationship existed between the potency of APCs to cause 
LDH leakage and their potency as PPEs, implicating apical membrane disruption in the 
observed effects on paracellular permeability. Further, HPC concentrations that caused 
significant increases in mannitol permeability (i.e. 100 μM; Figure 2.7.B) also caused 
significant leakage of LDH into the apical compartment (Figure 5.6) 
Collectively, results generated in both cellular and non-cellular systems with APCs 
raised questions with respect to the proposed cause-effect relationship between PLC 
inhibition and tight junction function, suggesting the need for a more direct approach to 
inhibit PLC activity in whole cells. Further, these results implied that the ability of APCs to 
increase paracellular permeability is due to their ability to disrupt the normal order of the 
apical cell membrane. HPC (miltefosine) is the first orally effective treatment for visceral 
leishmaniasis35; interestingly, its major side effects include nausea, vomiting, and diarrhea36, 
likely related to local irritation of the gastrointestinal tract, a hypothesis substantiated in this 
dissertation. 
Activation of PLC by U73122 in a Cell Free System  
 Studies in Chapter 2 confirmed the ability of another reported PPE and inhibitor of 
PLC activity in the MDCK cell model, i.e. U731226, which is not amphiphilic and is 
structurally distinct from APCs, to both increase paracellular permeability and inhibit PLC 
activity in the Caco-2 cell model. Importantly, the reported inactive analog of U73122, 
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U73343, did not affect either parameter, providing support for a role for PLC inhibition in 
the regulation of intestinal tight junction function. However, the potency of U73122 as both a 
PPE and PLC inhibitor was reduced in Caco-2 cells as compared to MDCK cells, as was the 
case with APCs. Interestingly, a recent report implied that the highly electrophilic maleimide 
moiety of U73122, which is not present in U73343, may be responsible for off target effects 
in cellular models11, and suggested that differences in available nucleophiles between 
different cellular systems may lead to differences in the potency of U73122 towards 
measured phenotypes. This report provided an explanation for the observed differences in 
potency of U73122 between MDCK and Caco-2 cells, with the implicit assumption that 
Caco-2 cells have a greater number of nucleophiles accessible to an apical dose of U73122 
than do MDCK cells, a hypothesis consistent with reports that Caco-2 cells express 
transporters that actively efflux glutathione37. 
 Despite the numerous studies reporting U73122 as an inhibitor of PLC, as well as its 
widespread use as a probe molecule to implicate the involvement of PLC in signaling 
pathways and phenotypic cellular response, little work had been done to understand the 
interaction of U73122 with PLC at the molecular level. This observation was particularly 
surprising given the presence of the highly reactive maleimide, a structural moiety that 
readily interacts with thiols. A reaction between U73122 and nucleophilic residues on PLC 
represented a potential molecular mechanism that could explain the oft reported inhibition of 
PLC activity by U73122. Studies in Chapter 4 were designed to study the direct interaction 
between U73122 and PLC in a cell free system. These studies uncovered for the first time 
that U73122 increases the activity of a PLC isozyme, hPLCβ3, by several fold in a cell free 
system, as opposed to its long reported ability to inhibit the activity of PLC. In addition, 
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studies in Chapter 4 have established for the first time that U73122 directly alkylates 
hPLCβ3 at up to eight different cysteine residues; alkylation of at least some of these 
cysteines appeared to be responsible for the increase in activity. Interestingly, a recent study 
reported an apparent weak and transient activation of PLC action following treatment of cells 
with U731228, an unexpected result that these authors could not explain; the results presented 
in this dissertation offer an explanation to support the observations from this report. 
These results demonstrate a novel mechanism of enzyme activation in this cell free 
system that may provide insight into mechanisms of regulation and subsequent activation of 
PLC isozymes in whole cells. The molecular mechanism of cellular PLC activation and 
substrate hydrolysis is not completely understood. Reversible modifications of proteins at 
cysteine residues have been implicated in conformation changes; thus, the present results 
may be indicative of events occurring in whole cells during receptor mediated activation, 
membrane binding, and subsequent substrate hydrolysis. Further, results presented herein, in 
combination with the recent report that U73122 also reacts with components of cell media11, 
clearly indicate that this molecule should no longer be used as a pharmacological probe to 
implicate PLC signal transduction in cellular response, and suggest that previous conclusions 
based solely on inhibition of PLC activity by U73122 treatment may warrant reconsideration. 
RNA Interference Studies to Determine the Role of PLC in Tight Junction Function 
 Because studies in both cellular and non-cellular systems with previously reported 
PLC inhibitors raised questions about the relationship between PLC activity and tight 
junction permeability, a more definitive approach was required to evaluate the hypothesized 
cause-effect relationship between the inhibition of PLC activity and increased paracellular 
permeability in epithelial cells. Studies in Chapter 3 utilized RNA interference technology to 
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specifically suppress the expression of individual PLC isozymes expressed in MDCK cells in 
order to more directly assess this possibility. MDCK cells were used in these studies due to 
their expeditious growth rate and tendency to rapidly establish confluent monolayers, 
characteristics which provided the opportunity to assess the effect of PLC depletion on both 
the assembly and maintenance of tight junction barrier function following transient 
transfection of cells with short interfering RNA. Results from these studies provided 
convincing evidence that a cause-effect relationship does not exist between inhibition of two 
major isozymes of PLC present in MDCK cells and tight junction function. Specific 
depletion of both PLCβ3 and PLCγ1 (the only isozymes of their respective families found in 
these cells), alone and in combination, had no impact on either tight junction assembly or on 
the barrier function of already formed tight junctions. However, as isozymes from other PLC 
families that may also be expressed in MDCK cells were not suppressed, these results do not 
rule out the possibility that inhibition of other PLC families leads to the observed changes in 
paracellular permeability. A report that HPC inhibits the activity of PLCδ1 provides support 
for such a hypothesis38. Further, results from Chapter 3 do not completely rule out the 
possible involvement of PLCβ and PLCγ isozymes in the regulation of tight junction 
function. A number of studies have indirectly suggested that PLC activation may lead to 
changes in the function of junctional complexes. For example, a number of agonists of 
receptors known to couple to PLCs have been reported to affect the functional integrity of 
tight junctions39-42. Further, increase in intracellular calcium levels43, 44, activation of specific 
PKC isozymes45, 46, as well as non-PLC-mediated depletion of membrane PIP2 content47, 48, 
all downstream actions of PLC activation, have been demonstrated to increase paracellular 
permeability or alter the barrier function of junctional complexes in a number of systems. 
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This hypothesis, in conjunction with evidence from Chapter 4 suggesting U73122 may 
activate PLC, leaves open the possibility of an alternative mechanism for the observed effects 
of U73122 on paracellular permeability in both MDCK and Caco-2 cells (Chapter 2)6, and 
may explain the discrepancy between results from studies using chemical inhibitors of PLC 
(Chapter 2) versus results from studies employing RNAi suppression of PLC (Chapter 3). 
 In summary, studies in this dissertation have significantly enhanced the current 
understanding of the role PLC enzymes play in the regulation of tight junction function. They 
have demonstrated that previous hypotheses implicating specific inhibition of PLCβ and 
PLCγ isozyme families as a cause for increased paracellular permeability via specific 
modulation of tight junction structure and function need to be re-examined. They have 
further provided convincing evidence that the effects of reported PLC inhibitors, APCs and 
U73122, on paracellular permeability are not mediated via direct inhibition of PLC activity. 
Evidence was presented to suggest that APCs modulate paracellular permeability via their 
interaction with and disruption of apical membrane integrity in Caco-2 cells, an interaction 
reported to be responsible for their anti-bacterial and anti-neoplastic activity. Evidence was 
also presented to support an alternative hypothesis to explain the observed increase in 
paracellular permeability following treatment of cells with U73122, a mechanism involving a 
novel interaction between PLC and U73122 leading to the unexpected activation of a PLC 
isozyme in a cell free system. 
 Thus, significant contributions were made in this dissertation to various scientific 
disciplines: (1) to the field of pharmaceutics and drug delivery by developing significant new 
information regarding a proposed mechanism for enhancing the oral absorption of 
hydrophilic drugs and macromolecules, (2) to the field of tight junction physiology by 
248 
providing evidence that regulation of epithelial tight junction barrier function does not appear 
to be affected by inhibition of PLCβ and/or PLCγ isozyme families, and (3) to the area of 
phospholipase C biochemistry by demonstrating a novel mechanism of enzyme activation in 
a cell free system that may provide insight into mechanisms of regulation and activation in 
whole cells. 
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